Assays for specific detection of her2 expression
An IHC assay with a HER2-specific reagent and AI/ML image analysis addresses the challenge of detecting low HER2 expression, enhancing the precision of patient selection for targeted therapies.
Patent Information
- Application Number
- PCT/IB2026/054600
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing HER2 expression assays struggle to accurately detect low levels of HER2 protein expression, which is crucial for determining eligibility for targeted therapies, leading to challenges in identifying patients who could benefit from HER2-directed treatments.
An IHC assay using a reagent that specifically binds to an epitope of the HER2 protein, such as the monoclonal anti-HER2/ErbB2 D8F12 antibody, with AI/ML-assisted image analysis to enhance sensitivity and precision in detecting HER2 expression levels, including low levels, and determining eligibility for targeted therapies.
The assay provides high sensitivity and quantitative detection of HER2 expression, enabling precise identification of patients eligible for HER2-directed therapies, improving treatment precision and efficacy.
Smart Images

Figure IMGF000056_0001_TABLE 
Figure IMGF000060_0001_TABLE 
Figure IMGF000061_0001_TABLE
Abstract
Description
[0001] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01)
[0002] ASSAYS FOR SPECIFIC DETECTION OF HER2 EXPRESSION CROSS-REFERENCE TO RELATED APPLICATION
[0003] This application claims the benefit of U.S. Provisional Patent Application No.
[0004] 63 / 803,185, filed May 9, 2025, which is incorporated by reference herein in its entirety.
[0005] SEQUENCE LISTING
[0006] The instant application contains a Sequence Listing which has been submitted herewith and is hereby incorporated by reference in its entirety. Said .xml copy, created on April 15, 2026, is named 776519 NIT-59888PC. xml, and is 86,452 bytes in size.
[0007] BACKGROUND OF THE INVENTION
[0008] Human Epidermal growth factor Receptor 2 (HER2, HER2 / neu, gene name as ERBB2) is a member of the ErbB family of receptor tyrosine kinases that mediate cell proliferation, survival, and differentiation (Schechter et aL, 1984). Approximately 15-20% of patients with breast cancer have tumors harboring ERBB2 amplification and / or overexpression, which has been associated with aggressive tumor growth and poor overall prognosis (Slamon, et aL, 1987). The discovery of HER2 has been one of the major breakthroughs in cancer research; HER2 is now a critical biomarker and therapeutic target. In the past two decades, HER2-targeted therapies, including monoclonal antibodies (mAbs), tyrosine-kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs), have demonstrated promising anti-tumor activity in HER2-amplified breast cancer (BrCa) and gastric cancer (GC) / gastroesophageal junction (GEJ) cancer.
[0009] Accurate assessment of HER2 expression levels is paramount for determining eligibility for targeted therapies. Clinical characterization of HER2 as a biomarker relies on conventional HER2 (HER2 clinical) IHC assays such as the PATHWAY® anti-HER2 / neu (4B5) Rabbit Monoclonal Primary Antibody test, which was optimized to discriminate HER2-amplified breast cancer or gastric cancer patients from HER2-unamplified. HER2 Low, HER2 Ultra-low, and HER2 Undetected breast cancers, characterized by minimal expression without gene amplification, challenge conventional classifications and treatment paradigms. Given the very broad range of HER2 expression in tumors from around 1000 molecules to over 1,000,000 molecules / cell (Moutafi et aL, 2022), little focus has been placed on developing assays to detect the lower end of the HER2 expression range. New assays are needed to fill this gap, allowing for objective and quantitative HER2 assessment and enhanced precision in identifying patients for targeted therapies.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) SUMMARY
[0010] The present disclosure describes an IHC assay that demonstrates high sensitivity for detecting HER2 expression, including low levels of expression. An IHC assay as described herein can be used to detect substantial HER2 protein expression in various tumor samples, even in the absence of HER2 IHC staining with the PATHWAY® anti-HER2 / neu (4B5) Rabbit Monoclonal Primary Antibody test. The objective and quantitative HER2 detection assays described herein can enhance precision in identifying patients for targeted therapies.
[0011] Accordingly, in one aspect, this disclosure describes a method of treating a tumor expressing a human epidermal growth factor receptor-2 (HER2) protein in a subject in need thereof, comprising: identifying the subject by detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a potential subject; wherein HER2 positive tumor cells are detected by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein, wherein the reagent lacks crossreactivity with any other epidermal growth factor (EGF) family member of tyrosine kinase receptors (TKRs); wherein the HER2 positive tumor cell exhibits membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions; and administering a therapeutically effective dose of a HER2-directed therapy to the subject.
[0012] In certain embodiments, the reagent specifically binds an epitope within a domain of the HER2 protein that is targeted by the HER2-directed therapy.
[0013] In certain embodiments, the reagent specifically binds an epitope within an extracellular domain of the HER2 protein.
[0014] In certain embodiments, the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein.
[0015] In certain embodiments, the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1 .
[0016] In certain embodiments, the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1.
[0017] In certain embodiments, the reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.
[0018] In certain embodiments, the membrane and / or cytomembrane staining intensity is determined using light microscopy, virtual microscopy, whole slide imaging, an imagetransmitting camera, imaging sensor, a charge-coupled device (CCD), a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
[0019] In certain embodiments, the HER2 positive tumor cells are detected by computer-assisted image analysis or manual analysis of the tissue sample.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample.
[0020] In certain embodiments, the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis.
[0021] In certain embodiments, the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
[0022] In certain embodiments, the method further comprises assessing the intensity of the IHC staining for each HER2 positive cell.
[0023] In certain embodiments, the method further comprises determining a percentage of HER2 positive tumor cells in an area of the tissue sample.
[0024] In certain embodiments, the percentage of HER2 positive tumor cells in the area is equal to or greater than 1%, equal to or greater than 10%, or equal to or greater than 30%.
[0025] In certain embodiments, the method further comprises determining an IHC score. In certain embodiments, the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
[0026] In certain embodiments, the IHC score is an H-score.
[0027] In certain embodiments, determining the IHC score comprises manual analysis, digital imaging analysis, computer-assisted image analysis, an AI / ML-assisted image analysis, fully automated analysis, and / or an end-to-end analysis.
[0028] In certain embodiments, the tumor is an epithelial-derived carcinoma.
[0029] In certain embodiments, the epithelial-derived carcinoma is selected from gastric cancer, gastroesophageal junction cancer, colorectal cancer, breast cancer, lung cancer, small cell lung cancer, salivary gland cancer, ovarian cancer, esophageal cancer, bladder cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, uterine cancer, cervical cancer, prostate cancer, ovarian cancer, and head and neck squamous cell carcinoma.
[0030] In certain embodiments, the tumor is a solid tumor selected from breast cancer, nonsmall cell lung cancer, small cell lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, gastroesophageal junction cancer, bladder cancer, head and neck squamous cell carcinoma, prostate cancer, ovarian cancer, and colorectal cancer.
[0031] In certain embodiments, the tissue sample is a biopsy sample or a surgical resection sample.
[0032] In certain embodiments, the tissue sample is a tissue section with a thickness between 4 pm and 5 pm.
[0033] In certain embodiments, the tissue section includes equal to or greater than 100 viable tumor cells.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, the IHC staining is performed within six months after the tissue was sectioned or within about five months, within about four months, within about three months, within about two months or within about 1 month after sectioning the tissue.
[0034] In certain embodiments, the tissue sample is a formalin-fixed tissue sample.
[0035] In certain embodiments, the tissue sample is a deparaffinized tissue sample.
[0036] In certain embodiments, administering the therapeutically effective dose of the HER2-directed therapy to the subject comprises administration of a HER2-targeting compound, a HER2-targeting radioligand, or a HER2-targeting radiotherapeutic to the subject.
[0037] In certain embodiments, administering the therapeutically effective dose of the HER2-directed therapy comprises administration of a HER2-targeting antibody, or a drug conjugate thereof, or a radiolabeled conjugate thereof, to the subject.
[0038] In certain embodiments, administering the therapeutically effective dose of the HER2-directed therapy comprises administration of trastuzumab, trastuzumab emtansine, ado-trastuzumab emtansine (TM1), trastuzumab deruxtecan (T-DXd), pertuzumab, margetuximab, zanidatamab, ertumaxomab, neratinib, tucatinib, pyrotinib, or lapatinib, or a bioequivalent or biosimilar thereof, or a radiolabeled conjugate thereof, to the subject.
[0039] In certain embodiments, administering the therapeutically effective dose of the HER2-directed therapy comprises administration of a HER2-targeting radiotherapeutic to the subject.
[0040] In certain embodiments, the HER2-targeting radiotherapeutic comprises at least one of67Cu,186Re,188Re,90Y,177Lu,161Tb,153Sm,213Bi,1311,149Tb,47Sc,225Ac,212Pb,211At,223Ra,227Th, and226Th.
[0041] In certain embodiments, the HER2-targeting radiotherapeutic comprises90Y,177Lu,1311,225Ac,211At, or227Th.
[0042] In certain embodiments, the HER2-targeting radiotherapeutic comprises225Ac.
[0043] In certain embodiments, the HER2-targeting radiotherapeutic comprises177Lu.
[0044] In an embodiment, the HER2-targeting radiotherapeutic is a radioligand therapy. In certain embodiments, the IHC staining further comprises contacting the tissue sample with an enzyme-labeled antibody specific for the reagent.
[0045] In certain embodiments, the enzyme-labeled antibody comprises an oxidoreductase, hydrolase, or peroxidase.
[0046] In certain embodiments, the enzyme-labeled antibody comprises a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, -galactosidase, p-glucuronidase, or p-lactamase.
[0047] In certain embodiments, the enzyme-labeled antibody comprises HRP or AP.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, the IHC staining further comprises contacting the tissue sample with 3,3’-diamino-benzidine (DAB), 4-nitrophenylphospate (pNPP), bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, AP Orange, AP blue, tetramethylbenzidine (TMB), 2,2'-azino-di-[3-ethylbenzothiazoline sulphonate] (ABTS), o-dianisidine, 4-chloronaphthol (4-CN), 4-Aminophenyl phosphate monosodium salt, Fast Red, Naphthol AS-BI-phosphate, nitrophenyl-p-D-galactopyranoside (ONPG), o-phenylenediamine (OPD), 5-bromo-4-chloro-3-indolyl-p-galactopyranoside (X-Gal), methylumbelliferyl-p-D-galactopyranoside (Mil-Gal), p-nitrophenyl-a-D-galactopyranoside (PNP), 5-bromo-4-chloro-3-indolyl-p-D-glucuronide (X-Gluc), 3-amino-9-ethyl carbazol (AEC), fuchsin, iodonitrotetrazolium (INT), tetrazolium blue, or tetrazolium violet.
[0048] In certain embodiments, the tissue sample is contacted with DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
[0049] In certain embodiments, the HER2 negative cell line comprises HL-60 or Farage cells.
[0050] In another aspect, the disclosure describes an in vitro method of identifying a HER2 protein expressing tumor, the method comprising: detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a potential subject,
[0051] wherein the HER2 positive tumor cells are detected by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein, which reagent lacks cross-reactivity with any other EGF family member of TKRs;
[0052] wherein the HER2 positive tumor cell exhibits membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions, thereby identifying the tumor as the HER2 protein expressing tumor.
[0053] In certain embodiments, the reagent specifically binds an epitope within a domain of the HER2 protein that is targeted by a HER2-directed therapy.
[0054] In certain embodiments, the reagent specifically binds an epitope within an extracellular domain of the HER2 protein.
[0055] In certain embodiments, the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein.
[0056] In certain embodiments, the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1.
[0057] In certain embodiments, the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, the reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.
[0058] In certain embodiments, the membrane and / or cytomembrane staining intensity is determined using light microscopy, virtual microscopy, whole slide imaging, an imagetransmitting camera, an imaging sensor, a charge-coupled device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
[0059] In certain embodiments, the HER2 positive tumor cells are detected by computer-assisted image analysis or manual analysis of the tissue sample.
[0060] In certain embodiments, computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample.
[0061] In certain embodiments, the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis.
[0062] In certain embodiments, the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
[0063] In certain embodiments, the method further comprises assessing the intensity of the IHC staining for each HER2 positive cell.
[0064] In certain embodiments, the method further comprises determining a percentage of HER2 positive tumor cells in an area of the tissue sample.
[0065] In certain embodiments, the percentage of HER2 positive tumor cells in the area is equal to or greater than 1%, equal to or greater than 10%, or equal to or greater than 30%.
[0066] In certain embodiments, the method further comprises determining an IHC score. In certain embodiments, the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
[0067] In certain embodiments, the IHC score is an H-score.
[0068] In certain embodiments, determining the IHC score comprises manual analysis, digital imaging analysis, computer-assisted image analysis, an AI / ML-assisted image analysis, and / or an end-to-end analysis.
[0069] In certain embodiments, the tumor is an epithelial-derived carcinoma.
[0070] In certain embodiments, the epithelial-derived carcinoma is selected from gastric cancer, gastroesophageal junction cancer, colorectal cancer, breast cancer, lung cancer, small cell lung cancer, salivary gland cancer, ovarian cancer, esophageal cancer, bladder cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, uterine cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma.
[0071] In certain embodiments, the tumor is a solid tumor selected from breast cancer, nonsmall cell lung cancer, small cell lung cancer, gastric cancer, pancreatic ductalAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) adenocarcinoma, gastroesophageal junction cancer, bladder cancer, head and neck squamous cell carcinoma, prostate cancer, ovarian cancer, and colorectal cancer.
[0072] In certain embodiments, the tissue sample is a biopsy sample or a surgical resection sample.
[0073] In certain embodiments, the tissue sample is a tissue section with a thickness between 4 pm and 5 pm.
[0074] In certain embodiments, the tissue section includes equal to or greater than 100 viable tumor cells.
[0075] In certain embodiments, the IHC staining is performed within six months after sectioning the tissue, or within about five months, within about four months, within about three months, within about two months or within about 1 month after the tissue has been sectioned.
[0076] In certain embodiments, the tissue sample is a formalin-fixed tissue sample.
[0077] In certain embodiments, the tissue sample is a deparaffinized tissue sample.
[0078] In certain embodiments, the IHC staining further comprises contacting the tissue sample with an enzyme-labeled antibody specific for the reagent.
[0079] In certain embodiments, the enzyme-labeled antibody comprises an oxidoreductase, hydrolase, or peroxidase.
[0080] In certain embodiments, the enzyme-labeled antibody comprises a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, p-galactosidase, p-glucuronidase, or p-lactamase.
[0081] In certain embodiments, the enzyme-labeled antibody comprises HRP or AP.
[0082] In certain embodiments, the IHC staining further comprises contacting the tissue sample with DAB, pNPP, fast red, BCIP, NBT, BCIP / NBT, AP Orange, AP blue, TMB, ABTS, 4-CN, 4-Aminophenyl phosphate monosodium salt, Naphthol AS-BI-phosphate, ONPG, OPD, X-Gal, MU-Gal, PNP, X-Gluc, AEC, fuchsin, INT, tetrazolium blue, or tetrazolium violet.
[0083] In certain embodiments, the IHC staining further comprises contacting the tissue sample with DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
[0084] In certain embodiments, the HER2 negative cell line sample comprises HL-60 or Farage cells.
[0085] In another aspect, the disclosure describes an in vitro method for predicting responsiveness of a tumor to a HER2-directed therapy, the method comprising:
[0086] assessing HER2 expression in a tumor by detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a potential subject; wherein the HER2Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) positive tumor cells are detected by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein, which reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors; and predicting that the tumor is responsive to HER2-directed therapy if a tumor cell of the tissue sample exhibits membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions.
[0087] In certain embodiments, the reagent specifically binds an epitope within a domain of the HER2 protein that is targeted by the HER2-directed therapy, the reagent specifically binds an epitope within an extracellular domain of HER2 protein; the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein; the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1 ; the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1 ; and / or the reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.
[0088] In certain embodiments, the membrane and / or cytomembrane staining intensity is determined using light microscopy, virtual microscopy, whole slide imaging, an imagetransmitting camera, an imaging sensor, a charge-coupled device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
[0089] In certain embodiments, the HER2 positive tumor cells are detected by computer-assisted image analysis or manual analysis of the tissue sample.
[0090] In certain embodiments, computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample.
[0091] In certain embodiments, the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis. In some cases, the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
[0092] In certain embodiments, the method further comprises assessing the intensity of the IHC staining for each HER2 positive cell.
[0093] In certain embodiments, the method further comprises determining a percentage of HER2 positive tumor cells in an area of the tissue sample.
[0094] In certain embodiments, the percentage of HER2 positive tumor cells in the area is equal to or greater than 1%, optionally equal to or greater than 10%, or equal to or greater than 30%.
[0095] In certain embodiments, the method further comprises determining an IHC score.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, the IHC score is selected from the group consisting of an Flscore, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
[0096] In certain embodiments, the IHC score is an H-score.
[0097] In certain embodiments, determining the IHC score comprises manual analysis, digital imaging analysis, computer-assisted image analysis, an AI / ML-assisted image analysis, and / or an end-to-end analysis.
[0098] In certain embodiments, the tumor is an epithelial-derived carcinoma.
[0099] In certain embodiments, the epithelial-derived carcinoma is selected from gastric cancer, gastroesophageal junction cancer, colorectal cancer, breast cancer, lung cancer, small cell lung cancer, salivary gland cancer, ovarian cancer, esophageal cancer, bladder cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, uterine cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma.
[0100] In certain embodiments, the tumor is a solid tumor selected from breast cancer, nonsmall cell lung cancer, small cell lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, gastroesophageal junction cancer, bladder cancer, head and neck squamous cell carcinoma, prostate cancer, ovarian cancer, and colorectal cancer.
[0101] In certain embodiments, the tissue sample is a biopsy sample or a surgical resection sample.
[0102] In certain embodiments, the tissue sample is a tissue section with a thickness between 4 pm and 5 pm.
[0103] In certain embodiments, the tissue section includes equal to or greater than 100 viable tumor cells.
[0104] In certain embodiments, the IHC staining is performed within six months after sectioning the tissue or within about five months, within about four months, within about three months, within about two months or within about 1 month after sectioning the tissue.
[0105] In certain embodiments, the tissue sample is a formalin-fixed tissue sample.
[0106] In certain embodiments, the tissue sample is a deparaffinized tissue sample.
[0107] In certain embodiments, the IHC staining further comprises contacting the tissue sample with an enzyme-labeled antibody specific for the reagent.
[0108] In certain embodiments, the enzyme-labeled antibody comprises an oxidoreductase, hydrolase, or peroxidase, optionally wherein the enzyme-labeled antibody comprises a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, p-galactosidase, p-glucuronidase, or p-lactamase.
[0109] In certain embodiments, the enzyme-labeled antibody comprises HRP or AP.
[0110] In certain embodiments, the IHC staining further comprises contacting the tissue sample with DAB, pNPP, fast red, BCIP, NBT, BCIP / NBT, AP Orange, AP blue, TMB, ABTS,Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 4-CN, 4-Aminophenyl phosphate monosodium salt, Naphthol AS-BI-phosphate, ONPG, OPD, X-Gal, MU-Gal, PNP, X-Gluc, AEC, fuchsin, INT, tetrazolium blue, or tetrazolium violet.
[0111] In certain embodiments, the IHC staining further comprises contacting the tissue sample with DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
[0112] In certain embodiments, the HER2 negative cell line comprises HL-60 or Farage cells.
[0113] In another aspect, the disclosure provides a kit for characterizing responsiveness of a tumor to a HER2-directed therapy, the kit comprising:
[0114] (a) a reagent that specifically binds an epitope of a HER2 protein, wherein the reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors;
[0115] (b) a HER2 negative cell line; and
[0116] (c) a set of instructions for:
[0117] (i) using the reagent for IHC staining on a tumor tissue sample obtained from a tumor of a potential subject, and
[0118] (ii) characterizing a tumor as being responsive to a HER2-directed therapy when a tumor cell exhibits HER2-positive membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions.
[0119] In certain embodiments, the reagent specifically binds an epitope within a HER2 protein domain targeted by the HER2-directed therapy; the reagent specifically binds an epitope within an extracellular domain of the HER2 protein; the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein; the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1 ; the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1 ; and / or the reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.
[0120] In certain embodiments, the set of instructions further comprises instructions for preparing the tissue sample, preparing a negative control using the HER2 negative cell line, preparing a positive control, determining the membrane and / or cytomembrane staining intensity, determining a percentage of HER2 positive tumor cells, and / or determining an IHC score.
[0121] In certain embodiments, the kit further comprises:
[0122] (d) at least one enzyme-labeled antibody that binds to the reagent of component (a), andAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) (e) at least one chromogenic substrate of the at least one enzyme-labeled antibody. In certain embodiments, the kit further comprises at least one counterstain, optionally wherein the counterstain comprises hematoxylin.
[0123] In certain embodiments, the HER2 negative cell line comprises HL-60 or Farage cells.
[0124] In another aspect, the disclosure provides an in vitro method for determining eligibility of a subject for treatment with a HER2-directed therapy, the method comprising:
[0125] performing an immunohistochemistry (IHC) assay on a tissue section from a tumor of the subject using a monoclonal anti-HER2 / ErbB2 D8F12 antibody;
[0126] calculating an IHC score; and
[0127] (c)(1) determining the subject is eligible for the treatment when the IHC score is greater than or equal to a pre-determined threshold for the tissue section, or
[0128] (c)(2) determining the subject is ineligible for the treatment when the IHC score is less than a pre-determined threshold for the tissue section.
[0129] In certain embodiments, the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
[0130] In certain embodiments, the IHC score is an H-score.
[0131] In certain embodiments, the IHC assay comprises staining the tissue section by incubation with the monoclonal anti-HER2 / ErbB2 D8F12 antibody for about 1 minute to about 2 hours at a temperature between about 15 to 45°C followed by contacting the tissue section with a horseradish peroxidase-conjugated secondary antibody that binds the monoclonal anti-HER2 / ErbB2 D8F12 antibody for about 0.5 to 30 minutes.
[0132] In certain embodiments, the method further comprises counterstaining the stained tissue section with hematoxylin for about 0.5 to 10 minutes; followed by bluing for about 0.5 to 10 minutes.
[0133] In certain embodiments, the IHC assay is performed using the monoclonal anti-HER2 / ErbB2 D8F12 antibody at a dilution of about 1 :2 to about 1 :10000.
[0134] In certain embodiments, the IHC assay is performed using the monoclonal anti-HER2 / ErbB2 D8F12 antibody at a dilution of about 1 :25 to about 1 :5000.
[0135] In certain embodiments, the IHC assay is performed using the monoclonal anti-HER2 / ErbB2 D8F12 antibody at a dilution of about 1 :50 to about 1 :200.
[0136] In certain embodiments, the IHC assay is performed using the monoclonal anti-HER2 / ErbB2 D8F12 antibody at a dilution of about 1 :100.
[0137] In certain embodiments, the tissue section is deparaffinized.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, the tissue section is treated with an antigen retrieval buffer for about 25 minutes to about 75 minutes.
[0138] In certain embodiments, the tissue section is evaluated by light microscopy, virtual microscopy, whole slide imaging, an image-transmitting camera, an imaging sensor, a charge-coupled device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
[0139] In certain embodiments, the IHC score is determined by manual analysis of the tissue section or by computer-assisted image analysis of the stained tissue.
[0140] In certain embodiments, computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue section.
[0141] In certain embodiments, the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis.
[0142] In certain embodiments, the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
[0143] In another aspect, the disclosure provides a kit for determining eligibility of a subject for treatment with a HER2-directed therapy comprising:
[0144] a monoclonal anti-HER2 / ErbB2 D8F12 antibody in an immunochemistry (IHC) buffer; at least one HER2 negative cell line; and
[0145] a set of instructions for performing an immunohistochemistry (IHC) assay on a tissue section from a tumor of the subject and determining the eligibility of the subject based membrane and / or cytomembrane staining intensity, wherein a HER2 positive tumor cell exhibits greater membrane and / or cytomembrane staining intensity than a HER2 negative cell line contacted with the monoclonal anti-HER2 / ErbB2 D8F12 antibody under substantially similar conditions.
[0146] In certain embodiments, the set of instructions further comprises instructions for preparing the tissue section, preparing the HER2 negative cell line, preparing a positive control, determining the intensity of the stained cells, determining a percentage of stained cells, and / or determining an IHC score.
[0147] In certain embodiments, the kit further comprises:
[0148] an enzyme-labeled antibody that binds to the monoclonal anti-HER2 / ErbB2 D8F12 antibody, and
[0149] a chromogenic substrate of the enzyme-labeled antibody.
[0150] In certain embodiments, the enzyme-labeled antibody comprises horseradish peroxidase (HRP) or alkaline phosphatase (AP).Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, the chromogenic substrate comprises 3,3’-diamino-benzidine (DAB), para-Nitrophenylphosphate (pNPP), 5-Bromo-4-chloro-3-indolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
[0151] In certain embodiments, the kit further comprises a counterstain, optionally wherein the counterstain comprises hematoxylin.
[0152] In certain embodiments, the HER2 negative cell line comprises HL-60 or Farage cells.
[0153] In another aspect, the disclosure provides a system for predicting whether a tumor will be responsive to HER2-directed therapy using an image of a solid tumor sample stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, the system comprising:
[0154] (i) a processor, and
[0155] (ii) a memory coupled to the processor, where the memory stores computerexecutable instructions that, when executed by the processor, cause the system to perform operations comprising:
[0156] detecting, with a ML / AI assisted image analyzer, a region of interest within a sample image of a solid tumor sample stained for HER2 expressing cells;
[0157] extracting stained features from the detected region of interest;
[0158] grouping data points representing detected region of interest based on the extracted stained features to identify homogeneous groups; and
[0159] signaling that the tumor is predicted to be responsive to HER2-directed therapy when one or more homogeneous groups of regions of interest are identified in the sample image. In certain embodiments, the region of interest delineates a portion of a whole cell or one or more whole cells of the solid tumor sample.
[0160] In certain embodiments, the ML / AI analyzer is trained using a dataset comprising a plurality of training images, wherein each training image of the plurality is derived from a biological specimen stained with the monoclonal anti-HER2 / ErbB2 D8F12 antibody.
[0161] In another aspect, the disclosure provides a non-transitory computer-readable medium storing instructions for predicting whether a tumor will be responsive to HER2-directed therapy using an image of a solid tumor sample stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, which, when executed by a processor, performs a method comprising:
[0162] detecting, with a ML / AI assisted image analyzer, a region of interest within a sample image of a solid tumor sample stained for HER2 expressing cells, wherein the ML / AI assisted image analyzer comprises a first portion configured to identify stained featuresAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) within the sample image and a second portion configured to detect the region of interest based on the stained features;
[0163] extracting at least a portion of the identified stained features from the first portion; and
[0164] grouping data points representing the detected region of interest in the sample image based on the extracted stained features to identify homogeneous groups; and
[0165] signaling that the tumor is predicted to be responsive to HER2-directed therapy when one or more homogeneous groups of regions of interest are identified in the sample image. In certain embodiments, the region of interest delineates a portion of a whole cell or one or more whole cells of the solid tumor sample.
[0166] In another aspect, the disclosure provides a method of predicting whether a subject’s tumor will be responsive to HER2-directed therapy using an image of a solid tumor obtained from the subject, the solid tumor being stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, the method comprising:
[0167] detecting, with a ML / AI assisted image analyzer, a region of interest within a sample image of a solid tumor sample stained for HER2 expressing cells, wherein the ML / AI assisted image analyzer comprises a first portion and a second portion, wherein the first portion is configured to identify stained features within the sample image and wherein the second portion is configured to detect the region of interest based on the stained features;
[0168] extracting a portion of the identified stained features from the first portion of the ML / AI assisted image analyzer;
[0169] grouping data points representing the detected region of interest in the sample image based on the extracted stained features to identify homogeneous groups;
[0170] signaling that the tumor is predicted to be responsive to HER2-directed therapy when one or more homogeneous groups of regions of interest are identified in the sample image.
[0171] In another aspect, the disclosure provides a kit for predicting whether a tumor will be responsive to HER2-directed therapy comprising:
[0172] a monoclonal anti-HER2 / ErbB2 D8F12 antibody in an immunochemistry (IHC) buffer; and
[0173] a non-transitory computer-readable medium that stores instructions for predicting whether a tumor will be responsive to HER2-directed therapy using an image of a solid tumor sample stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, which, when executed by a processor, performs a method comprising:
[0174] a. detecting a region or cells in a sample image of the solid tumor using a ML / AI assisted image analyzer, wherein the ML / AI assisted image analyzer comprises a firstAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) portion configured to identify stained features within the sample image and a second portion configured to detect the region cells based on the stained features;
[0175] b. extracting at least a portion of the identified stained features from the first portion; c. grouping data points representing the detected region or cells in the sample image based on the extracted stained features to identify homogeneous groups; and
[0176] d. signaling that the tumor is predicted to be responsive to HER2-directed therapy when one or more homogeneous groups of regions of interest are identified in the sample image.
[0177] BRIEF DESCRIPTION OF DRAWINGS
[0178] The following detailed description can be read in conjunction with one or more of drawings for a further understanding of the nature, objects, and advantages of one or more embodiments of the present disclosure. Reference is made to the following drawings:
[0179] Figure 1 depicts a graphical representation of the American Society of Clinical Oncology / College of American Pathologists (ASCO / CAP) algorithm for evaluation of HER2 protein expression by IHC assay of the invasive component of a breast cancer specimen.
[0180] Figure 2 depicts a graphical representation of the ASCO / CAP algorithm for pathologists of HER2 testing in patients with gastroesophageal adenocarcinoma (GEA).
[0181] Figure 3 depicts a graphical representation of the epitope mapping of Rabbit Monoclonal Antibody HER2 / ErbB2 (D8F12) XP® against erb-b2 receptor tyrosine kinase 2 [Homo sapiens (human)] (ERBB2) (peptide sequences are set forth as SEQ ID Nos: 1 , 29, 51 , 53-77 and 78-97).
[0182] Figure 4 depicts a graphical representation of the epitope mapping of Rabbit Monoclonal Antibody PATHWAY® anti-HER2 / Neu (4B5) antibody against ERBB2 (peptide sequences are set forth as SEQ ID Nos: 2-3, 5-52 and 98).
[0183] Figure 5 shows Western blot analysis of extracts from cell lines using HER2 (D8F12) or HER2 (4B5).
[0184] Figure 6 shows representative images of HER2 immunohistochemistry (IHC) using 4B5 in control cell pellets.
[0185] Figure 7 shows representative images of HER2 IHC using 4B5 and the HER2 IHC assay of the present disclosure in HER2 dynamic range analyte (“AnalyteDR”) control cell lines plus HL-60.
[0186] Figure 8 shows representative images of HER2 IHC of selected low HER2 expressing cell lines using the HER2 IHC assay of the present disclosure.
[0187] Figure 9 shows the graphical concordance of ERBB2 ISH with HER2 IHC using 4B5 and the HER2 IHC assay of the present disclosure in Estrogen Receptor-positive Breast Cancer (ER+ BrCa).Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Figure 10 shows representative images of HER2 IHC using 4B5 and the HER2 IHC assay of the present disclosure in breast cancer (BrCa).
[0188] Figure 11 depicts HER2 protein expression by the HER2 IHC assay of the present disclosure in breast cancer.
[0189] Figure 12 shows representative images of HER2 IHC using 4B5 and the HER2 IHC assay of the present disclosure in non-small cell lung cancer (NSCLC).
[0190] Figure 13 depicts HER2 expression by the HER2 IHC assay of the present disclosure in NSCLC subtypes.
[0191] Figure 14 shows representative images of HER2 IHC using 4B5 and the HER2 IHC assay of the present disclosure in gastric cancer (GC).
[0192] Figure 15 HER2 IHC scores distribution in GC subtypes.
[0193] Figure 16 shows representative images of HER2 IHC using 4B5 and the HER2 IHC assay of the present disclosure in bladder cancer.
[0194] Figure 17 shows HER2 expression by the HER2 IHC assay of the present disclosure in bladder cancer.
[0195] Figure 18 shows HER2 expression by the HER2 IHC assay of the present disclosure in colorectal cancer (CRC).
[0196] Figures 19A-B show HER2 expression by IHC in BrCa, NSCLC, GC, bladder cancer, and colorectal cancer (CRC): (A) provides the patients % for ASCO scores distribution and (B) summarizes the scoring based on the HER2 IHC assay of the present disclosure.
[0197] Figures 20A-B show the number of tumor samples binned by HER2 IHC Scores using the HER2 IHC assay of the present disclosure in each ASCO HER2 IHC score category (A) and across indications (B).
[0198] Figures 21 A-B show results of Teir 3 Validation studies of membranous HER2 expression using the HER2 IHC assay of the present disclosure in BrCa, NSCLC (Adenocarcinoma), GC, and bladder cancer. (A) summarizes the scoring based on the HER2 IHC assay of the present disclosure; and (B) shows the number of samples binned by HER2 IHC Scores across indications.
[0199] Figure 22 shows HER2 expression by the HER2 IHC assay of the present disclosure in high-grade serous ovarian carcinoma (HGSOC).
[0200] Figure 23 shows HER2 expression by the HER2 IHC assay of the present disclosure in Head and Neck squamous cell carcinoma (HNSCC).
[0201] Figure 24 shows HER2 expression by the HER2 IHC assay of the present disclosure in pancreatic ductal adenocarcinoma (PDAC).
[0202] Figure 25 shows HER2 expression by the HER2 IHC assay of the present disclosure in prostate carcinoma (PCa).Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Figure 26 shows HER2 expression by the HER2 IHC assay of the present disclosure in Small-cell Lung cancer (SCLC).
[0203] DETAILED DESCRIPTION
[0204] Materials, methods, kits, and systems for performing and analyzing immunohistochemistry (IHC) assays are described. An IHC assay of the present disclosure can permit objective and quantitative HER2 detection in tumor cells using a reagent that specifically binds an epitope of a HER2 protein. As described further herein, the reagent lacks cross-reactivity with any other epidermal growth factor (EGF) family member of tyrosine kinase receptors (TKRs) and has high sensitivity for detecting HER2 expression even in the absence of HER2 IHC staining with PATHWAY® anti-HER2 / neu (4B5) Rabbit Monoclonal Primary Antibody test.
[0205] MATERIALS FOR IHC ASSAYS HER2-specific Reagents
[0206] The HER2-IHC assay of the present disclosure includes materials and methods for immunohistochemistry (IHC) staining, including a reagent that specifically binds an epitope of a HER2 protein, referred to herein as a HER2-specific reagent. A HER2-IHC assay as described herein can be used to evaluate HER2 protein expression in various tissue and / or tumor samples.
[0207] As used herein, the phrase “specific binding,” “specifically binds to,” or “specific for,” or the like, refers to measurable and reproducible interactions between a HER2 protein and a reagent, which is determinative of the presence of the HER2 protein in the presence of a heterogeneous population of molecules including biological molecules. For example, a HER2-specific reagent can be an antibody that binds this target with greater affinity, avidity, more readily, and / or with greater duration than it binds to other targets. In one embodiment, the extent of binding of a reagent to an unrelated target is less than about 10% of the binding of the antibody to the target as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, a HER2-specific reagent has a dissociation constant (Kd) of <1 pM, <100 nM, <10 nM, <1 nM, or <0.1 nM.
[0208] Unless indicated otherwise, the terms “HER2,” and “HER2 / neu” when used herein refer to a human HER2 protein or a portion thereof. Endogenous HER2 protein is encoded by the human epidermal growth factor receptor 2 (HER2) gene, also known as ERBB2, and is a member of the ErbB / HER receptor tyrosine kinase (RTK) family. HER2 protein is a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity. While HER2 lacks an identified ligand, HER2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB / HER RTK family members. HER2 nucleic acid and amino acid sequences are publicly available. TheAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) HER2gene is located on chromosome 17q12 and its sequence is disclosed as GenBank Accession No. NC_000017.10 (37844167-37884915). GenBank Accession Nos.
[0209] NM OO 1005862, NM_004448, XM_005257139, and XM_005257140 disclose HER2 nucleic acid sequences, and GenBank Accession Nos.: NP 001005862, NP 004439,
[0210] XP 005257196, and XP 005257197 disclose HER2 amino acid sequences.
[0211] Portions of the HER2 protein include, for example, truncated HER2 molecules resulting from proteolytic cleavage (HER2 shedding). Portions of the HER2 protein include the extracellular domain (ECD), transmembrane domain (TMD), and intercellular region of the HER2 protein, or a region thereof. The HER2 ECD includes four subdomains (l-l V), with two leucine-rich domains, and two cysteine-rich domains.
[0212] As used herein, the term “reagent” refers to any compound that can be used to detect the presence of or measure the amount of HER2 in a cellular sample by depositing a stain in proximity to the HER2-specific reagent. Non-limiting examples of reagents can include HER2-specific reagents (such as primary antibodies), secondary detection reagents (such as secondary antibodies capable of binding to a primary antibody), tertiary detection reagents (such as tertiary antibodies capable of binding to secondary antibodies), secondary detection reagents (detection reagent capable of specifically binding to the HER2-specific reagent), enzymes directly or indirectly associated with the HER2-specific reagent, chemicals reactive with such enzymes to effect deposition of a fluorescent or chromogenic stain, wash reagents used between staining steps, and the like.
[0213] As used herein, “a reagent that specifically binds an epitope of a HER2 protein” refers to a reagent capable of differentiating between different epitopes of the epidermal growth factor (EGF) family member of tyrosine kinase receptors (TKRs) with specificity for a HER2 protein epitope, and that does not exhibit cross-reactivity for other EGF-TKRs including EGFR (ErbB1), ErbB3 (HER3), and ErbB4 (HER4). HER2 protein binding sites can be localized within continuous peptide sequences and interact as linear epitopes, or stretch across different points within the sequence and interact as conformational epitopes. Linear epitope mapping can be based on a single peptide length and the maximum peptide overlap for high resolution epitope data, suitable for monoclonal antibodies. The epitope can be part of any antigenic portion of the HER2 protein. The antigenic portion can be a region of the extracellular domain (ECD), transmembrane domain (TMD), or intercellular region of the HER2 protein.
[0214] In a specific embodiment, the HER2-specific reagent specifically binds an epitope within a domain of the HER2 protein that is targeted by a HER2-directed therapy. For example, HER2-directed therapy ADCs (Antibody-Drug Conjugates) and antibodies such as trastuzumab, margetuximab, zanidatamab, ertumaxomab, and pertuzumab can bind to anAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) epitope located within the ECD of the HER2 protein, such as within domain I, II, III, or IV of the HER2 protein.
[0215] In a specific embodiment, a HER2-specific reagent specifically binds an epitope within domain I of the HER2 protein, such as within the first 500, the first 250, or the first 100 amino acids (aa) residues of the HER2 protein N-terminus. In a specific embodiment, the reagent specifically binds an epitope within aa residues 25 to 60 of the HER2 protein ECD domain I, or binds aa residues 38 to 44 of the N-terminus of the HER2 protein. In a specific embodiment, the HER2-specific reagent specifically binds an aa sequence comprising the sequence SPETHLD (SEQ ID NO: 1). In a specific embodiment, the HER2-specific reagent specifically binds an epitope comprising at least three consecutive aa residues of SEQ ID NO: 1 , such as at least 3, 4, 5, or 6 consecutive aa residues of SEQ ID NO: 1. In certain embodiments, the HER2-specific reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1.
[0216] In certain embodiments, the HER2-specific reagent comprises an antibody produced by immunizing animals with a synthetic peptide corresponding to residues near the N-terminus of a human HER2 / ErbB2 protein, such as domain I of the ECD. The term “antibody” is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they bind specifically to a HER2 protein and lack cross-reactivity with a HER1 protein, HER3 protein, and HER4 protein, or a portion thereof. The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention can be made by the hybridoma method. The “monoclonal antibodies” can also be isolated from phage antibody libraries.
[0217] The monoclonal antibodies herein can include “chimeric” antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from anotherAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
[0218] “Humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, the variable fragment (Fv) framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
[0219] In a specific embodiment, the HER2-specific reagent can be a monoclonal anti-HER2 / ErbB2 D8F12 antibody, such as a rabbit monoclonal anti-HER2 / ErbB2 D8F12 antibody, sold by Cell Signaling Technology, Inc. under the trade name HER2 / ErbB2 (D8F12) XP® Rabbit mAb #4290.
[0220] In certain embodiments, a HER2-specific reagent can be a bioequivalent of the anti-HER2 / ErbB2 D8F12 antibody. As used herein, the term “bioequivalent” refers to all antibody clones that exhibit substantially similar affinity and specificity for a HER2 protein. A bioequivalent can include aptamers, affimers, or specially engineered peptides, which can also bind to target antigens with high affinity and specificity, allowing for detection in diagnostic assays.
[0221] In a specific embodiment, the HER2-specific reagent is not mouse monoclonal antibody TAB250, rabbit monoclonal antibody SP3, mouse monoclonal antibodies CB-11 , TA9145, Ab-17, 3B5, or PN2A, or rabbit monoclonal antibodies SP3, 4B5, EP1045Y, or EP3.
[0222] Staining Reagents
[0223] IHC is an affinity technique for histochemical detection involving labelling a biomarker or other structures in a tissue sample with a biomarker-specific reagent and staining via deposition of a detection reagent. A detection reagent can include a detectable moiety.
[0224] Staining by the detection reagent can permit detection of the biomarker or other structures in the context of a tissue sample. Other examples of histochemical detection includeAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) chromogenic in situ hybridization (CISH), fluorescent in situ hybridization (FISH), and silver in situ hybridization (SISH), and hematoxylin and eosin (H&E) staining.
[0225] As used herein, the term “stain” can refer to any substance that can be used to visualize specific molecules or structures in a cellular sample for analysis, such as by brightfield microscopy, fluorescent microscopy, electron microscopy, and the like, or digital image analysis techniques. When used as a verb, the term “stain” refers to any process that results in deposition of a stain on a cellular sample.
[0226] In certain embodiments, a detectable moiety is directly conjugated to the HER2-specific reagent, and is deposited on the sample upon binding of the HER2-specific reagent to HER2 (i.e., direct labeling). Direct labeling methods can permit direct quantification of HER2 protein expression.
[0227] In certain embodiments, a detectable moiety is deposited via use of a detection reagent associated with the HER2-specific reagent (i.e., via indirect labeling). Indirect labeling can be more sensitive than direct labeling methods, and permit quantitative and semi-quantitative detection. In some embodiments, an indirect IHC assay allows for amplification of the signal because several secondary antibodies can react with different epitopes on the primary antibody.
[0228] The primary and / or secondary antibody used for immunohistochemistry typically will be labeled with a detectable moiety. Numerous labels are available including radioisotopes, such as35S,14C,125l,3H, and1311, colloidal gold particles, fluorescent labels, and various enzyme-substrate labels. In certain embodiments, the label is directly conjugated with the antibody. Alternatively, the label can be indirectly conjugated with the antibody. For example, the antibody can be conjugated with biotin and any of the four broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner.
[0229] Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody can be conjugated with a small hapten and one of the types of labels mentioned above is conjugated with an anti-hapten antibody.
[0230] In specific embodiments, the primary and / or secondary antibody used for IHC is labeled with an enzyme that is reactive with a chromogenic substrate, signaling conjugate, or enzyme-reactive dye under appropriate reaction conditions to effect in situ generation of the dye and / or deposition of the dye on the tissue sample. The enzyme can catalyze a chemical alteration of the chromogenic substrate that can be visualized or measured using various techniques. For example, the enzyme can catalyze a color change in a substrate, which can be measured spectrophotometrically, detected by an optical scanner, or visualized microscopically. Alternatively, the enzyme can alter the fluorescence or chemiluminescence of the substrate. A chemiluminescent substrate becomes electronically excited by a chemicalAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) reaction and then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Non-limiting examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRP), alkaline phosphatase, p-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. In certain embodiments, the enzyme-labeled antibody comprises a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, p-galactosidase, p-glucuronidase, or p-lactamase.
[0231] In certain embodiments, the enzyme can be used in a metallographic detection technique. Metallographic detection techniques include using an enzyme such as alkaline phosphatase in combination with a water-soluble metal ion and a redox-inactive substrate of the enzyme. In a specific embodiment, the substrate is converted to a redox-active agent by the enzyme, and the redox-active agent reduces the metal ion, causing it to form a detectable precipitate. Metallographic detection methods include using an oxido-reductase enzyme (such as horseradish peroxidase) along with a water-soluble metal ion, an oxidizing agent, and a reducing agent, again to for form a detectable precipitate.
[0232] In certain embodiments, the enzymatic action occurs between the enzyme and the dye itself, where the reaction converts the dye from a non-binding species to a species deposited on the sample. For example, reaction of DAB with a peroxidase (such as HRP) oxidizes the DAB, causing it to precipitate.
[0233] In certain embodiments, the substrate is a chromogenic substrate such as 3,3’-diamino-benzidine (DAB), 4-nitrophenylphospate (pNPP), bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, AP Orange, AP blue, tetramethylbenzidine (TMB), 2,2'-azino-di-[3-ethylbenzothiazoline sulphonate] (ABTS), o-dianisidine, 4-chloronaphthol (4-CN), 4-Aminophenyl phosphate monosodium salt, Fast Red, Naphthol AS-Bl-phosphate, nitrophenyl-p-D-galactopyranoside (ONPG), o-phenylenediamine (OPD), 5-bromo-4-chloro-3-indolyl-p-galactopyranoside (X-Gal), methylumbelliferyl-p-D-galactopyranoside (Mil-Gal), p-nitrophenyl-a-D-galactopyranoside (PNP), 5-bromo-4-chloro-3-indolyl-p-D-glucuronide (X-Gluc), 3-amino-9-ethyl carbazol (AEC), fuchsin, iodonitrotetrazolium (INT), tetrazolium blue, or tetrazolium violet. In certain embodiments, the substrate is DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
[0234] Non-limiting examples of enzyme-substrate combinations include, for example, HRP with hydrogen peroxidase as a substrate, wherein the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidineAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) hydrochloride (TMB)); alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and p-D-galactosidase (P-D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl-p-D-galactosidase) or fluorogenic substrate (e.g., 4-methylumbelliferyl-p-D-galactosidase).
[0235] In certain embodiments, reagents for performing assays of the present disclosure can include morphological stains. Morphological stains can include dyes capable of staining nuclear structures of a tissue sample (also referred to as nuclear counterstains) or stains for staining cytoplasmic structures, identifying viable tumor cells, and / or identifying tumor regions within the sample, such as an invasive tumor region. Morphological stains include but are not limited to, hematoxylin and eosin (H&E) stain and Lee's Stain (Methylene Blue and Basic Fuchsin).
[0236] In certain embodiments, reagents for performing assays of the present disclosure can include a counterstain. Examples of counterstains include chromogenic nuclear counterstains, such as hematoxylin (stains from blue to violet), Methylene blue (stains blue), toluidine blue (stains nuclei deep blue and polysaccharides pink to red), nuclear fast red (stains red), and methyl green (stains green); non-nuclear chromogenic stains, such as eosin (stains pink); fluorescent nuclear stains, including 4', 6-diamino-2-phenylindole (DAPI, stains blue), propidium iodide (stains red), Hoechst stain (stains blue), nuclear green DCS1 (stains green), nuclear yellow (Hoechst S769121, stains yellow under neutral pH and stains blue under acidic pH), DRAQ5 (stains red), DRAQ7 (stains red); fluorescent non-nuclear stains, such as fluorophore-labelled phalloidin, (stains filamentous actin, color depends on conjugated fluorophore).
[0237] Assay Controls
[0238] Materials for use with the IHC assay of the present disclosure can include positive and negative controls with known HER2 protein expression. In certain embodiments, the positive and / or negative controls comprise tissue. In certain embodiments, the positive and / or negative controls include cell lines, such as cancer cell lines with defined HER2 protein expression levels (e.g., high, medium, and low expression) and transfected overexpressing cell lines. The control tissue and / or cell lines can be processed and embedded in a manner that recapitulates the procedures used for sample tissue processing. For example, a control cell line can be processed into formalin-fixed, paraffin-embedded cell pellet controls. The cell pellets can be processed into a paraffin block that can ultimately be used for making histologic sections.
[0239] In certain embodiments, an assay control includes a panel of control cells with dynamic range of HER2 expression level. For example, a positive control can include formalin-fixed, paraffin-embedded (FFPE) pellets of one or more of SK-BR-3, BT-474, MDA-Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) MB-361, MDA-MB-453, T47D, MCF7, MDA-MB-231 , SW-480, BT-549, AU565, HCC1954, HCC38, BT20, HCC70, and MDA-MB-436 and a negative control can include FFPE pellets of one or more of cell lines that are recognized as being HER2-negative, including but not limited to HL-60 and Farage cell lines. One of skill in the art is capable of determining suitable cell lines exhibiting the appropriate level of HER2 expression, e.g., zero or negligible HER2 expression, for use as negative controls using any known protein quantification techniques (e.g., fluorescence-based assays such as Qubit®, Quant iT®, EZQ®, and NanoOrange®; immunological methods such as ELISA, Western blotting, and dot blotting; or Mass Spectrometry).
[0240] METHODS OF USING A HER2 SPECIFIC REAGENT
[0241] Methods of the present disclosure include an in vitro method of detecting HER2 protein expression. The method can include detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of subject. HER2 positive tumor cells can be detected by IHC staining using a reagent that specifically binds an epitope of a HER2 protein, which reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors (e.g., a HER2-specific reagent as described above). A HER2 positive tumor cell can exhibit membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions thereby identifying the tumor as the HER2 protein expressing tumor.
[0242] As used herein, the term “subject” or “individual” refers to a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human. In certain embodiments, a subject with a tumor can be a potential subject for a HER2-directed therapy.
[0243] A tissue sample for use in the present methods that is or has been obtained from a tumor of subject can be referred to as a “Test sample”. As used herein, “test sample” refers to tumor sample obtained from a subject having an unknown outcome at the time the sample is obtained. In certain embodiments, the tumor sample can be a sample of an epithelial-derived carcinoma. Non-limiting examples of epithelial-derived carcinoma include gastric cancer, gastroesophageal junction cancer, colorectal cancer, breast cancer, lung cancer, small cell lung cancer, salivary gland cancer, ovarian cancer, esophageal cancer, bladder cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, uterine cancer, cervical cancer, prostate cancer, ovarian cancer, and head and neck squamous cell carcinoma. In certain embodiments, the tumor is a solid tumor selected from breast cancer, non-small cellAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) lung cancer, small cell lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, gastroesophageal junction cancer, bladder cancer, head and neck squamous cell carcinoma, prostate cancer, ovarian cancer, and colorectal cancer. In certain embodiments, the epithelial-derived carcinoma can be a high-grade serous ovarian carcinoma (HGSOC) or a prostate carcinoma (PCa).
[0244] Examples of tissue samples that can be used include, but are not limited to, breast, bladder, prostate, ovary, fallopian tube, colon, lung, endometrium, esophagus, stomach, salivary gland, adrenal glands, tissue in and around the ears, eyes, mouth, nose, throat (pharynx), nasopharynx, sinus, larynx (or voice box), thyroid, mouth and lips and base of the skull, skin of the head and neck, and pancreas. The tissue sample can be a frozen sample, a fixed (preserved) sample, an embedded sample, or a preserved and embedded in a protective solid.
[0245] The tissue sample can be obtained by a variety of procedures including, but not limited to surgical resection, surgical excision, aspiration, or biopsy. As used herein a “surgical resection sample” refers to a tissue specimen obtained by surgically removing an entire diseased area or organ during a procedure called a surgical resection, which aims to completely remove the affected tissue, often as a treatment for a known disease. Unlike a biopsy, which only takes a small sample for diagnosis, a resection sample can encompass the whole affected region.
[0246] In certain embodiments, the tissue sample comprises a tumor or portion thereof. A tumor comprises a plurality of tumor cells. For example, a tissue sample can include a surgically resected tumor, tissue located inside of a tumor region (e.g., an intra-tumoral region), and tissue located at the interface between invasive neoplastic tissue and normal tissue, such as an invasive margin or a region of a tumor in the immediate vicinity of the invasive margin, which can also include a portion of the extra-tumoral tissue.
[0247] The tissue sample can be a frozen sample, a fixed (preserved) sample, an embedded sample, or a preserved and embedded in a protective solid.
[0248] The tissue sample can be fixed (i.e., preserved) by any method known in the art as being suitable for histochemical techniques. The selection of a fixative can be determined by the purpose for which the tissue is to be histologically stained or otherwise analyzed. The length of fixation depends upon the size of the tissue sample and the fixative used. By way of example, neutral buffered formalin, Bouin’s solution, or paraformaldehyde, can be used to fix a tissue sample. In certain embodiments, the time from the removal of the tissue from the subject to the initiation of tissue fixation can be 1 hour or less.
[0249] In a specific embodiment, the tissue sample is fixed and embedded in paraffin or the like. A tissue sample can be first fixed and then dehydrated through a series of increasingly concentrated alcohol solutions, infiltrated and embedded with paraffin or other sectioningAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) media (e.g., wax) so that the tissue sample can be sectioned. Alternatively, the tissue can be sectioned and the sections can be fixed. In specific embodiments, the tissue sample can be formalin-fixed and paraffin-embedded tissue sections.
[0250] The tissue sample, such as a frozen or embedded sample, can be sliced into sections using microtome, or other suitable instrument. As used herein, the term “section” can refer to a thin slice of a tissue sample suitable for microscopic analysis. The term “section” can also refer to the process of generating a section.
[0251] In certain embodiments, a series of sections can be cut in sequence from a tissue sample. For two sections to be considered “serial sections” of one another can contain sufficiently similar tissue structures in the same spatial relationship, such that the structures can be matched to one another after histological staining. Serial sections do not necessarily need to be consecutive sections from the tissue.
[0252] Section thickness can vary for different tissue types. In one or more embodiments, the sections can be about 1 pm to about 15 pm thick, such as about 3 pm to about 13 pm, about 3 pm to about 11 pm, about 3 pm to about 9 pm, about 3 pm to about 7 pm, about 3 pm to about 5 pm, about 2 pm to about 7 pm, about 5 pm to about 15 pm, about 4 pm to about 15 pm, about 5 pm to about 15 pm, about 7 pm to about 15 pm, about 3 pm to about 8 pm, about 3 pm to about 8 pm, about 3 pm to about 7 pm, about 3 pm to about 6 pm, about 4 pm to about 8 pm, about 5 pm to about 7 pm, about 3 pm, about 4 pm, about 5 pm, about 6 pm, about 7 pm, or about 8 pm thick. In a specific example, a section of a tissue sample can be between 4 pm and 5 pm. In certain embodiments, the tissue section includes at least 30 viable tumor cells. In a specific embodiment, the tissue section includes a number of viable tumor cells equal to or greater than 100.
[0253] Once sectioned, the sections can be attached to slides by several standard methods. In one or more embodiments, the tissue sections can be attached to adhesion slides comprising a coating for improved adhesion. Examples of adhesive coatings include, but are not limited to, silane, gelatin, poly-L-lysine, and the like. Byway of example, the paraffin embedded sections can be attached to positively charged slides and / or slides coated with poly-L-lysine. An adhesive coating can be selected for compatibility with a specific stain, such as to reduce background.
[0254] If paraffin or other wax has been used as the embedding material, a method of the present disclosure can include deparaffinizing, or dewaxing, and rehydrating the tissue sample. In some embodiments, deparaffinizing or dewaxing can include incubating the FFPE tissue sample in a xylene or combination thereof, and a series of increasingly dilute alcohol solutions.
[0255] In certain embodiments, the method can include further treatment of the tissue sample prior to, during or following IHC. As used in the context of IHC, “treatment” broadlyAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) refers to any step or process applied to the tissue sample after it has been collected, but before the application of a primary antibody. For example, prior to IHC, epitope (antigen) retrieval methods, such as heating the tissue sample in citrate buffer, can be performed. For an automated IHC system, epitope retrieval methods can use CC1 , a proprietary antigen retrieval solution manufactured by Ventana. In certain embodiments, the tissue sample can be treated with an antigen retrieval buffer for at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 70 minutes, or more. Optimal duration can be determined by experimentation. In certain embodiments, the tissue sample can be treated with an antigen retrieval buffer for about 25 minutes to about 75 minutes.
[0256] Prior to IHC, the sample can be subjected to an optional blocking step.
[0257] For IHC, the tissue section can be exposed to the HER2-specific reagent for a sufficient period of time and under suitable conditions such that the reagent binds to HER2-antigen in the tissue sample.
[0258] In certain embodiments, exposing the tissue sample (e.g., section) to the HER2-specific reagent can include incubating the tissue sample with the HER2-specific reagent (e.g., a monoclonal anti-HER2 / ErbB2 D8F12 antibody or bioequivalent thereof) for a period of at least about 1 minute, about 2 minutes, about 4 minutes, about 8 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 1 hour, about 1.25 hours, about 1.5 hours, about 1.75 hours, or more, such as about 1 minute to about 2 hours. For example, in certain embodiments, the tissue sample can be incubated for at least about 2 minutes to 2 hours, about 5 minutes to 2 hours, about 10 minutes to 2 hours, about 30 minutes to 2 hours, about 1 to 2 hours, about 1 minute to 1.5 hours, about 1 minute to about 1.25 hours, about 1 minute to about 1 hour, about 1 minute to about 50 minutes, about 1 minute to about 45 minutes, about 1 minute to about 30 minutes. Optimal conditions can be determined by experimentation.
[0259] In certain embodiments, incubating can be performed at a temperature between about 15 to 45°C. The temperature can be maintained at a set temperature within the range of about 15 to 45°C for the entire duration, or the temperature can fluctuate within the range of about 15 to 45°C during the duration of the incubation period. For example, in certain embodiments the temperature can fluctuate within a range of about 15 to 45°C, about 18 to 45°C, about 20 to 45°C, about 25 to 45°C, about 30 to 45°C, about 15 to 40°C, about 15 to 35°C, about 15 to 30°C, about 18 to 40°C, or about 20 to 35°C during the incubation period. In certain embodiments the temperature can be maintained at a specific set point, such as about 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21 °C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31 °C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41 °C, 42°C, 43°C, 44°C, or 45°C for at least a portion of the incubation period, such as any of theAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) incubation periods described above. Optimal conditions can be determined by experimentation.
[0260] In certain embodiments, the tissue sample can be incubated with undiluted HER2-specific reagent.
[0261] In certain embodiments, the HER2-specific reagent is diluted. In a non-limiting example, the tissue sample can be incubated with HER2-specific reagent (e.g., anti-HER2 / ErbB2 D8F12 antibody or a bioequivalent thereof) at a dilution within a range of about 1 :2 to about 1 :10000, such as a dilution of about 1 :25 to about 1 :5000 or about 1 :2, about 1 :3, about 1 :4; about 1 :5, about 1 :10, about 1 :15, about 1 :20, about 1 :25, about 1 :50, about 1 :75, about 1 :100, about 1 :200; about 1 :500; about 1 :1000; about 1 :2000, about 1 :3000; about 1 :4000; about 1 :5000; about 1 :6000: about 1 :7000; about 1 :8000; about 1 :9000; or about 1 :10000, or any value within an interval between two of these dilutions. Optimal dilutions can be determined by experimentation. In a particular embodiment, the tissue sample can be incubated with HER2-specific reagent (e.g., anti-HER2 / ErbB2 D8F12 antibody or a bioequivalent thereof) at a dilution of about 1 :100. As used in context of a dilution of the HER2-specific reagent, the term “about” refers to ±10% of the stated value.
[0262] The HER2-specific reagent can be diluted in a solution comprising a diluent suitable for optimizing reagent concentration for immunohistochemistry. Non-limiting examples of diluents include buffers, such as Phosphate-buffered saline (PBS) Tris-buffered saline (TBS), TBS with Tween-20® (TBS-T), and commercially available proprietary solutions, e.g., Antibody Diluent ab64211 from Abeam®, VP Monet Blue diluent from Biocare Medical, DAKO diluent from Agilent, and SignalStain® Antibody Diluent from Cell Signaling Technology. In certain embodiments, the solution is buffered to maintain a specific pH. Optimal pH for a HER2-specific reagent can be determined by experimentation. In certain embodiments, the solution can further include protein stabilizers such as Bovine Serum Albumen, and / or a preservative such as sodium azide.
[0263] The extent of binding of the HER2-specific reagent to the sample can be determined using any one of the detection reagents discussed above. In a specific embodiment, the detection reagent is an enzyme-labeled antibody specific for the HER2-specific reagent. The enzymatic label can catalyze a chemical alteration of a chromogenic substrate. The enzyme-labeled antibody can include an oxidoreductase, a hydrolase, or a peroxidase. For example, the enzyme-labeled antibody can include a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, p-galactosidase, p-glucuronidase, or P-lactamase. In a specific embodiment, the enzyme-labeled antibody includes HRP or AP.
[0264] In certain embodiments, a method of the present disclosure can include contacting the tissue section that was incubated with the HER2-specific reagent with an HP-conjugated secondary antibody that binds the HER2-specific reagent. The duration of contact with theAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) HP-conjugated secondary antibody can be any period within the range of about 0.5 to 30 minutes. For example, the duration can be 0.5, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 minutes. Optimal durations can be determined by experimentation.
[0265] Selection of a chromogenic substrate will vary based on an enzyme-labeled antibody. Suitable substrates can be selected from DAB, pNPP, fast red, BCIP, NBT, BCIP / NBT, AP Orange, AP blue, TMB, ABTS, 4-CN, 4-Aminophenyl phosphate monosodium salt, Naphthol AS-BI-phosphate, ONPG, OPD, X-Gal, MU-Gal, PNP, X-Gluc, AEC, fuchsin, INT, tetrazolium blue, or tetrazolium violet. In a specific embodiment, the substrate comprises DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, or Naphthol AS-BI-phosphate.
[0266] In certain embodiments, the IHC staining is performed within a specific timeframe relative to when the tissue was sectioned and fixed and such timeframes include hours, days, weeks, or months within sectioning and fixing the tissue. In certain embodiments, the IHC staining is performed within about six months after sectioning and fixing the tissue. As used herein, “about” with respect to a time period refers to a variation of ±20% or a range that would be understood by a person of ordinary skill in the art as achieving substantially the same result.
[0267] In particular embodiments, IHC staining is performed within less than about 7 months, 6 months, 3 months, or 1 month after sectioning and fixing the tissue. For example, IHC staining can be performed on slides less than or equal to about 3 months postsectioning (e.g., less than or equal to about 2.5 months, about 2 months, about 1.5 months, about 5 weeks, about 4 weeks, about 3 weeks, about 2 weeks, about 12 days, about 11 days, about 10 days, about 9 days, about 8 days, about 7 days, about 6 days, about 5 days, about 4 days, about 3 days, about 2 days, about 20 hours, about 15 hours, about 10 hours, or within about 5 hours post-sectioning).
[0268] In certain embodiments, IHC staining is completed within about 72 hours of deparaffinization of a FFPE tissue sample.
[0269] In certain embodiments, IHC slide staining can be performed manually. In other embodiments, IHC slide staining can be performed by a combination of manual and automatic methods. In specific embodiments, IHC slide staining can be performed by a staining system such as an automated slide staining platform. Automated slide Stainers can include one or more reservoirs of the various reagents used in the staining protocols, reagent dispense unit(s) adapted for dispensing reagent to onto a slide, a waste removal system for removing used reagents and other waste from the slide, and a control system that coordinates the actions of the reagent dispense unit(s) and waste removal system. In addition to performing staining steps, an automated slide Stainer can perform steps ancillaryAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) to staining or be part of a system comprising one or more apparatus for slide baking (for adhering the sample to the slide), dewaxing (also referred to herein as deparaffinization), epitope retrieval, counterstaining, dehydration and clearing, and coverslipping.
[0270] Non-limiting examples of automated IHC slide Stainers include Labotronics automated IHC Stainers (Labotronics Scientific), Tissue-Tek Genie Advanced Staining System (SAKURA), Q-Stain X autostainer (NOVODIAX), AMOS IHC Stainer (AMOS Scientific), Epredia autostainers, intelliPATH (Biocare Medical) staining systems, WAVE (Celerus Diagnostics) systems, DAKO OMNIS and DAKO AUTOSTAINER LINK 48 (Agilent Technologies), BENCHMARK (Ventana Medical Systems, Inc.) systems, Leica BOND automated Stainers, and Lab Vision Autostainer (Thermo Scientific). Automated staining units can permit open individual slide staining, liquid overlay, or capillary gap staining (utilizing capillary forces draw up and keep liquid reagents in contact with the samples). In some cases, an automated IHC slide Stainer can include inkjet technology to deposit reagents on slides.
[0271] In certain embodiments, staining can include counterstaining (e.g., morphological staining). Counterstaining techniques can include staining nuclear structures with a first dye, and staining cytoplasmic structures with a second stain. Counterstains can include but are not limited to, hematoxylin and eosin (H&E) stain and Lee's Stain (Methylene Blue and Basic Fuchsin). Further examples of counterstains include chromogenic nuclear counterstains, such as Methylene blue, toluidine blue, nuclear fast red, and methyl green; non-nuclear chromogenic stains, such as eosin; fluorescent nuclear stains, including 4', 6-diamino-2-phenylindole, propidium iodide, Hoechst stain, nuclear green DCS1 , nuclear yellow, DRAQ5, DRAQ7; fluorescent non-nuclear stains, such as fluorophore-labelled phalloidin.
[0272] In a specific embodiment, at least one section of each HER2-stained slide is H&E stained. Any method of applying H&E stain may be used, including manual and automated methods. In an embodiment, at least one section of the sample is an H&E stained sampled stained on an automated staining system. Automated systems for performing H&E staining typically operate on one of two staining principles: batch staining or individual slide staining. Batch stainers can use vats or baths of reagents in which many slides are immersed at the same time. Individual slide stainers can apply reagent directly to each slide, with no two slides share the same aliquot of reagent.
[0273] In certain embodiments, the method further comprises counterstaining with hematoxylin for about 0.5 to 10 minutes and bluing for about 0.5 to 10 minutes. Optimal durations can be determined by experimentation.
[0274] An exemplary protocol, including pre-treatment and other steps is provided in the Experimental Embodiments of the Examples below. One of skill in the art can makeAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) adjustments to these conditions (for example, minor adjustments to times and / or temperatures of incubations, wash steps, etc.).
[0275] Tissue samples thus prepared can be mounted and coverslipped for evaluation. Evaluation can include determining staining intensity, e.g., the intensity of cellular membrane and / or cytomembrane staining produced by the detection reagent. Slide evaluation can include manual and / or automated analysis using light microscopy, virtual microscopy, whole slide imaging, an image-transmitting camera, an imaging sensor, a charge-coupled device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
[0276] A HER2 positive tumor cell can be identified by detecting membranous staining or cytomembranous staining. In certain embodiments, the staining of a HER2 positive tumor cell has an intensity that is greater than the staining intensity of a negative control, such as a HER2 negative cell line contacted with the reagent under substantially similar conditions. In a specific embodiment, the HER2 negative cell line sample comprises HL-60 or Farage cells, such as a FFPE pellet comprising HL-60 or Farage cells.
[0277] In certain embodiments, specifically stained regions of the tumor and / or HER2 positive tumor cells can be detected by computer-assisted image analysis or manual analysis of the tissue sample. In certain embodiments, specifically stained regions and / or HER2 positive tumor cells can be detected by computer-assisted image analysis of digital or digitized images. In certain embodiments, computer-assisted image analysis employs techniques such as image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample.
[0278] In certain embodiments, HER2 specific staining of the sample is detected using software that, when executed by a computer processor, performs automated quantitation of a region (per unit area) based on pixels (e.g., using AQUA, Visiopharm, HALO, or QuPath). The software can identify and measure the pixels that are stained allowing for the quantification of HER2 protein expression per unit area and / or analysis of the distribution of HER2 expression. In certain embodiments, the intensity of the staining in each pixel can be measured, and this information can be used to calculate the overall HER2 protein expression in the sample.
[0279] In certain embodiments, computer-assisted image analysis includes artificial intelligence / machine learning (AI / ML)-assisted image analysis, such as an artificial neural network, optionally a pre-trained neural network or a foundational model. As used herein, “a pre-trained neural network” refers to an Al model that has been trained on a large dataset for a specific task, which is then used as a starting point for training a new model for a similar, but potentially different, task (i.e., by a transfer learning process). As used herein, a “foundational model” refers to Al models pre-trained on vast, diverse datasets, capable ofAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) performing a wide range of tasks with fine-tuning, rather than being trained from scratch for specific application.
[0280] In certain embodiments, the level of HER2 protein expression detected can be objectively quantified. Hence, an IHC assay of the present disclosure can be a quantitative assay. Various systems for quantifying HER2 protein expression in a tissue sample are described in detail below.
[0281] In certain embodiments, the staining intensity can be rated by a slide reader on a numeric scale, such as a scale of 0-3 (for example, where 0 indicates no staining relative to background, 1 indicates weak staining, 2 indicates moderate staining, and 3 indicates strong staining). Hence, an IHC assay of the present disclosure can be a qualitative or semi-quantitative assay. A skilled person in the art of histochemical techniques, for example a skilled pathologist, is able to readily identify “weak”, “moderate” or “strong” staining, because such artisans apply these criteria within the scope of their everyday practice when evaluating IHC staining.
[0282] In certain embodiments, the sample can be considered positive or negative for HER2 expression in the presence of appropriately stained extrinsic or internal control. In certain embodiments, the intensity of the IHC staining can be evaluated for each HER2 positive cell of the tissue sample. In certain embodiments, the percentage of HER2 positive tumor cells in an area of the tissue sample can be determined. A HER2 positive tumor can include ate least about 1% HER2 positive tumor cells. As used herein, “about” when referring to a percentage of HER2-positive cells means within ±5 percentage points of the stated value. In certain embodiments, a HER2 positive tumor can include equal to or greater than about 1%, equal to or greater than about 10%, or equal to or greater than about 30% HER2 positive tumor cells within a specific area of the tissue sample, such as within the intertumoral region of a tissue section. In particular embodiments, a HER2 positive tumor can include equal to or greater than 1%, equal to or greater than 10%, or equal to or greater than 30% HER2 positive tumor cells within a specific area of the tissue sample, such as within the intertumoral region of a tissue section.
[0283] In certain embodiments, the intensity can be a statistical value based on the measurement of image objects (e.g., cells or region) generated from image analysis. For example, a statistical value for staining intensity can be a mean, median (2-quantile), minimum, maximum, or standard deviation of signal intensity of a subset of the image objects. One example of a subset of image objects can be the set of cells exhibiting membranes and / or cytomembranes that are completely HER2 stained.
[0284] The intensity and / or the percentage of HER2 positive cells can be used to determine an IHC score for the tissue sample. An IHC score can include an H-score, a percent positiveAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
[0285] As used herein, an “Allred score” refers to a score obtained by adding a proportion score (where 1 = 0 / 8 (negative), 2 = 1 / 8-2 / 8 (negative), 3 = 3 / 8-4 / 8 (weak), 4 = 5 / 8-6 / 8, 5 (moderate) = 7 / 8-8 / 8 (strong)) and an intensity score (0 = none, 1 = weak, 2 = intermediate, 3 = strong). The Allread score has an analytical range from 0 to 8. A “modified Allred score” can be derived from an Allred score using continuous tumor proportion scores (0-100), multiplied by an average intensity score (0 = none, 1 = weak, 2 = intermediate, 3 = strong), and have a range from 0-300.
[0286] As used herein, a “tumor proportion score” is a continuous proportion score from 0-100%, with staining of any intensity considered HER2-expression positive.
[0287] In a specific embodiment, the IHC score can be an H score, where the intensity of staining is multiplied by the percentage (P) of cells staining negative (0), weak (1+), moderate (2+), and strong (3+), according to the following formula:
[0288] H-score=0 x Po + 1 x Pi++ 2 x P2+ + 3 x Ps+.
[0289] The H-score has an analytical range from 0 to 300.
[0290] An IHC score can be determined using manual analysis, digital imaging analysis, computer-assisted image analysis, computer-assisted image analysis algorithm, an AI / ML-assisted image analysis, a fully automated analysis, and / or an end-to-end analysis.
[0291] In certain embodiments, an IHC score can be determined using manual scoring with digital image review and annotation (e.g., using ImageJ, an Al assist tool, such as AIM-HER2, other analysis / annotation tool within a whole-slide imaging platform).
[0292] In certain embodiments, counting and scoring the staining intensity of cells is performed manually. In certain embodiments, manual counting and scoring can include selecting a representative sample of the whole slide, such as 100 or more cells, 200 or more cells, or 300 or more cells, as an alternative to counting and scoring the whole slide.
[0293] In certain embodiments, scoring is performed automatically using automatic scoring methodologies. Non-limiting examples of automatic scoring methodologies include the average threshold method (ATM), Automated Quantitative Analysis (AQUA) score, Automatic H-score Quantification (AHSQ), HALO implementation of H-score (H-score (HALO)), pixelwise H-score (pix H-score), and AIM-HER2.
[0294] In certain embodiments, scoring is performed automatically using digital pathology image analysis tools, such as AlSight, QuPath, CellProfiler, HALO (Indica Labs), QuantCenter (MembraneQuant application) by 3DHISTECH Ltd., EndoNet, Image J / Fiji, InForm, Cell Profiler Analyst, llastik, Orbit, Cytomine, Icy, PathML, Image-Pro, HistoMetriX, MIPAR, Augmentiqs and Definiens Tissue Studio. In certain embodiments, scoring is performed using browser accessible and cloud-based digital pathology image analysis toolsAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) (e.g., through PathAI). In certain embodiments, scoring is performed automatically using a Whole Slide Imaging (WSI) platform with integrated analysis software. An WSI platform can include integrated software for automated digital slide creation, image management, viewing, and / or annotating, in addition to analysis software.
[0295] A method of the present disclosure can include identifying a tumor as being responsive to a HER2-directed therapy. The method can include performing a chromogenic immunohistochemistry (IHC) technique on a tissue section obtained from the tumor using a HER2-specific antibody as described above and characterizing the tumor as being responsive to the HER2-directed therapy if the intensity of chromogenic staining in the sample is greater than the intensity of staining in a HER2 negative control sample.
[0296] In certain embodiments, a method of the disclosure can be used to determine eligibility of a subject for treatment with a HER2-directed therapy. For example, a method of determining eligibility for HER2-directed therapy can include performing an immunohistochemistry (IHC) assay on a tissue section from a tumor of the subject using a monoclonal anti-HER2 / ErbB2 D8F12 antibody, or a bioequivalent thereof and calculating a IHC score. The IHC score can be calculated using any of the steps described above (e.g., evaluating stain intensity for each HER2-positive cell, calculating an average intensity for the HER2-positive cells, determining the percentage of HER2-positive cells in the tissue sample (e.g., based on a whole slide or a portion thereof), and determining the IHC score based on the average intensity and the percentage of HER2-positive cells). In certain embodiments, the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score, as described above. In a specific embodiment, the subject can be considered eligible for the treatment if the IHC score is above a predetermined threshold. Appropriate thresholds vary based on the scoring methodology. In certain embodiments, the threshold is set by the cytologist based on a calibration dataset, such as a dataset obtained from samples from responders to a HER2-directed therapy.
[0297] In certain embodiments, a subject can be considered eligible for treatment when the IHC score is a percent positive score that is about 1% or greater, about 5% or greater, about 10% or greater, about 15% or greater, about 20% or greater, about 30% or greater (e.g., when the pre-determined threshold is a percent positive score of at least about 1%, 5%, 10%, 15%, 20%, or 30%). As used in the context of a percent positive score, “about” refers to ±10% of the recited percentage value.
[0298] In certain embodiments, a subject can be considered eligible for treatment when the IHC score is a tumor proportion score that is about 1% or greater, about 5% or greater, about 10% or greater, about 20% or greater, about 30% or greater (e.g., when the predetermined threshold is a tumor proportion score of at least about 1%, 5%, 10%, 20%, orAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 30%). As used in the context of a tumor proportion score, “about” refers to ±10% of the recited percentage value.
[0299] In certain embodiments, a subject can be considered eligible for treatment when the IHC score is an intensity score of: weak (1), moderate (2), or strong (3) (e.g., when the predetermined threshold is an intensity score of at least 1 , 2, or 3).
[0300] In certain embodiments, a subject can be considered eligible for treatment when the IHC score is an Allred score of about 2 or higher, about 3 or higher, about 4 or higher (e.g., when the pre-determined threshold is an Allred score of at least about 2, 3, 4, 5, 6, or 7).
[0301] In certain embodiments, a subject can be considered eligible for treatment when the IHC score is an immunoreactivity score (HER2 index) of about 5% or higher, about 10% or higher, about 15% or higher, about 20% or higher, about 25% or higher, about 30% or higher, about 40% or higher, about 50% or higher (e.g., when the pre-determined threshold is a HER2 index of at least about 1%, 5%, 10%, 15%, 20%, 30%, 40%, or 50%). As used in the context of an immunoreactivity score or HER2 index, “about” refers to ±10% of the recited percentage value.
[0302] In certain embodiments, a subject can be considered eligible for treatment when the IHC score is an H-score of about 1 or higher, about 5 or higher, about 10 or higher, about 15 or higher, about 20 or higher, about 30 or higher, about 40 or higher, about 50 or higher, or about 60 or higher up to 300 (e.g., when the pre-determined threshold is an H-score of at least about 1 , 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, and so on). As used in the context of an H-score, “about” refers to ±10% of the recited percentage value.
[0303] In certain embodiments, a method of the present disclosure can further include determining whether the HER-2 / neu gene is amplified in the tumor sample. Measurement of gene amplification can be quantitative or qualitative. The number of gene copies can be used to assess the disease status. Detecting amplification can include obtaining an appropriate sample, e.g., a tissue sample from the surgically removed tumor, and measuring gene amplification directly by DNA analysis or by measuring gene expression based on the level of mRNA transcription. DNA analysis can include Southern blot or dot blot techniques employing use of a labeled DNA probe, such as a radiolabeled probe specific for the HER-2 / neu gene. mRNA transcription can be measured by a variety of techniques, including Northern blotting, dot blots, in situ hybridization (ISH), and next generation sequencing. ISH techniques include fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH) or silver-enhanced in situ hybridization (SISH), and dual-color methods thereof.
[0304] In certain embodiments, a method of the present disclosure further includes performing ISH by contacting the sample (e.g., a prepared slide) with a labeled probeAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) specifically hybridizable or specific for the HER-2 / neu gene (or an mRNA transcript thereof). The probe can be a fluorescently labeled probe. The sample can be pretreated, e.g., to remove materials that can interfere with uniform hybridization. The probe can be formulated in a suitable hybridization buffer. The sample and the probe can both be treated to denature double stranded nucleic acids, e.g., by heating. The probe and the sample can be combined under conditions for sufficient time to permit hybridization to occur and the sample can be washed to remove excess probe. Detection of the specifically labeled HER-2 / neu gene (or mRNA) can be performed using standard techniques.
[0305] In certain embodiments, a subject can be considered eligible for treatment if the IHC percent positive score is about 1% or greater, the tumor proportion score is about 1% or greater, the intensity score is weak (1), moderate (2), or strong (3), and / or the H-score is about 1 or higher, and the ISH result is negative.
[0306] In certain embodiments, a method of the present disclosure can include one or more treatment steps. For example, where a tumor has been identified as being responsive to the HER2-directed therapy (e.g., HER2 protein expression is detected in a subject’s tumor tissue), any method as described above can include providing or administering one or more doses of an appropriate active pharmaceutical ingredient to the subject. In certain embodiments, the method can include providing or administering one or more therapeutic agents of a HER2-directed therapy to the subject. A HER2-directed therapy can include a HER2-targeting antibody, or a drug conjugate thereof, or a radiolabeled conjugate thereof. The one or more doses can be provided in unit dosage forms.
[0307] In certain embodiments, where HER2 protein expression is detected in a subject’s tumor tissue, any method as described above can include providing or administering one or more doses of trastuzumab, transtuzumab, trastuzumab emtansine, ado-trastuzumab emtansine (TM1), trastuzumab deruxtecan (T-DXd), pertuzumab, margetuximab, zanidatamab, ertumaxomab, neratinib, tucatinib, pyrotinib, or lapatinib, or a bioequivalent or biosimilar thereof, or a radiolabeled conjugate thereof, formulated for administration to the subject.
[0308] In certain embodiments, where HER2 protein expression is detected in a subject’s tumor tissue, any method as described above can include providing or administering one or more doses of an antibody-drug conjugate (ADC). An ADC can include a therapeutic anti-HER2 antibody and a drug payload. An antibody of an ADC can include trastuzumab, transtuzumab, disitamab, or a biosimilar thereof. As used herein, “biosimilar” refers to version of a biologic that is highly similar to an FDA-approved reference product. A biosimilar can be made from the same type of source as the reference product, such as living cells or microorganisms, and can work the same way as the reference product, be administered via the same route (e.g., as a subcutaneous injection or an intravenous infusion), and can haveAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) the same strength and dosage as the reference product. A drug of an ADC can include a topoisomerase inhibitor (e.g., Dxd), maytansine (DM1), tubulysin, an auristatin (e.g., monomethylauristatin E (MMAE)), Duocarmycin (DUBA), and a TLR7 / 8 agonist, for example. An ADC can include a linkage formed by a hetero-bifunctional crosslinker that contain N-hydroxysuccinimide (NHS) ester and maleimide conjugating the antibody to the drug, such as Lysine-SMCC. Other linkages can include a cysteine-maleimide, site-specific lysine, and a hydroxylamine-PEG4 linkage. The linkage can be a cleavable linkage or a noncleavable linkage. In certain embodiments, an ADC for HER2-directed therapy can include trastuzumab emtansine, ado-trastuzumab emtansine (TM1), trastuzumab deruxtecan (T-DXd), and disitamab vedotin. Examples of ADCs under investigation include SYD985, MRG002, ARX788, BDC-1001, A166, FS-1502, SHR-A1201, DP303c, BI-CON-02, ALT-P7, DX126-262, HS630, B003, SBT6050, SHR-A1811 , MT-5111 , and GQ1001 .
[0309] In certain embodiments, where HER2 protein expression is detected in a subject’s tumor tissue, any method as described above can include providing or administering one or more unit dosages of a HER2-targeting radiotherapeutic formulated for administration to the subject. For example, a HER2-targeting radiotherapeutic can include at least one of67Cu,186Re,188Re,90Y,177Lu,161Tb,153Sm,213Bi,1311,149Tb,47Sc,225Ac,212Pb,211At,223Ra,227Th, and226Th, such as90Y,177Lu,1311,225Ac,211At, or227Th. In specific embodiments, the HER2-targeting radiotherapeutic can include225Ac or177Lu. In an embodiment, the HER2-targeting radiotherapeutic is a radioligand therapy, and the radioligand therapy includes at least one of67Cu,186Re,188Re,90Y,177Lu,161Tb,153Sm,213Bi,1311,149Tb,47Sc,225Ac,212Pb,211At,223Ra,227Th, and226Th, such as90Y,177Lu,1311,225Ac,211At, or227Th. In specific embodiments, the radioligand therapy can include225Ac or177Lu.
[0310] Thus, methods of the present disclosure include treating a tumor expressing a human epidermal growth factor receptor-2 (HER2) protein in a subject in need thereof, comprising identifying the subject by detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a potential subject; wherein HER2 positive tumor cells are detected by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein, wherein the reagent lacks cross-reactivity with any other epidermal growth factor (EGF) family member of tyrosine kinase receptors (TKRs), as described above; wherein the HER2 positive tumor cell exhibits specific staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions; and administering a therapeutically effective dose of a HER2-directed therapy to the subject. Detecting HER2 positive tumor cells can include any IHC technique that includes exposing the tissue sample to a HER2-specific reagent for a sufficient period of time and under suitable conditions such that the reagent binds to HER2-antigen in the tissue sample.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, detecting HER2 positive tumor cells further includes one or more steps for performing an IHC assay described above. In specific embodiments, the method can further include at least one step selected from obtaining a tissue sample from a tumor of a subject, fixing the tissue sample, embedding the tissue sample, sectioning the tissue sample to a desired thickness, attaching the tissue sample or section thereof to a slide, deparaffinizing an embedded tissue sample, retrieving a HER2-epitope (antigen) in the tissue sample, performing a blocking step, contacting the tissue section that was incubated with the HER2-specific reagent with an enzyme-conjugated secondary antibody that binds the HER2-specific reagent, adding a chromogenic substrate to the tissue sample, counterstaining the tissue sample, evaluating staining intensity, e.g., the intensity of cellular membrane and / or cytomembrane staining produced by the detection reagent, determining a percentage of HER2 positive tumor cells, and determining an IHC score.
[0311] In specific examples, the method can further include at least the steps of contacting the tissue section that was incubated with the HER2-specific reagent with an enzyme-conjugated secondary antibody that binds the HER2-specific reagent and adding a chromogenic substrate to the tissue sample. In specific embodiments, the method can further include contacting the tissue section that was incubated with the HER2-specific reagent with an enzyme-conjugated secondary antibody that binds the HER2-specific reagent and adding a chromogenic substrate to the tissue sample, and at least one or more of evaluating staining intensity, e.g., the intensity of cellular membrane and / or cytomembrane staining produced by the detection reagent, determining a percentage of HER2 positive tumor cells, and determining an IHC score.
[0312] In specific embodiments, one or more of the steps above for detecting HER2 positive tumor cells can be performed using an automated slide staining platform, as discussed above (e.g., an intelliPATH (Biocare Medical), WAVE (Celerus Diagnostics), DAKO OMNIS and DAKO AUTOSTAINER LINK 48 (Agilent Technologies), BENCHMARK (Ventana Medical Systems, Inc.), Leica BOND, or Lab Vision Autostainer (Thermo Scientific) automated slide Stainer, Labotronics automated IHC Stainers (Labotronics Scientific), Tissue-Tek Genie Advanced Staining System (SAKURA), Q-Stain X autostainer (NOVODIAX), AMOS IHC Stainer (AMOS Scientific), and Peridia autostainers).
[0313] In specific embodiments, one or more of the steps above for detecting HER2 positive tumor cells can include the use of light microscopy, virtual microscopy, whole slide imaging, an image-transmitting camera, an imaging sensor, a charge-coupled device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner. Detecting HER2 positive tumor cells can include identifying tumor cells and then identifying HER2-specifically stained tumor cells, followed by scoring the intensity of HER2-specifically stained tumor cells and / or scoring the intensity of the tumor, or a region thereof (e.g.,Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) regional analysis). In certain embodiments, detecting HER2 positive tumor cells can include identifying subpopulations of tumor cells with varying HER2 protein expression. In certain embodiments, identifying tumor cells can include determining the leading edge of an invasive margin of a tumor, an edge denoting a transition from tumor core to invasive margin, or an edge denoting a center of the invasive margin.
[0314] HER2 specific staining can be detected by computer-assisted image analysis or manual analysis of the tissue sample. In certain embodiments, HER2 positive tumor regions and / or HER2 positive tumor cells can be detected by analyzing a digitized image or digital image. The digitized image or digital image can be processed using computer-assisted image analysis techniques such as image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample. In certain embodiments, computer-assisted image analysis includes artificial intelligence / machine learning (AI / ML)-assisted image analysis, such as an artificial neural network, optionally a pre-trained neural network or a foundational model.
[0315] In particular embodiments, a method of the present disclosure can include identifying a tumor as being responsive to a HER2-directed therapy by performing a chromogenic immunohistochemistry (IHC) technique on a tissue section obtained from the tumor using a HER2-specific antibody, as described above, and characterizing the tumor as being responsive to the HER2-directed therapy if the intensity of chromogenic staining in the sample is greater than the intensity of staining in a HER2 negative control sample.
[0316] In certain embodiments, a method of the present disclosure can be a therapeutic method. For example, after a tumor has been identified as being responsive to the HER2-directed therapy (e.g., HER2 protein expression is detected in a subject’s tumor tissue) using the techniques described above, a method of the present disclosure can include providing or administering one or more doses of an appropriate active pharmaceutical ingredient to the subject. In certain embodiments, the method can include providing or administering one or more therapeutic agents of a HER2-directed therapy to the subject. A HER2-directed therapy can include a HER2-targeting antibody, or a drug conjugate thereof, or a radiolabeled conjugate thereof. The one or more doses can be provided in unit dosage forms.
[0317] DETECTION KITS
[0318] The present disclosure describes detection kits comprising a HER2-specific reagent packaged together with one or more reagents for IHC staining, morphological staining, and / or counterstaining, and assay controls described above.
[0319] In certain embodiments, a kit of the present disclosure allows for detection and / or quantification of HER2 protein expression, where the results of detection and / orAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) quantification can be used to predict the response to HER2-targeted therapies. In certain embodiments, the results of IHC staining with the disclosed kits can be used by medical professionals to determine a course of treatment.
[0320] In certain embodiments, the kit includes a primary antibody. The primary antibody can be packaged in a container comprising an IHC buffer. In some embodiments, the primary antibody is a HER2-specific reagent (e.g., the primary antibody specifically binds an epitope within a domain of the HER2 protein targeted by a HER2-directed therapy, a primary antibody that specifically binds an epitope within domain I, II, III, or IV of the HER2 protein, a primary antibody that specifically binds an epitope within domain I of the HER2 protein, such as within the first 100 amino acids residues of the HER2 protein N-terminus, a primary antibody that specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein ECD domain I, or binds amino acid residues 38 to 44 of the N-terminus of the HER2 protein, a primary antibody that specifically binds an aa sequence comprising the sequence SPETHLD (SEQ ID NO: 1) or an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1 , such as at least 3, 4, 5, or 6 consecutive amino acid residues of SEQ ID NO: 1). In certain embodiments, the primary antibody is one that was produced by immunizing animals with a synthetic peptide corresponding to residues near the N-terminus of a HER2 protein, such as domain I of the ECD. In a specific embodiment, the primary antibody can be a monoclonal anti-HER2 / ErbB2 D8F12 antibody, such as a rabbit monoclonal anti-HER2 / ErbB2 D8F12 antibody, sold by Cell Signaling Technology, Inc. under the trade name HER2 / ErbB2 (D8F12) XP® Rabbit mAb #4290.
[0321] In certain embodiments, a kit of the present disclosure includes a panel of control cell pellets, and instructions for preparing formalin-fixed, paraffin-embedded (FFPE) block. The panel can include cell pellets of one or more of SK-BR-3, BT-474, MDA-MB-361 , MDA-MB-453, T47D, MCF7, MDA-MB-231 , SW-480, and BT-549, as a positive control, and cell pellets of one or more of AU565, HCC1954, HCC38, BT20, HCC70, MDA-MB-436, HL-60 and Farage cell lines, as a negative control. In a particular embodiment, the negative control cell pellets include HL-60 or Farage cell lines. In certain embodiments, a kit of the present disclosure includes a panel of FFPE blocks of control cells pellets.
[0322] In certain embodiments, the kit further comprises one or more detection reagents or detection kits. In some embodiments, the kit further comprises a labeling conjugate specific to the primary antibody. In some embodiments, the kit further comprises substrates or signaling conjugates. The labeling conjugates, signaling conjugates, and / or substrates can include any of those enumerated herein or otherwise known to those of skill in the art. In some embodiments, the kit further comprises one or more enzyme inactivation compositions specific to the enzymes of the labeling conjugates. Detection kits can include secondary antibodies conjugated to enzymes, including HRP and AP, biotinylated anti-speciesAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) secondary antibodies and streptavidin-conjugated enzymes, an anti-species secondary antibody conjugated to a hapten and an anti-hapten tertiary antibody conjugated to an enzyme multimer, unconjugated secondary antibodies, or an anti-species secondary antibody conjugated to a hapten, an anti-hapten tertiary antibody conjugated to an enzyme multimer, and a tyramide conjugated to the same hapten. A detection kit can be selected for use with an automated IHC platform.
[0323] A kit of the present disclosure can include reagents for automated IHC. A reagent for automated IHC can be formulated for stability. For example, a reagent for automated IHC can be sufficiently stable in a container so that can be shipped to clinicians who can then store and use the reagents over a significant period of time. In certain embodiments, a reagent formulated for automated IHC can exhibit significant room temperature stability. A reagent formulated for stability can include formulations to provide a shelf-life equal to or greater than 1 -month, 3-months, 6-months, 12-months, 18-months, 24-months, or greater. In certain embodiment reagent containers of a kit of the present disclosure includes a label or insert specifying storage conditions. Absolute stability is not required. Rather, sufficiently stable can refer to a formulation in which a substantial amount of the reagent remains after an established amount of time so that the use of the reagent in a method of the present disclosure is not adversely affected by the decomposition of the reagent.
[0324] In certain embodiments, a kit of the present disclosure can include instructions for detection of HER2 protein expression and / or instructions or protocols for scoring. In certain embodiments, the instructions include guidance for assessing the intensity of the IHC staining for each HER2 positive cell, determining a percentage of HER2 positive tumor cells in an area of the tissue sample and utilizing the intensity and / or percentage to determine an IHC score.
[0325] In certain embodiments, the instructions include protocols for determining an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
[0326] In certain embodiments, the instructions can include protocols for determining the IHC score by manual analysis, digital imaging analysis, computer-assisted image analysis, an AI / ML-assisted image analysis, fully automated analysis, and / or an end-to-end analysis.
[0327] In certain embodiments, a kit of the present disclosure can include instructions for predicting the outcome of a therapy based on the presence of a HER2 protein expression in a cell or region of the tumor. For example, kit instructions can include methods for assessing the likelihood that a subject will respond to a HER2-directed therapy based on a stain intensity (e.g., membranous staining or cytomembranous staining intensity), the percentage of stained cells in a tissue sample, or based on an IHC score.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, a kit can include instructions for determining HER2 specific staining intensity using light microscopy, virtual microscopy, whole slide imaging, an imagetransmitting camera, imaging sensor, a charge-coupled device (CCD), a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner. In certain embodiments, a kit can include instructions for detecting HER2 positive tumor cells using computer-assisted image analysis or manual analysis of the tissue sample. In certain embodiments, instructions can include protocols or techniques for image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample using computer-assisted image analysis. In certain embodiments, instructions can include protocols or techniques for the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis. For example, the instructions can include protocols and techniques for image analysis using an artificial neural network. In a specific embodiment, the instructions can include protocols for training a neural network for image analysis of the tissue sample using an artificial neural network. In certain embodiments, the instructions include deep-learning techniques to train an end-to-end model to map raw inputs to desired outputs using a large amount of labeled data.
[0328] In certain embodiments, a kit of the present disclosure can be utilized in an in vitro method of identifying a HER2 protein expressing tumor. For example, a kit can include materials and instructions for detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a subject, by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein, which reagent lacks cross-reactivity with any other EGF family member of TKRs, as described above. In specific embodiments, the instructions can include protocols for detecting and / or analyzing membrane and / or cytomembrane staining intensity, and comparing the intensity to the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions, thereby identifying the tumor as the HER2 protein expressing tumor.
[0329] In certain embodiments, a kit of the present disclosure can be utilized for characterizing responsiveness of a tumor to a HER2-directed therapy. The kit can include (a) a reagent that specifically binds an epitope of a HER2 protein, wherein the reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors, as described above; (b) a HER2 negative cell line, as described above; and (c) a set of instructions for: (i) using the reagent for IHC staining on a tumor tissue sample obtained from a tumor of a potential subject, and (ii) characterizing the tumor as being responsive to the HER2-directed therapy when the HER2-positive tumor cell exhibits membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions. In specific embodiments, the set of instructions further comprises instructions forAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) preparing the tissue sample, preparing the negative control (e.g., using HL-60 or Farage cells), preparing a positive control, determining the membranous staining and / or cytomembranous staining intensity, determining a percentage of HER2 positive tumor cells, and / or determining an IHC score. In specific embodiments, the kit can further include (d) at least one enzyme-labeled antibody that binds to the reagent of component (a), and (e) at least one chromogenic substrate of the at least one enzyme-labeled antibody. In specific embodiments, the kit can include at least one counterstain (e.g., hematoxylin, or the like as described above).
[0330] In certain embodiments, a kit of the present disclosure can be utilized in an in vitro method for determining eligibility of a subject for treatment with a HER2-directed therapy. The kit can include materials for performing an immunohistochemistry (IHC) assay on a tissue section from a tumor of the subject using a monoclonal anti-HER2 / ErbB2 D8F12 antibody, or bioequivalent thereof; calculating a IHC score; and (c)(1) determining the subject is eligible for the treatment when the IHC score is greater than or equal to a predetermined threshold for the tissue section, or (c)(2) determining the subject is ineligible for the treatment when the IHC score is less than the pre-determined threshold for the tissue section. The kit can include a set of instructions including instructions for determining an IHC score (e.g., an H-score, an Allred score, a modified Allred score, a percent positive score, a tumor proportion score, an intensity score, a Quick score, or an Immunoreactivity score). In a specific embodiment, the instructions can include protocols for determining an H-score. One non-limiting example of such instructions can be found in the experimental embodiments of the Example section, below.
[0331] In certain embodiments, a kit for determining eligibility of a subject for treatment with a HER2-directed therapy can include a monoclonal anti-HER2 / ErbB2 D8F12 antibody or bioequivalent thereof in an immunochemistry (IHC) buffer; at least one HER2 negative cell line, as described above; and a set of instructions for performing an immunohistochemistry (IHC) assay on a tissue section from a tumor of the subject and determining the eligibility of the subject based on membranous staining or cytomembranous staining intensity, wherein a HER2 positive tumor cell exhibits greater membrane and / or cytomembrane staining intensity than a HER2 negative cell line contacted with the monoclonal anti-HER2 / ErbB2 D8F12 antibody under substantially similar conditions.
[0332] In certain embodiments, the set of instructions includes instructions for preparing the tissue section, preparing the HER2 negative cell line (e.g., HL-60 or Farage cells), preparing a positive control, determining the intensity of the stained cells, determining a percentage of stained cells, and / or determining an IHC score.
[0333] In certain embodiments, the kit further includes an enzyme-labeled antibody that binds to the monoclonal anti-HER2 / ErbB2 D8F12 antibody or the bioequivalent thereof, andAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) a chromogenic substrate of the at least one enzyme-labeled antibody, such as a chromogenic substrate described above. In a specific example, the enzyme-labeled antibody includes horseradish peroxidase (HRP) or alkaline phosphatase (AP) and the chromogenic substrate includes 3,3’-diamino-benzidine (DAB), para-Nitrophenylphosphate (pNPP), 5-Bromo-4-chloro-3-indolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate. In certain embodiments, the kit further includes a counterstain (e.g., hematoxylin and / or bluing).
[0334] In certain embodiments, a kit of the present disclosure can be utilized to identify a tumor as being responsive to a HER2-directed therapy. The kit can include one or more reagents for performing a chromogenic immunohistochemistry (IHC) technique on a tissue section obtained from the tumor using a HER2-specific antibody, as described above, and a set of instructions for characterizing the tumor as being responsive to the HER2-directed therapy if the intensity of chromogenic staining in the sample is greater than background the intensity of chromogenic staining in a HER2-negative control sample. In a specific embodiment, the HER2-specific antibody specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1 . In a specific embodiment, the HER2-specific antibody can be a monoclonal anti-HER2 / ErbB2 D8F12 antibody or bioequivalent thereof.
[0335] In certain embodiments, a kit of the present disclosure can include other reagents or materials, e.g., buffers, blocking agents, microscope coverslips, etc., for performing an IHC assay.
[0336] TREATMENT KITS
[0337] In certain embodiments, a detection kit as described above can further
[0338] include instructions for the administration of appropriate active pharmaceutical ingredients based on results of an IHC assay of the present disclosure. In some embodiments, the kits can include one or more therapeutic agents of a HER2-directed therapy. For example, a kit of the present disclosure can include one or more unit dosages of a HER2-targeting antibody, or a drug conjugate thereof, or a radiolabeled conjugate thereof, and instructions for administering the HER2-targeting antibody, or a drug conjugate thereof, or a radiolabeled conjugate thereof to the subject.
[0339] In certain embodiments, a kit can include one or more unit doses of trastuzumab, transtuzumab, trastuzumab emtansine, ado-trastuzumab emtansine (TM1), trastuzumab deruxtecan (T-DXd), pertuzumab, margetuximab, zanidatamab, ertumaxomab, neratinib, tucatinib, pyrotinib, or lapatinib, or a bioequivalent or biosimilar thereof, or a radiolabeled conjugate thereof, formulated for administration to the subject.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, a kit can include one or more unit dosages an antibody-drug conjugate (ADC). An ADC can include an anti-HER2 antibody and a drug payload. An antibody of an ADC can include Trastuzumab, Transtuzumab, Disitamab, or a biosimilar thereof. A drug of an ADC can include a topoisomerase inhibitor (e.g., Dxd), maytansine (DM1), tubulysin, an auristatin (e.g., monomethylauristatin E (MMAE)), Duocarmycin (DUBA), and a TLR7 / 8 agonist, for example. An ADC can include a linkage formed by a hetero-bifunctional crosslinker that contain N-hydroxysuccinimide (NHS) ester and maleimide conjugating the antibody to the drug, such as Lysine-SMCC. Other linkages can include a cysteine-maleimide, site-specific lysine, and a hydroxylamine-PEG4 linkage. The linkage can be a cleavable linkage or a noncleavable linkage. In certain embodiments, an ADC for HER2-directed therapy can include trastuzumab emtansine, ado-trastuzumab emtansine (TM1), trastuzumab deruxtecan (T-DXd), and disitamab vedotin. Examples of ADCs under investigation include SYD985, MRG002, ARX788, BDC-1001, A166, FS-1502, SHR-A1201, DP303C, BI-CON-02, ALT-P7, DX126-262, HS630, B003, SBT6050, SHR-A1811, MT-5111, and GQ1001.
[0340] In certain embodiments, a kit can include one or more unit dosages a HER2-targeting radiotherapeutic formulated for administration to the subject. For example, a HER2-targeting radiotherapeutic can include at least one of67Cu,186Re,188Re,90Y,177Lu,161Tb,153Sm,213Bi,1311,149Tb,47Sc,225Ac,212Pb,211At,223Ra,227Th, and226Th, such as90Y,177Lu,1311,225Ac,211At, or227Th. In specific embodiments, the HER2-targeting radiotherapeutic can include225Ac or177Lu. In an embodiment, the HER2-targeting radiotherapeutic is a radioligand therapy. The radioligand therapy can include at least one of67Cu,186Re,188Re,90Y,177Lu,161Tb,153Sm,213Bi,1311,149Tb,47Sc,225Ac,212Pb,211At,223Ra,227Th, and226Th, such as90Y,177Lu,1311,225Ac,211At, or227Th. In specific embodiments, the radioligand therapy can include225Ac or177Lu.
[0341] In certain embodiments, the HER2-targeting radiotherapeutic is selected from a HER2-targeting radiotherapeutic disclosed in U.S. Pre-Grant Publication No.
[0342] US20250332300A1 , published October 30, 2025, which is hereby incorporated by reference in its entirety. In a particular embodiment, the HER2-targeting radiotherapeutic is selected from Example J1 and Example J2 disclosed in US20250332300A1 . In another embodiment, the HER2-targeting radiotherapeutic is Example J1 disclosed in US20250332300A1 . In yet another embodiment, the HER2-targeting radiotherapeutic is Example J2 disclosed in US20250332300A1 . In a particular embodiment, the HER2-targeting radiotherapeutic is selected from Example H1 and Example H2 disclosed in US20250332300A1. In a more particular embodiment, the HER2-targeting radiotherapeutic is Example H1 disclosed in US20250332300A1 . In yet another embodiment, the HER2-targeting radiotherapeutic is Example H2 disclosed in US20250332300A1.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In another embodiment, the HER2-targeting radiotherapeutic is a radiolabeled affibody-based HER2 targeting agent such as177Lu-ABY-271 (Pharmaceutics. 2021 Jun 7;13(6):839. doi: 10.3390 / pharmaceutics13060839. PMID: 34200197; PMCID:
[0343] PMC8226825).
[0344] In certain embodiments, a kit of the present disclosure can be utilized by a clinician treating a tumor expressing HER2 protein in a subject in need thereof.
[0345] SYSTEMS FOR DETECTING HER2 PROTEIN EXPRESSION
[0346] Embodiments of the present disclosure further include systems for implementing one or more of the methods described above. In certain embodiments of the methods above, following IHC staining, digital images of the tissue sample can be acquired using a microscope or by a computer-aided imaging system. An imaging system can include a light or fluorescence microscope, an image-transmitting camera, imaging sensor, a charge-coupled device (CCD), a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner. An image acquisition system can include a view screen.
[0347] In a specific embodiment, an image acquisition system can include a scanning platform such as a slide scanner. The scanner can be configured or adapted to scan stained slides at 20x, 40x, or other magnifications to produce high resolution whole-slide digital images. An image acquisition system can include a slide scanner that includes a microscope with lens objectives, a light source (such as halogen, light emitting diode, white light, and / or multispectral light sources, depending on the dye), and one or more digital cameras for image capture.
[0348] A slide scanner can further include robotics to move glass slides around (or to move the optics around the slide), and a computer and associated software to control the robotics and to manipulate, manage, and view digital slides.
[0349] A slide scanner can capture digital data at a number of different X-Y locations and optionally at multiple Z planes on the slide using a charge-coupled device (CCD). The acquired images can be joined together to form a composite image of the entire scanned surface. Methods to form a composite image are known in the art. For example, forming a composite image can include moving the slide stage or the optics in very small increments to capture square image frames, which overlap adjacent squares to a slight degree. The captured squares can be automatically matched to one another to build the composite image. Forming a composite image can include moving the slide stage in a single axis during acquisition to capture a number of composite image “strips.” The image strips can then be matched with one another to form the larger composite image.
[0350] In certain embodiments, a suitable slide scanner can be a fluorescent or brightfield whole slide scanner. Non-limiting examples of commercially available slide scanners includeAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 3DHistech PANNORAMIC SCAN II; DigiPath PATHSCOPE; Hamamatsu NANOZOOMER RS, HT, and XR; Huron TISSUESCOPE 4000, 4000XT, and HS; Leica SCANSCOPE AT, AT2, CS, FL, and SCN400; Mikroscan D2; Olympus VS120-SL; Omnyx VL4, and VL120; PerkinElmer LAMINA; Philips ULTRA-FAST SCANNER; Sakura Finetek VISIONTEK; Unic PRECICE 500, and PRECICE 600x; VENTANA ISCAN COREO and ISCAN HT; and Zeiss AXIO SCAN.Z1.
[0351] Images acquired or generated by the scanning platform can be transferred to an image analysis system or to a server or database accessible by image analysis system. In certain embodiments, the digital images can be transferred to the image analysis system automatically via one or more local-area networks and / or wide-area networks. In some embodiments, image analysis system can be integrated with or included in scanning platform and / or other modules of an image acquisition system. In certain embodiments, an image can be transferred to image analysis system through a memory accessible by both the scanning platform and the image analysis system. In certain embodiments, the image acquisition system is not communicatively coupled to image analysis system, in which case the images can be stored on a non-volatile (AKA non-transitory) storage medium of any type (e.g., a flash drive, or other medium on which the data stored remains accessible and intact, even after the computer or device is powered down). Stored images can be downloaded from the medium to the image analysis system or to a server or database communicatively coupled thereto.
[0352] An automatic image analysis system of the present disclosure can be configured to obtain an image of a tissue sample as described above. The tissue sample can be a sample that is affixed to a slide and stained by manual methods described above or by an automatic IHC staining platform, as described above. The slide can be imaged using a slide scanner or another type of scanning platform, as discussed above.
[0353] The acquired digital image can be analyzed using an image analysis system. An image analysis system of the present disclosure can include a computer processor that can be used to direct the operation of the system and a memory to store and manipulate the information collected. The computer processor can include one or more computing devices such as desktop computers, laptop computers, tablets, smartphones, servers, applicationspecific computing devices, or any other type(s) of electronic device(s) capable of performing the techniques and operations described herein. In some embodiments, the image analysis system can be implemented as a single device. In other embodiments, the image analysis system can be implemented as a combination of two or more devices together achieving the various functionalities discussed herein. For example, the image analysis system can include one or more server computers and one or more clientAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) computers communicatively coupled to each other via one or more local-area networks and / or wide-area networks such as the Internet.
[0354] In certain embodiments, an image analysis system of the present disclosure can include a memory, a processor, and a display. The system memory can include any combination of any type of volatile or non-volatile memories, such as random-access memories (RAMs), read-only memories such as an Electrically-Erasable Programmable Read-Only Memory (EEPROM), flash memories, hard drives, solid state drives, optical discs, and the like, and memory can be housed in a single device or be distributed across two or more devices. The system processor can include one or more processors of any type, such as central processing units (CPUs), graphics processing units (GPUs), special-purpose signal or image processors, field-programmable gate arrays (FPGAs), tensor processing units (TPUs), and so forth. The system display can include any suitable technology, such as LCD, LED, OLED, TFT, Plasma, etc., and can be a touch-sensitive display (a touchscreen).
[0355] An image analysis system of the present disclosure can further include an object identifier, a region of interest ( ROI) generator, a user-interface module, and a scoring engine. The object identifier, ROI generator, user-interface module, and scoring engine can be standalone modules, and two or more modules can be combined into a single module. An image analysis system of the present disclosure can further include input devices, and networking and communication modules.
[0356] The functionality of some or all modules can be implemented in hardware, software, firmware, or as any combination thereof. An image analysis system of the present disclosure can include commercially-available software packages. Non-limiting examples of software packages that can be useful in an image analysis system can include VENTANA VIRTUOSO; Definiens TISSUE STUDIO, DEVELOPER XD, and IMAGE MINER; HALO, Image J / Fiji, QuPath, InForm, Cell Profiler, Cell Profiler Analyst, llastik, Orbit, Cytomine, Icy, PathML, Image-Pro, HistoMetriX, MIPAR, Augmentiqs and Visopharm BIOTOPIX, ONCOTOPIX, and STEREOTOPIX software packages.
[0357] After acquiring the digital image, an image analysis system can be configured to pass the image to an object identifier that functions to identify and mark relevant objects and other features within the image that will be used for scoring. The object identifier can extract from (or generate for) each image a plurality of image features characterizing the various objects in the image as a well as pixels representing expression of a HER2 protein. The extracted image features may include pixel intensities, shapes, patterns, and macro features. The values of the plurality of image features may be combined into a high-dimensional vector, hereinafter referred to as the “feature vector” characterizing the expression of a HER2 protein. The output of object identifier is effectively a map of the image annotating the position of objects and pixels of interest and associating those objects and pixels with aAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) feature vector describing the object or pixels. For example, if M features are extracted for each object and / or pixel, each object and / or pixel can be characterized by an M-dimensional feature vector.
[0358] A HER2 protein can be scored on the basis of its association with a particular type of object (such as cells, tumor cells, membranes and / or cytomembranes, etc.), the features extracted by object identifier can include features or feature vectors sufficient to categorize the objects in the sample as HER2-positive objects of interest or HER2-negative markers of interest and / or by level or intensity of HER2 staining of the object. In cases where extent of HER2-expression is scored regardless of association with objects, the features extracted by object identifier can include for example location and / or intensity of HER2-positive pixels. The precise features extracted from the image can vary depending on the type of classification function being applied, and would be well-known to a person of ordinary skill in the art.
[0359] The image analysis system can be configured to pass the image to an ROI generator. An ROI generator can be used to identify an ROI or ROIs of the image from which further information will be extracted. In cases where the object identifier is not applied to the whole image, the ROI or ROIs generated by the ROI generator can be used to define a subset of the image on which object identifier is executed. In certain embodiments, an ROI generator can be accessed through a user-interface module.
[0360] An image of the IHC-stained sample (or a morphologically-stained serial section of the IHC-stained sample) can be displayed on a graphic user interface of the user interface module. In some embodiments, a user can annotate one or more regions in the image as ROIs. ROI annotation can be manually defined (“manual ROI annotation”) or the ROI generator can assist the user in annotating the ROI (“semi-automated ROI annotation”). In semi-automated ROI annotation, a user can delineate one or more regions on the digital image, which the system can automatically transforms the delineated region(s) into a complete ROI. In certain embodiments, the system can identify similar morphological regions by, for example, using computer vision and machine learning. In certain embodiments, a user can annotate an edge in the image such as, for example, a leading edge of an invasive margin of a tumor, an edge denoting a transition from tumor core to invasive margin, or an edge denoting a center of the invasive margin, and the ROI generator can automatically define an ROI based on the user-defined edge. Regions of the ROI or objects within the ROI can be annotated for exclusion from analysis, etc.
[0361] In certain embodiments, an ROI generator can be configured to automatically suggest an ROI without any direct input from a user (for example, by applying a tissue segmentation function to an unannotated image), and the system can permit the user to accept, reject, or edit the suggested ROI. In certain embodiments, the system can operateAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) without any user input. In certain embodiments, an ROI generator can include a registration function, whereby an ROI annotated in one section of a set of serial sections can be automatically transferred to other sections of the set of serial sections.
[0362] The object identifier and the ROI generator can be implemented in any order. For example, the object identifier can be applied to an entire image, and the positions and features of the identified objects can then be stored and recalled later when the ROI generator is implemented. A score can be generated using the scoring engine upon generation of the ROI. A scoring engine can be implemented after both the object identifier and ROI generator have been implemented. The scoring engine can calculate feature metric(s) for the ROI from at least one ROI metric (such as ROI area or linear length of an ROI edge), relevant metrics for objects in the ROI (such as number of marker-positive objects), and, if being used, pre-determined maximum and / or minimum cutoffs and / or normalization factors. A ROI feature vector including the calculated feature metrics and any other variable derived from the ROI used by the scoring function are obtained and the scoring function is applied to the ROI feature vector. The image analysis system can generate a report including the score.
[0363] In certain embodiments, after the digital image is acquired, an intensity segmentation function can be performed. “Intensity segmentation” refers to a technique whereby pixels of an image can be grouped into different clusters based on of intensity of HER2 staining.
[0364] In certain embodiments, after the digital image is acquired, a pattern segmentation function can be performed. “Pattern segmentation” refers to a technique whereby an image can be divided into regions having distinct patterns of staining. For example, a pattern segmentation function can include whole slide segmentation based on a predefined staining pattern. Segmentation can be performed by extracting features from the neighborhood of a grid of points sampled on the acquired image and classifying the extracted features into different staining pattern types.
[0365] In certain embodiments, a color digital image of the tissue sample is acquired. For example, an R,G,B color image of the stained tissue sample can be generated and stored in a storage device, such as a local computer, disc drive, solid state drive, a server machine, or the like. One or more processors can implement an image channel extraction module to execute a channel extraction function on the acquired color image to separate the input image into different image channels. The image channel or channels corresponding to the features to be extracted can be selected, and a feature-mapped image can be generated with pixels corresponding to the features that are relevant to the pattern segmentation. For example, where both HER2 protein expression-related features and structure-related features are relevant, separate channels representing the local amounts of stains correlating with those features can be generated (e.g., where hematoxylin and DAB staining areAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) relevant to the pattern analysis). In a specific example a color deconvolution or unmixing method can be applied to decompose the original RGB image into Hematoxylin (HTX) and DAB channels. These channels can highlight different tissue structures in the tissue image. For chromogenically-stained images, structural image channels can include a counterstain channel, one or more chromogen channels, hue, and / or luminance.
[0366] In an exemplary embodiment, a staining pattern of the IHC stain and / or the counterstain can be classified according to: (1) tumor or non-tumor regions; and (2) the pattern of HER2 staining. For example, a hematoxylin channel can be selected to identify features relevant to the presence or absence of tumor regions, and the channel corresponding to the IHC stain can be selected to identify features relevant to HER2 staining patterns.
[0367] For co-occurrence features, a feature extraction module can be configured to compute the co-occurrence matrix of pixel intensity, and compute a pixel intensity, shape, pattern, and / or macro feature from the co-occurrence matrix, such as energy, correlation, inertia, entropy, inverse difference moment, sum average, sum variance, sum entropy, difference average, difference variance, difference entropy, and two information measures of correlation. A color co-occurrence matrix can be used. The color co-occurrence matrix can be created from the co-occurrence of pixel intensities in two different image channels to capture the spatial relationship between different tissue structures (highlighted in different channels).
[0368] In certain embodiments, an image analysis system can include one or more processors configured to implement a classifier. The classifier can execute a trained pattern recognition algorithm to classify ROI according to the patterns being investigated. The output of the classifier module can include a confidence score indicating the likelihood that an ROI belongs to one of the patterns being investigated.
[0369] A trained pattern recognition algorithm can be built by causing a processor or processors to implement the classifier to execute a training function on a set of training images stored in a training database. The images of the training database can be annotated on the basis of the particular staining pattern. By evaluating images with known patterns, the classifier module can identify particular features that signify membership in a particular pattern category.
[0370] Various different pattern recognition algorithms can be implemented, including supervised learning algorithms selected from the group consisting of decision tree, ensemble, k-nearest neighbor, linear regression, naive Bayes, neural network, logistic regression, perceptron, support vector machine (SVM), and relevance vector machine (RVM). In another embodiment, the classifier is selected from the group consisting of SVM, random forest, and k-nearest neighbor classification.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, supervised learning algorithms can be implemented on a whole slide image to segment the image into different regions. For example, a supervised learning algorithm can be used to divide tissue samples according to the predominant tissue type (i.e., tumor, stroma, immune cell infiltrates, etc.) found in a particular region or identify regions corresponding to viable tumor cell membranes and / or cytomembranes. The supervised learning algorithm can be used to generate a regional map that categorizes pixels according to the region type that the pixels are associated with. The regional map can be used for positive selection or for negative selection, i.e., to identify particular regions of the cellular sample in which the analysis and / or quantification should be focused (positive selection), or it could be used for identifying regions of the cellular sample that can be ignored in analysis and / or quantification (negative selection).
[0371] In an example of positive selection for identifying whether a tumor expresses HER2, tumor regions are relevant to an analysis and / or quantification of a tissue sample. A tissue segmentation can be performed to identify tumor regions within the tissue sample. A tumor map can then be made of the tissue sample. This tissue map can then be used as the input image for pattern segmentation, membrane and / or cytomembrane segmentation, and / or HER2 staining intensity segmentation.
[0372] In an example of negative selection, a tissue segmentation can be performed to identify non-tumor regions within the tissue sample. A non-tumor map can then be made of the tissue sample. This tissue map can then be combined with a pattern map, a cellular membrane and / or cytomembrane map, and a HER2 staining intensity map to exclude pixels corresponding to non-tumor regions from quantification.
[0373] Each pixel can be assigned to a particular tissue type classification. Exemplary tissue type classifications may include, for example: (1) tumor or non-tumor; (2) stromal or non-stromal; (3) immune or non-immune; and (4) tumor, stromal, or immune. Additionally, regions of necrosis or staining artifacts may be identified by similar methods. Thus, a tissue sample map can be generated that is segmented according to the designated tissue type and / or presence of necrosis or artifact.
[0374] In certain embodiments, the computer-implemented method can include the use of one or more models of a neural network. For example, a model for image analysis can have a convolutional neural network (CNN) architecture to automatically detect and exclude non-tumor cells before performing a standard image analysis algorithm to learn and recognize IHC staining. The convolutional neural network architecture or model may be trained using pre-labeled images.
[0375] Once patterns of the acquired image have been identified and features have been mapped, staining can be quantified. For example, the pixels belonging to a cellular membranes and / or cytomembranes of tumor cells can be used to compute the area of theAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) membranes and / or cytomembranes as well as the average, min, max, standard deviation of the intensity of these pixels (staining intensity quantification), according to known methods.
[0376] In certain embodiments, the system includes an end-to-end model that includes an artifact detection model, a tissue segmentation and classification model, and a HER2 scoring model. The artifact model can be trained on annotations of whole slide images. The tissue segmentation and classification model can be trained on annotations on a cohort of cancer slides stained as described above. The HER2 scoring model can utilize an additive multiple instance learning (aMIL) approach to predict HER2 scores directly from scanned IHC.
[0377] PathAI's AIM-HER2 is an example of an end-to-end model that can be used with the methods of the present disclosure.
[0378] The computer implemented methods described above can include a specialized computer system. The specialized system can be configured to execute instructions (i.e., programming instructions) that cause the system to perform operations on digital images of tissue samples stained for HER2 protein expression as described above.
[0379] The instructions can include image analysis operations for assessing responsiveness to a HER2-directed therapy. Such image analysis operations can include steps such as detecting a region of interest in a sample image with a ML / AI assisted image analyzer, extracting features from the detected region of interest (e.g., staining features from cells or portions thereof identified or delineated within the region of interest), and grouping data points representing a detected region of interest to identify homogeneous groups based on the extracted features. In certain embodiments, the instructions can cause the processor to signal that one or more positive predictors of response to HER2-directed therapy have been identified based on the presence of homogenous groups. As used herein, “sample image” refers to an image of a IHC stained tumor sample obtained from a subject having an unknown level of HER2 expression at the time the sample is obtained. As used herein, “region of interest” refers to a specific area within the sample image that is selected for analysis. The area can be defined to specifically encompass tumor tissue, specific cell types or areas thereof, or regions of tissue or individual cells exhibiting particular staining characteristics. A region of interest can be defined manually (e.g., by a pathologist drawing a boundary around a tumor area) or automatically using image analysis algorithms (e.g., an Al identifying and segmenting specific tissue compartments).
[0380] In certain embodiments, grouping data points can include using a clustering algorithm to group detected regions of interest based on the similarity of their extracted stained features, to identify distinct populations of regions of interest within the sample image, and thereby, the tumor. For example, if the clustering algorithm identifies one or more distinct groups (homogeneous groups) of tumor regions that exhibit staining, this can be interpreted as a positive predictor of response to HER2-directed therapy.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, the present disclosure provides a system for predicting whether a tumor will be responsive to HER2-directed therapy using an image of a solid tumor sample, wherein the solid tumor sample has been stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, the system can include one or more processors, and a memory coupled to the processor(s). The memory can store computerexecutable instructions, that, when executed by the processor(s) cause the system to perform operations including detecting a region or cells in a sample image, extracting stained features from the detected region cells, and grouping data points representing detected region or cells in the image based on the extracted stained features to identify homogeneous groups. Identification of homogeneous groups of detected regions indicates that the tumor can be predicted to be responsive to a HER2-directed therapy, as described above. The detecting step can be performed using an ML / AI assisted image analyzer.
[0381] In certain embodiments, the ML / AI analyzer can be trained to classify images based on HER2-staining using a dataset comprising a plurality of training images. In certain embodiments, the plurality of training images can be images of a biological specimen stained with a monoclonal anti-HER2 / ErbB2 D8F12 antibody or a bioequivalent thereof.
[0382] In certain embodiments, the computer implemented method of predicting whether a subject’s tumor will be responsive to HER2-directed therapy can use a digital image of a solid tumor obtained from the subject, section thereof, or series of sections thereof. The solid tumor or section thereof can be stained for HER2 expressing cells by any of the methods above.
[0383] A system for predicting whether a tumor will be responsive can include a central processing unit (CPU), one or more input / output (I / O) device interfaces, which can allow for the connection of various I / O devices (e.g., keyboards, displays, scanners, etc.) to the system, a network interface (which can include a transmitter for transmitting data and a receiver for receiving data), memory, storage, and an interconnect. Storage can be located either inside or outside the system. When the storage is located outside the system, the storage can be connected via the network. The CPU can retrieve and execute instructions stored in the memory. The interconnect can transmit instructions and data, among the CPU, I / O device interface, network interface, memory, and storage. The CPU can represent a single CPU, multiple CPUs, a single CPU having multiple processing cores, and the like. The memory can be volatile memory, such as random access memory. As used herein “storage” can represent non-volatile (non-transitory) memory, such as memory on a disk drive, and can be a single unit, or a combination of fixed or removable storage devices, such as fixed disc drives, removable memory cards or optical storage, network attached storage (NAS), or a storage area-network (SAN).Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) In certain embodiments, a non-transitory computer-readable medium storing the instructions for executing any of the processes described above can be a component of a detection kit or a treatment kit described above.
[0384] EXAMPLES
[0385] Example I. HER2 protein expression in Breast Cancer, Non -small Cell Lung Cancer, Gastric Cancer, Bladder Cancer, and Colorectal Cancer.
[0386] The human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of receptor tyrosine kinases and is closely related to the other family members, EGER, HER3 and HER4. HER2 encodes a 185-kDa transmembrane receptor tyrosine kinase, which plays a crucial role in cell proliferation, survival, and differentiation (McCabe et aL, 2005). Clinical characterization of HER2 relies on HER2 clinical IHC testing, to guide the clinical management of patients. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) first published a practice guideline on human HER2 testing in breast cancer in 2007 (Wolff, et aL, 2007); the latest update became available in 2023 (Wolff, et aL, 2023). ASCO / CAP published guideline recommendations on HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma in 2016 (Bartley et aL, 2016) . These HER2 testing guidelines have focused on identifying HER2 protein overexpression as a surrogate for HER2 gene amplification to identify patients for HER2-targeted therapies. Currently, there are no ASCO / CAP scoring guidelines for HER2 in indications beyond breast cancer and gastric / GEJ cancer, although use of the Ventana PATHWAY® anti-HER2 / neu (4B5) clinical IHC assay with the ASCO / CAP scoring guidelines for gastric / GEJ cancer is being used to determine eligibility for treatment with Trastuzumab deruxtecan (T-DXd). (Meric-Bernstam, et aL, 2024)
[0387] As HER2-targeting therapy enters a new era of treating lower HER2 expressing (HER2-low) breast cancer and other tumor types, it is increasingly important to accurately detect low levels HER2 expression to identify those patients most likely to benefit from the new generation of HER2-targeting therapies, such as T-DXd (Bardia, et aL, 2024; Modi, et aL, 2020).
[0388] METHODS
[0389] Epitope Mapping
[0390] PEPperMAP® Linear Epitope Mapping of both HER2 / ErbB2 (D8F12) antibody and PATHWAY® anti-HER2 / Neu (4B5) antibody were conducted, to identify the antibody binding sites on the amino acid level.
[0391] Control cell lines
[0392] As HER2 expression levels vary among cell lines, a panel of control cells was selected with dynamic range of HER2 expression level. In summary, 17 cell lines wereAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) tested (Table 1), Nine of them (SK-BR-3, BT-474, MDA-MB-361 , MDA-MB-453, T47D, MCF7, M DA- MB- 231 , SW-480 and BT-549) with known HER2 protein expression level (McCabe, et aL, 2005) and an additional 8 cell lines (AU565, HCC1954, HCC38, BT20, HCC70, MDA-MB-436, HL-60 and Farage) with dynamic HER2 mRNA expression level based on the gene expression TPM values of the protein coding genes for DepMap cell lines that was released in “DepMap 23Q2 Public” (DepMap, Broad (2023) available online at “depmap.org / portal”). Commercial HER2 analyteDRcell line array block (HCL028; HistoCyte as described at “cellmarque.com / cms / histocyte / HER2.php”) that contains 4 pellets with known HER2 status ranging from 0 to 3+, was used as an IHC run control.
[0393] For the Ventana PATHWAY® anti-HER2 Clinical Assay, PATHWAY® HER24-in- 1 Control slides (Ventana, Cat# 781-2991) that contain 4 cell pellets with known HER2 status, ranging from 0 to 3+, was used as an IHC run control.
[0394] Table 1 : Control cells with reference mRNA and / or protein levels for HER2.
[0395] Cell Lines lineage RNASeq_Expr. HER2 protein Fold gene ERBB2 (TPM)* expression (pg / pg of amplification** lysate) **
[0396] SK-BR-3 Breast 2822.738 2700 43 BT-474 Breast 1794.196 3826.3 47 MDA-MB- Breast
[0397] 848.705 852.3 11 361
[0398] MDA-MB- Breast
[0399] 310.758 528.6 11 453
[0400] T47D Breast 84.803 426 2.2 MCF7 Breast 55.806 110 2.5 MDA-MB- Breast
[0401] 28.81 157.6 0.8 231
[0402] SW-480 Gl 19.67 243.6 NA BT-549 Breast 19.422 180 2.5 AU565 Breast 3984.644
[0403] HCC1954 Breast 3829.764
[0404] HCC38 Breast 115.351
[0405] BT20 Breast 72.356
[0406] HCC70 Breast 38.006
[0407] MDA-MB- Breast
[0408] 15.444
[0409] 436
[0410] HL-60 Leukemia 4.185
[0411] Farage Lymphoma
[0412]
[0413] 0.66
[0414] *DepMap, Broad (2023). DepMap 23Q2 Public.
[0415] **HER2 protein expression quantification and gene amplification fold change data were reference (McCabe et aL, 2005).
[0416] Cell line preparationAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Five cell lines (BT474, MDA-MB-453, T47D, HL-60 and Farage) were selected for a side-by-side comparison of IHC with western blot (WB), using the CST HER2 / ErbB2 (D8F12) rabbit monoclonal antibody. For each cell line, a large batch of cells (~ 100 million) were grown and combined into a single pellet. From this pellet, a portion was obtained for western blot, while the remaining cells were used to make FFPE blocks for IHC.
[0417] Western blot of cell lines
[0418] Cell lysates of following cell lines: BT-474, MDA-MB-453, T47D, HL-60, and Farage, were prepared using NP40 Cell lysis Buffer (Invitrogen, Cat# FNN0021), supplemented with 1x HALT™ Protease Phosphatase Inhibitor Cocktail (Thermo Scientific, Cat# 1861281). Fifteen micrograms of total cell lysates were separated by SDS-Page and electrotransfered to PVDF membrane (Invitrogen, Cat# LC2007) at 100v for one hour. Nonfat dry milk (5%) was prepared fresh in Tris-buffered saline Tween-20 (TBS-T) and added to the membrane as a blocking agent for 1 hour at room temperature. Primary antibody (CST, HER2 / ErbB2 [DF812] Rabbit monoclonal antibody, Cat# 4290) was added at 1 :1000 dilution and incubated overnight with gentle rocking at 4°C. Ventana PATHWAY® anti-HER-2 / neu (4B5) antibody which is prediluted and ready for use format was also tested with the same protocol. Immunoblots were washed three times, 5 minutes each with TBS-T, and a secondary antibody against the primary antibody species (Jackson ImmunoResearch Inc, Cat# 111 -035-144) was added at 1 :10,000 dilution into the TBS-T / milk mixture for one hour on a shaker at room temperature.
[0419] IHC Assays
[0420] HER2 clinical IHC assay (Ventana PATHWAY® HER2 Clinical Assay)
[0421] An US Food and Drug Administration (FDA) approved monoclonal IHC antibody testing system (Ventana PATHWAY® anti-HER-2 / neu 4B5 Rabbit Monoclonal Primary Antibody on the BenchMark ULTRA instrument) was used as the HER2 clinical IHC assay. Ventana PATHWAY® HER24-in-1 run control slide (Cat# 781-2991) was used. A HER2 / ErbB2 rabbit mAb was obtained from Ventana (Cat#790-2991 , clone 4B5) and used with the ultraView Universal DAB Detection Kit (Cat# 760-500). The mAb was stored at 4°C until use. Briefly, the IHC protocol included deparaffinization followed by 36 min antigen retrieval using CC1. Afterwards, primary antibody was added, and slides were further incubated for 12 minutes at 36°C. Finally, slides were counterstained for 4 minutes with Hematoxylin II (Ventana, Cat# 760-2208) and then Bluing (Ventana, Cat# 760-2037) for 4 minutes. Slides were then dehydrated in increasing concentrations of ethanol (95-100%), then in xylenes, followed by coverslipping. Coverslipped slides were scanned using a Leica / Aperio Scan Scope slide scanner (Vista, CA) and evaluated by light microscopy.
[0422] Validation of HER2-IHC assay of the present disclosure on Ventana Discovery UltraAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Various conditions were evaluated to maximize the signal to noise ratio of the HER2 / ErbB2 rabbit monoclonal antibody from CST (Cat#4290, clone D8F12). Antigen retrieval conditions examined included no antigen retrieval and varying antigen retrieval times. Primary antibody variables tested included staining at 37°C vs. room temperature.
[0423] The HER2 rabbit mAb was stored at -20°C until use. The optimal protocol for FFPE samples was determined using control cell lines described above. Briefly, the IHC protocol included deparaffinization followed by 64 min antigen retrieval using CC1. Afterwards, primary antibody diluted at 1 :50 in Dako antibody diluent (Cat# S0809) was added, and slides were further incubated for 60 minutes at 37°C. Then, incubation with Ventana OmniMap pre-diluted HRP-conjugated anti-rabbit secondary antibody (Cat# 760-4311) was performed for 4 minutes. Finally, slides were counterstained for 4 minutes with Hematoxylin (Ventana, Cat# 760-2021) and then Bluing (Ventana, Cat# 760-2037) for 4 minutes. Slides were then dehydrated in increasing concentrations of ethanol (95-100%), then in xylenes, followed by coverslipping. Coverslipped slides were scanned using a Leica / Aperio Scan Scope slide scanner (Vista, CA) and evaluated by light microscopy.
[0424] Transfer the HER2-IHC assay of the present disclosure to Ventana BenchMark Ultra The HER2 / ErbB2 rabbit mAb was obtained from CST (Cat#4290, clone D8F12) and stored at -20°C until use. The optimal protocol for FFPE samples was determined using control cell lines and tissues described above. Briefly, the IHC protocol included deparaffinization followed by 36 min antigen retrieval using CC1. Afterwards, primary antibody diluted at 1 :100 in Dako antibody diluent (Cat# S0809) was added, and slides were further incubated for 36 minutes at 37°C. Finally, slides were counterstained for 4 minutes with Hematoxylin (Ventana, Cat# 760-2021) and then Bluing (Ventana, Cat# 760-2037) for 4 minutes. Slides were then dehydrated in increasing concentrations of ethanol (95-100%), then in xylenes, followed by coverslipping. Coverslipped slides were scanned using a Leica / Aperio Scan Scope slide scanner (Vista, CA) and evaluated by light microscopy.
[0425] HER2 Dual in-situ hybridization (ISH)
[0426] A US Food and Drug Administration (FDA) approved Ventana HER2 Dual ISH DNA Probe (HER2 and Chromosome 17) Cocktail on the BenchMark ULTRA instrument was used. Ventana HER2 Dual ISH 3-in- 1 Xenograft Slides (Cat# 783-4422) were used as run control slides. A Ventana HER2 Dual ISH DNA Cocktail Probe (Cat# 760-6072) was obtained from Ventana and used with its Red ISH DIG Detection Kit (Cat# 08318832001) in conjunction with Ventana Silver ISH DNP Detection Kit (Cat# 08318883001), HybReady Solution (Cat# 780-4409), Discovery Inhibitor (Cat# 760-4840), ISH Protease 3 (Cat# 780-4149), and counterstaining reagents Bluing (Cat# 760-2037) and Hematoxylin II (Cat# 790-2208). All reagents were stored at 4°C until use. The Ventana HER2 Dual ISH DNA assay is a locked assay, and no protocol information is provided.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) ERBB2 ISH
[0427] Forty ER+ human BrCa samples were evaluated ERBB2 mRNA expression by ISH using RNAscope™2.5 LSx Brown Reagent Kit (Cat. No. 322700), ISH probe Hs-ERBB2-no-X-Mm (Catalog# 418748), in addition, Hs-PPIB (positive control) and dapB (negative control) probes were tested on these samples prior to ERBB2 probe as RNA quality control.
[0428] Human tissues
[0429] FFPE blocks containing human tissue samples were obtained from a variety of sources. All samples were quality checked with H&E and Ki67 (Invitrogen, Cat# MA5-14520, clone SP6). All human tissue samples were sourced from vendors approved for research applications, according to internal compliance standards.
[0430] Slide interpretation
[0431] Manual scoring of HER2 clinical IHC assay
[0432] HER2 clinical IHC staining was scored manually by pathologists, following the HER2 testing ASCO / CAP guidelines. For BrCa samples, HER2 staining was scored as 0 to 3+ according to the HER2 testing in Breast Cancer ASCO / CAP guidelines that was updated in 2023 (Wolff, et al., 2023). A tumor lesion was considered HER2-positive with a score of 3+ and HER2-negative with a score of 0 or 1 +. In the case of a score 2+ (equivocal) samples, reflex ISH testing required to determine HER2 gene amplification status. Scoring algorithm for pathologists is shown in Figure 1 (Wolff, et aL, 2023). BrCa samples with a IHC score of 1+ or 2+ with ISH negative are defined as “HER2-low” (Modi, et aL, 2020; Modi, et aL, 2022).
[0433] Recently, it has been proposed to subdivide the ASCO 0 into two categories, according to membrane and / or cytomembrane staining that is faint and is seen in 10% of tumor cells or fewer (“HER2-ultralow”) or no observable staining in tumor cells (HER2-undetected) (Geukens, et aL, 2023; Wolff, et aL, 2023).
[0434] For GC cancer, NSCLC, bladder cancer, and CRC samples, HER2 scoring followed 2016 ASCO / CAP guidelines on HER2 testing in Gastroesophageal adenocarcinoma (GEA), according to the scoring algorithm for pathologists (Figure 2) (Bartley, et aL, 2016).
[0435] Manual scoring of the HER2-IHC assay of the present disclosure
[0436] A modified Allred scoring system was adopted by pathologists for evaluating the cyto-membranous HER2 staining in the invasive tumor region. The average intensity score of positive tumor cells was recorded: 0 (no staining), 1+ (weak staining), 2+ (moderate staining) and 3+ (strong staining). Then, the percentage of tumor cells with positive staining was estimated (from 0-100). Next, HER2-IHC-Score (the HER2-IHC assay of the present disclosure) was calculated using the following equation: IHC-Score = average intensity score x percentage of tumor positive staining, range from 0-300.
[0437] Interpretation of HER2 Dual ISH DNA assay resultAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) The entire ISH slide was scanned prior to counting at least 20 cells or using IHC to define the areas of potential HER2 amplification. If there was a second population of contiguous cells with increased HER2 signals / cell and this cell population consisted of more than 10% of tumor cells on the slide (defined by image analysis or visual estimation of the ISH or IHC slide), a separate counting of at least 20 nonoverlapping cells was also performed within this cell population and reported (Wolff, et aL, 2023). For infrequent but challenging ISH results in the cases of monosomy CEP17 and polysomy CEP17 cases and equivocal cases with HER2 / CEP17 ratio < 2 and HER2 copy number > 4 and < 6, specific criteria for the classification of five subgroups of dual probe HER2 ISH findings are provided (Wolff, et aL, 2018; Wolff, et aL, 2023).
[0438] ERBB2 ISH ACD score
[0439] ACD pathologist reviewed the stained slide and provided the ISH score, following RNAscope™ quantification method (Table 2). Based on the number of dots per cell and predominant staining pattern throughout the entire sample, a single score was assigned to each sample. The percentage of positive cells was scored visually based on number of cells with >1 dot / cell and binned into categories (i.e., 0%, 1-25%, 26-50%, 51-75%, 76-99%, 100%).
[0440] Table 2: RNAscope™ semi quantitative scoring criteria.
[0441] Score Criteria
[0442] 0 No staining or <1 dot / 10 cells
[0443] 1 1-3 dots / cell
[0444] 2 4-9 dots / cell, no or very few dot clusters
[0445] 3 10-15 dots / cell and / or <10% dots are in clusters
[0446]
[0447] 4 >15 dots / cell and / or >10% dots are in clusters
[0448] Statistical analyses
[0449] To assess any statistical significance between groups, two-sided Mann-Whitney test were employed, and P values <0.05 were considered statistically significant. All statistical analyses were carried out with GraphPad Prism 10 (GraphPad, San Diego, CA) software.
[0450] RESULTS
[0451] Epitope mapping for HER2 antibodies
[0452] Epitope Mapping of Rabbit Monoclonal Antibody HER2 / ErbB2 (D8F12) XP® against ERBB2
[0453] PEPperMAP® Linear Epitope Mapping report showed that incubation of an ERBB2 peptide microarray with rabbit monoclonal antibody HER2 / ErbB2 (D8F12) XP® resulted in a strong monoclonal antibody response against peptides with the common motif SPETHLDAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) (SEQ ID NO: 1), located at amino acids 38-44 of the antigen near the N-terminus of ERBB2 (Figure 3). The region in HER2 harboring epitopes recognized by antibody HER2 / ErbB2 (D8F12) was aligned with the corresponding regions in EGFR, ERBB3 and ERBB4, using the National Center for Biotechnology Information (NCBI) Protein blast tool (located on the World Wide Web at blast.ncbi.nlm.nih.gov), the results indicated that the epitope SPETHLD (SEQ ID NO: 1) is specific in HER2 / ERBB2; there was no significant similarity with EGFR, HER3 / ERBB3 and HER4 / ERBB4. Summarized epitope mapping result in Table 3.
[0454] Epitope Mapping of Rabbit Monoclonal Antibody PATHWAY® anti-HER2 / Neu (4B5) against ERBB2
[0455] PEPperMAP® Linear Epitope Mapping report showed that incubation of an ERBB2 peptide microarray with rabbit monoclonal antibody anti-HER2 / Neu (4B5) resulted in a strong monoclonal antibody response against peptides with the common motif AENPEYL (SEQ ID NO: 2), located at the C-terminus of the antigen. An additional but significantly weaker cross-reaction was observed with peptides with the common motif GAVENPEYL (SEQ ID NO: 3), due to an obvious sequence similarity to the main motif (Figure 4). The region in HER2 harboring epitopes recognized by the PATHWAY® anti-HER2 / Neu (4B5) antibody was aligned with the corresponding regions in EGFR, ERBB3 and ERBB4, using the NCBI Protein blast tool; the results indicated that the epitope AENPEYL (SEQ ID NO: 2) showed 100% homology in HER2 / ERBB2 and HER4 / ERBB4. In addition, epitope AENPEYL (SEQ ID NO: 2) also shares partial sequence homology in EGFR. There was no significant similarity with HER3 / ERBB3. The instant epitope mapping result is consistent with Schrohl and colleague’s findings (Schrohl, et aL, 2011). Summarized epitope mapping result is presented in Table 3.
[0456] Table 3: Summary of epitope mapping results.
[0457] Antibody Epitope in HER2 Specificity
[0458] HER2 / ErbB2 SPETHLD (SEQ ID NO: 1) Specific to Human ERBB2 (D8F12) N-terminus (amino acid 38-44)
[0459] PATHWAY® AENPEYL (SEQ ID NO: 2) Cross reacts with Human anti-HER2 / Neu C-terminus (amino acid 1243-1249) ERBB2 & ERBB4
[0460] (4B5) (partial “ENPEYL” (SEQ ID NO: 4)
[0461]
[0462] amino acid 1192-1197)
[0463] Western blot of cell lines
[0464] Western blot was performed on 5 cell lines with a dynamic range of mRNA expression, based on the RNAseq results described above and Table 1. Western blot analysis of extracts from these cells, using HER2 (D8F12) and PATHWAY® 4B5, are shown in Figure 5. BT-474 and MDA-MB-453 with higher mRNA expression showed robust target bands at the expected molecular weight for HER2 protein. T47D cells showed weak bands with HER2 (D8F12) but were negative with PATHWAY® 4B5. HL-60 and Farage showed noAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) bands with either of the HER2 antibodies, confirming that they are true negatives for HER2 (HER2 null) (Figure 5).
[0465] Characterization of control cell lines and tissue for IHC
[0466] IHC of control cell pellets
[0467] The representative images for the HER2 clinical IHC staining of control cell lines with dynamic range of HER2 expression are shown in Figure 6. The results indicate that HER2 clinical IHC works well in higher HER2 mRNA expressing cell lines but has limited sensitivity in lower HER2 mRNA expressing cell lines.
[0468] HER2-IHC assay of the present disclosure on control cell pellets Representative images of the HER2 clinical IHC and the HER2-IHC assay of the present disclosure staining of HER2 AnalyteDR4-in- 1 control slide plus confirmed HER2 negative cell pellet HL-60 are shown in Figures 6-8. The upper row showed that the HER2 clinical IHC staining results in cell lines A, B, C and D complied with the corresponding HER2 status as described on the vendor’s website (cellmarque.com / cms / histocyte / HER2.php).
[0469] The lower row demonstrated that staining of the HER2-IHC assay of the present disclosure in the same panel of cells shows significantly higher positivity and staining intensity in ASCO 1+ (B) and 2+ (C) cell lines, while HL-60, the true HER2 negative (HER2 null) cell line, remained negative.
[0470] IHC staining in 11 cell pellets with relatively low HER2 mRNA expression levels, including two true HER2 negative (HER2 null) cells, HL-60 and Farage, using the HER2-IHC assay of the present disclosure, are shown in Figure 6.
[0471] HER2 protein expression by IHC in breast cancer
[0472] Concordance of ERBB2 mRNA and HER2 protein expression in ER+ breast cancer HER2 protein (HER2 clinical IHC and the HER2-IHC assay of the present disclosure) and mRNA (by ERBB2 ISH) cross-comparison were evaluated in a set of 37 ER+ BrCa (18 of ER+HER2- and 19 of ER+HER2+). Good concordance of ERBB2 mRNA with protein (both IHC assays) was achieved in ER+HER2+ subtype. In ER+HER2- subtype, poor concordance was observed among three assays, HER2 clinical IHC exhibited poor sensitivity compared to the mRNA expression by ISH, while the HER2-IHC assay of the present disclosure showed better sensitivity in the ER+HER2- subtype with lower HER2 expression (Figure 9). Preanalytical viables such as formalin fixation or storage conditions may have contributed to the poor concordance between the HER2-IHC assay of the present disclosure and ERBB2 ISH, as the majority of BrCa FFPE blocks were greater than 10 years old. Reports indicate that FFPE blocks stored for 2-20 years may demonstrate decreased mRNA amplification efficiency (Agrawal, et al., 2017). In addition, the ISH signals are tiny,Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) and it is challenging to accurately score low levels mRNA expression by ISH, which may also contribute to the dis-concordance in the ER+HER2- subtype samples.
[0473] HER2 protein expression by IHC in breast cancer
[0474] In total 68 breast cancer samples were included in HER2 IHC analysis, the majority (87%, 59 / 68) were treatment naive and about 13% (9 / 68) had neo-adjuvant chemotherapy and / or radiotherapy prior to surgery. The subtype distribution among this set of BrCa samples was as follows: 30 of ER+HER2-, 20 of ER+HER2+ and 18 of ER-HER2-, based on the clinical diagnostic data that was received from the vendor. Table 5 lists the internal manual pathologist scoring results for HER2 ASCO score and the score of the HER2-IHC assay of the present disclosure. Within this set of BrCa samples, about 46% (31 / 68) were with ASCO score 0; 29% (20 / 68) samples with ASCO score 1+ or 2+ / ISH-neg; 24% (16 / 68) samples were HER2-positive with ASCO score 3+ or 2+ / ISH-pos. There were three BrCa samples with discordance between the original HER2 status at diagnosis and internal data; these samples were defined as ER+HER2+ subtype externally, but internal HER2 clinical IHC staining of a single FFPE block from the vendor resulted in an ASCO score 1+. The external data was adopted for general subtype comparison analysis but relied on the internal ASCO scores data for analysis of sub-categories in Figure 11 and Figure 19B.
[0475] Representative images for staining in each subtype are shown in Figure 10.
[0476] With the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, all samples across different subtypes were above the threshold. Using a more stringent threshold, the data indicate that in this set of BrCa samples, 57% (17 / 30) of ER+HER2- samples, 83% (15 / 18) of ER-HER2- samples, and 95% (19 / 20) of ER+HER2+ samples have 50% or more of tumor cells positive with moderate to strong staining (Table 5).
[0477] When comparing HER2 protein expression by the HER2-IHC assay of the present disclosure in this set of BrCa samples using the newly proposed categories (HER2-pos, HER2-low, HER2-ultralow and HER2-undetected) as described in slide interpretation for HER2 clinical IHC (above), the data affirmed that the HER2-pos category has significantly higher HER2 expression than the rest of categories (PcO.0001). The HER2-undetected category showed significantly lower HER2 expression compared to HER2-pos (PcO.0001) and HER2-low (P=0.0017), but not HER2-ultralow samples (P=0.0753). Similarly, there was no statistical difference between HER2-low and HER2-ultralow categories (P=0.8257) (Figure 11). The data reveal that there is substantial overlap of HER2 protein expression using the HER2-IHC assay of the present disclosure in HER2-negative BrCa samples, across HER2-low, HER2-ultralow and HER2-undetected categories (Figure 11).
[0478] Table 4: HER2 IHC scoring in breast cancer.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Tissue Biomarker- HER2 ASCO HER2 HER2-IHC assay of the Sample defined subtype Score categories present disclosure No. (WHO)
[0479] IS %TPS score 1 ER+HER2- 0 HER2-Zero 1 + 90 90 2 ER+HER2- 0 HER2-Zero 1+-2+ 100 150 3 ER+HER2- 0 HER2-Zero 2+~3+ 100 250 4 ER+HER2- 0 HER2-Zero 1 + 70 70 5 ER+HER2- 0 HER2-Zero 1 + 10 10 6 ER+HER2- 0 HER2-Zero 1+-2+ 100 150 7 ER+HER2- 0 HER2-Zero 2+ 100 200 8 ER+HER2- 0 HER2-Zero 2+ 80 160 9 ER+HER2- 0 HER2-Zero 1 + 80 80 10 ER+HER2- 0 HER2-Zero 1 + 60 60 11 ER-HER2- 0 HER2-Zero 1 + 100 100 12 ER-HER2- 0 HER2-Zero 2+ 60 120 13 ER-HER2- 0 HER2-Zero 1 + 60 60 14 ER-HER2- 0 HER2-Zero 2+ 80 160 15 ER-HER2- 0 HER2-Zero 2+ 80 160 16 ER-HER2- 0 HER2-Zero 2+~3+ 90 225 17 ER-HER2- 0 HER2-Zero 2+ 90 180 18 ER-HER2- 0 HER2-Zero 2+~3+ 100 250 19 ER-HER2- 0 HER2-Zero 2+ 95 190 20 ER-HER2- 0 HER2-Zero 2+ 90 180 21 ER-HER2- 0 HER2-Zero 2+~3+ 100 250 22 ER-HER2- 0 HER2-Zero 2+ 60 120 23 ER+HER2- 0 HER2-Zero faint-1 + 20 10 24 ER+HER2- 0 HER2-ultralow 3+ 100 300 25 ER+HER2- 0 HER2-ultralow 3+ 100 300 26 ER+HER2- 0 HER2-ultralow 1+-2+ 90 135 27 ER+HER2- 0 HER2-ultralow 1 + 80 80 28 ER+HER2- 0 HER2-ultralow 3+ 100 300 29 ER-HER2- 0 HER2-ultralow 2+~3+ 100 250 30 ER-HER2- 0 HER2-ultralow 1 + 90 90 31 ER+HER2- 0 HER2-ultralow 2+ 100 200 32 ER-HER2- 1 + HER2-Low 2+~3+ 100 250 33 ER+HER2- 1 + HER2-Low 2+ 100 200 34 ER+HER2- 1 + HER2-Low 2+~3+ 100 250 35 ER+HER2- 1 + HER2-Low 2+ 100 200 36 ER+HER2- 1 + HER2-Low 1 + 95 95 37 ER+HER2- 1 + HER2-Low 2+ 90 180 38 ER+HER2+ 1 + HER2-Low 2+ 100 200
[0480]
[0481] 39 ER+HER2+ 1 + HER2-Low 2+~3+ 100 250Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Tissue Biomarker- HER2 ASCO HER2 HER2-IHC assay of the Sample defined subtype Score categories present disclosure No. (WHO)
[0482] IS %TPS score 40 ER+HER2+ 1 + HER2-Low 1+-2+ 100 150 41 ER-HER2- 1 + HER2-Low 3+ 100 300 42 ER-HER2- 1 + HER2-Low 2+~3+ 100 250 43 ER-HER2- 1 + HER2-Low 2+ 100 200 44 ER+HER2- 1 + HER2-Low 1+-2+ 100 150 45 ER+HER2- 1 + HER2-Low 2+ 100 200 46 ER+HER2- 2+ HER2-Low 2+~3+ 100 250 47 ER+HER2- 1 + HER2-Low 2+~3+ 100 250 48 ER+HER2- 1 + HER2-Low 1 + 95 95 49 ER+HER2- 1 + HER2-Low 2+ 100 200 50 ER+HER2- 1 + HER2-Low 2+~3+ 100 250 51 ER+HER2- 1 + HER2-Low 2+ 100 200 52 ER+HER2+ 2+ HER2-pos 2+~3+ 100 250 53 ER+HER2+ 2+ HER2-pos 2+ 100 200 54 ER+HER2+ 3+ HER2-pos 3+ 100 300 55 ER+HER2+ 3+ HER2-pos 3+ 100 300 56 ER+HER2+ 3+ HER2-pos 3+ 100 300 57 ER+HER2+ 3+ HER2-pos 3+ 100 300 58 ER+HER2+ 3+ HER2-pos 3+ 100 300 59 ER+HER2+ 3+ HER2-pos 3+ 100 300 60 ER+HER2+ 2+1 ISH-pos HER2-pos 2+~3+ 100 250 61 ER+HER2+ 2+ / ISH-pos HER2-pos 2+ 95 190 62 ER+HER2+ 2+ / ISH-pos HER2-pos 2+ 90 180 63 ER+HER2+ 2+ / ISH-pos HER2-pos 2+~3+ 100 250 64 ER+HER2+ 3+ HER2-pos 3+ 100 300 65 ER+HER2+ 3+ HER2-pos 3+ 100 300 66 ER+HER2+ 3+ HER2-pos 3+ 100 300 67 ER+HER2+ 2+ / ISH-pos HER2-pos 2+~3+ 100 250
[0483] ER+HER2+
[0484]
[0485] 68 n / a n / a 3+ 100 300 Table 5: HER2 expression by the HER2-IHC assay of the present disclosure in BrCa. HER2-IHC assay of ER+HER2- ER+HER2+ ER-HER2- the present
[0486] disclosure
[0487] > 10% (any intensity) 30 / 30 (100%) 20 / 20 (100%) 18 / 18 (100%) > 50% (2+ & 3+) 17 / 30 (56.7%) 19 / 20 (95%) 15 / 18 (83.3%) > 75% (2+ & 3+) 17 / 30 (56.7%) 19 / 20 (95%) 13 / 18 (72.2%)
[0488]
[0489] HER2 protein expression by IHC in NSCLCAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) A set of 46 NSCLC samples were analyzed by HER2 IHC, including 26 adenocarcinoma and 20 squamous cell carcinoma (SCC). All were treatment naive primary resections. Table 6 lists the manual pathologist scoring results for HER2 ASCO score and the score of the HER2-IHC assay of the present disclosure. Representative images for staining in each subtype are shown in Figure 12.
[0490] With the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, all adenocarcinoma samples and 95% (19 / 20) of SCC samples were above the threshold. Using a more stringent threshold, the data indicate that 57% (15 / 26) of adenocarcinoma and 15% (3 / 20) of SCC samples have 50% or more of tumor cells positive with moderate to strong staining intensity (Table 7). The HER2 expression by the HER2-IHC assay of the present disclosure is significantly higher in adenocarcinoma subtype compared to SCC subtype (PcO.0001).
[0491] Within this set of NSCLC samples, the vast majority (76%, 35 / 46) had an ASCO score 0, about 15% (7 / 46) samples had an ASCO score 1+, around 4% (2 / 46) samples had an ASCO score 2+, and only one case (2%, 1 / 46) had an ASCO score 3+. The data indicate that with the HER2-IHC assay of the present disclosure, there was statistically significant higher HER2 expression in ASCO 1+ than ASCO score 0 NSCLC samples (PcO.0001) (Figure 13). With extremely limited number of samples in ASCO 2+ and 3+ categories, there was insufficient data for statistical analysis.
[0492] Table 6: HER2 IHC scoring in NSCLC.
[0493] Tissue Sample Brief subtype HER2 ASCO HER2-IHC assay of the present No. score disclosure
[0494] %TPS IS score 1 NSCLC_Adeno 0 100 2 200 2 NSCLC_Adeno 0 100 2 200 3 NSCLC_Adeno 0 100 1 100 4 NSCLC_Adeno 0 100 1 100 5 NSCLC_Adeno 1 100 2 200 6 NSCLC_Adeno 0 100 2 200 7 NSCLC_Adeno 0 95 1 95 8 NSCLC_Adeno 1 100 3 300 9 NSCLC_Adeno 0 100 1 100 10 NSCLC_Adeno 2 100 3 300 11 NSCLC_Adeno 1 100 2 200 12 NSCLC_Adeno 1 100 2.5 250
[0495]
[0496] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Tissue Sample Brief subtype HER2 ASCO HER2-IHC assay of the present No. score disclosure %TPS IS score 13 NSCLC_Adeno 0 100 1 100 14 NSCLC_Adeno 0 100 1 100 15 NSCLC_Adeno 0 100 1.5 150 16 NSCLC_Adeno 0 60 1 60 17 NSCLC_Adeno 1 100 2 200 18 NSCLC_Adeno 0 100 1 100 19 NSCLC_Adeno 0 65 1 65 20 NSCLC_Adeno 1 100 2 200 21 NSCLC_Adeno 1 99 2.5 247.5 22 NSCLC_Adeno 1 100 2 200 23 NSCLC_Adeno 1 100 2 200 24 NSCLC_Adeno 0 100 1 100 25 NSCLC_Adeno 1 100 2 200 26 NSCLC_Adeno 1 100 2.5 250 27 NSCLC_SCC 0 90 1 90 28 NSCLC_SCC 0 100 1 100 29 NSCLC_SCC 0 100 1 100 30 NSCLC_SCC 1 60 0.5 30 31 NSCLC_SCC 0 98 2 196 32 NSCLC_SCC 0 100 2 200 33 NSCLC_SCC 0 85 1 85 34 NSCLC_SCC 0 80 1 80 35 NSCLC_SCC 0 97 1 97 36 NSCLC_SCC 1 0 0 0 37 NSCLC_SCC 0 70 0.5 35 38 NSCLC_SCC 0 95 1 95 39 NSCLC_SCC 0 80 1 80 40 NSCLC_SCC 0 75 1 75 41 NSCLC_SCC 0 50 1 50 42 NSCLC_SCC 0 70 0.5 35
[0497]
[0498] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Tissue Sample Brief subtype HER2 ASCO HER2-IHC assay of the present No. score disclosure
[0499] %TPS IS score 43 NSCLC_SCC 0 30 1 30 44 NSCLC_SCC 0 100 2 200 45 NSCLC_SCC 0 15 1 15 46 NSCLC_SCC 0 10 1 10
[0500]
[0501] Table 7: HER2 expression by IHC in NSCLC subtypes.
[0502] HER2-IHC assay of the present disclosure NSCLC_Adeno NSCLC_SCC
[0503] > 10% (any intensity) 100% (26 / 26) 95% (19 / 20)
[0504] > 50% (2+ & 3+) 57.7% (15 / 26) 15% (3 / 20)
[0505] > 75% (2+ & 3+) 57.7% (15 / 26) 15% (3 / 20)
[0506]
[0507] HER2 protein expression by IHC in GC
[0508] Twenty-six treatment-naive GC primary resection samples were analyzed by HER2 IHC, including 14 diffuse-type, 5 intestinal-type, and 7 mixed-type. Table 8 lists the manual pathologist scoring results for HER2 ASCO score and HER2-IHC score according to the present disclosure. Representative images for staining in each subtype show in Figure 14.
[0509] HER2 expression appeared highly heterogenous in this set of GC samples by both HER2 clinical IHC and HER2-IHC according to the present disclosure. The vast majority of GC samples (81%, 21 / 26) had ASCO score 0, 3 samples (12%) had ASCO score 1+ or 2+ / ISHneg, and 2 samples (8%) were HER2pos with ASCO score 3+. With the HER2-IHC assay of the present disclosure and applying an arbitrary threshold of 10% of tumor cells positive with any staining intensity, all GC samples across different histology subtypes were above the threshold. However, using a more stringent threshold, only 2 (14%) diffuse subtype samples, 1 (20%) intestinal subtype sample, and 3 (43%) mixed subtype samples had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 9).
[0510] As the ASCO score distribution was highly skewed in the GC sample set, it was not possible to perform statistical analysis to compare the HER2 expression by the HER2-IHC assay of the present disclosure among the HER2 ASCO score groups. Figure 15 illustrates that most of the GC samples have substantial HER2 expression with the HER2-IHC assay of the present disclosure.Attorney Docket No. 776519: NIT-59888PC
[0511] (PAT059888-PCT-SEC01)
[0512] Table 8: HER2 IHC scoring in gastric cancer.
[0513] Tissue
[0514] Sample HER2 HER2-IHC assay of the present disclosure No. Subtype
[0515] ASCO IS %TPS score 1 0 diffuse 1-2+ 80 120 2 0 diffuse 1 + 80 80 3 0 diffuse 1 + 10 10 4 0 diffuse 1 + 75 75 5 0 diffuse 1 + 90 90 6 0 diffuse 1-2+ 100 150 7 0 diffuse 1 + 80 80 8 0 diffuse 1 + 85 85 9 0 diffuse 1 + 60 60 10 0 diffuse 1 + 80 80 11 0 diffuse 2+ 80 160 12 0 diffuse 1 + 35 35 13 0 diffuse 2+ 80 160 14 0 diffuse 1 + 80 80 15 0 intestinal 1 + 80 80 16 0 intestinal 1 + 40 40 17 1 + intestinal 1-2+ 90 135 18 1 + intestinal 2+ 100 200 19 0 intestinal 1 + 100 100 20 0 mixed 1-2+ 75 112.5 21 0 mixed 1 + 50 50 22 0 mixed 2+ 95 190 23 0 mixed 1 + 90 90 24 2+ mixed 1-2+ 50 75 25 3+ mixed 3+ 100 300 26 3+ mixed 3+ 65 195
[0516]
[0517] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Table 9: HER2 expression by IHC in GC subtypes.
[0518] HER2-IHC assay of the Diffuse type Intestinal type Mixed type present disclosure
[0519] > 10% (any intensity) 100% (14 / 14) 100% (5 / 5) 100% (7 / 7)
[0520] > 50% (2+ & 3+) 14.3% (2 / 14) 20% (1 / 5) 42.9% (3 / 7) > 75% (2+ & 3+) 14.3% (2 / 14) 20% (1 / 5) 42.9% (3 / 7)
[0521]
[0522] HER2 Protein Expression by IHC in Bladder Cancer
[0523] A set of 23 treatment-naive bladder cancer surgical resections were analyzed by HER2 IHC. Table 10 lists the manual pathologist scoring results for HER2 ASCO score and the score of the HER2-IHC assay of the present disclosure. Representative images of staining are shown in Figure 16.
[0524] HER2 ASCO score distribution in this set of bladder cancer sample was as follows: 35% (8 / 23) with ASCO score 0, 17% (4 / 23) with ASCO score 1+, 35% (8 / 23) with ASCO score 2+, and 13% (3 / 23) with ASCO score 3+.
[0525] Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, all bladder cancer samples were above the threshold.
[0526] Using a more stringent threshold, more than half of the samples (12 / 23, 52%) had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 11).
[0527] The instant data indicate that HER2 expression by the HER2-IHC assay of the present disclosure was significantly lower in ASCO 0 samples, compared to ASCO 1+, 2+ and 3+ (P=0.0136, 0.0003 & 0.0121, respectively). HER2 expression by the HER2-IHC assay of the present disclosure was significantly lower in ASCO 1+ samples than ASCO 3+ samples (P=0.0477), but not ASCO 2+ samples (P=0.1573) (Figure 17). There was no statistical difference between ASCO 2+ vs. 3+ groups (P=0.1244) (Figure 17).
[0528] Table 10: HER2 IHC scoring in bladder cancer.
[0529] Tissue Sample No. HER2 HER2-IHC assay of the present disclosure ASCO Score
[0530] (follow GEA) IS %TPS score
[0531] 1 2+ 2+~3+ 100 250 2 0 1 + 95 95 3 0 1 + 50 50 4 2+ 2+ 95 190 5 2+ 2+~3+ 100 250 6 1 + 2+ 100 200
[0532]
[0533] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01)
[0534] Tissue Sample No. HER2 HER2-IHC assay of the present disclosure ASCO Score
[0535] (follow GEA) IS %TPS score
[0536] 7 1 + 2+ 100 200 8 2+ 1+-2+ 100 150 9 0 1+-2+ 90 135 10 0 2+ 10 20 11 0 1 + 70 70 12 0 1 + 75 75 13 2+ 2+~3+ 100 250 14 0 1 + 40 40 15 3+ 2+~3+ 100 250 16 0 1 + 80 80 17 1 + 1 + 100 100 18 3+ 2+~3+ 100 250 19 1 + 1+-2+ 100 150 20 2+ 2+~3+ 50 125 21 2+ 2+~3+ 100 250 22 3+ 3+ 100 300 23 2+ 2+~3+ 100 250
[0537]
[0538] Table 11: HER2 expression by IHC in bladder cancer.
[0539] HER2 IHC Assay Bladder Cancer
[0540] of the present disclosure
[0541] > 10% (any intensity) 23 / 23 (100%)
[0542] > 50% (2+ & 3+) 12 / 23 (52.2%)
[0543] > 75% (2+ & 3+) 11 / 23 (47.8%)
[0544]
[0545] HER2 protein expression by IHC in CRC
[0546] In total 36 CRC samples were tested by HER2 IHC, including 10 MSI-high (Microsatellite instability-high) and 26 MSS (Microsatellite Stable); all were treatment-naive primary resections. HER2 ASCO scores and scores of the HER2-IHC assay of the present disclosure are recorded in Table 12 and Table 13.
[0547] HER2 ASCO score distribution in this set of CRC sample was as follows: 56% (20 / 36) with ASCO score 0, 22% (8 / 36) with ASCO score 1+, 22% (8 / 36) with ASCO score 2+, and 0 with ASCO score 3+.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, all MSI-high samples and 96% (25 / 26) of MSS samples were above the threshold. Using a more stringent threshold, only 2 MSI-high and 4 MSS samples had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 13).
[0548] The instant data indicate that HER2 expression level by the HER2-IHC assay of the present disclosure was significantly lower in ASCO 0 samples, compared to ASCO 1+ and 2+ (P=0.0204 and P=0.0023), but there was no statistical difference between ASCO 1+ and 2+ samples (P=0.2889) (Figure 18).
[0549] Table 12: HER2 IHC scoring in CRC.
[0550] Tissue Sample HER2 ASCO Score HER2-IHC assay of the No. (follow GC / GEJ) present disclosure IS %TPS score 1 negative 2+ 99 198 2 negative 1 + 100 150 3 negative 1 + 95 95 4 negative 1 + 95 95 5 negative 1 + 95 47.5 6 negative 1 + 99 148.5 7 negative 1 + 60 30 8 negative 1 + 95 95 9 negative 1 + 95 95 10 negative 2+ 95 190 11 negative 1 + 95 142.5 12 negative 1 + 80 80 13 negative 1 + 100 150 14 negative 1 + 95 95 15 negative 0 0 0 16 negative 1 + 50 50
[0551]
[0552] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 17 negative 1 + 80 80 18 negative 1 + 95 142.5 19 negative 1 + 80 80 20 negative 1 + 75 75 21 negative 1 + 95 95 22 equivocal 2+ 100 200 23 equivocal 2+ 100 200 24 negative 1 + 100 100 25 negative 1-2+ 100 150 26 negative 1 + 90 90 27 equivocal 2+ 100 200 28 equivocal 1 + 100 100 29 equivocal 1-2+ 95 142.5 30 negative 1-2+ 100 150 31 equivocal 1 + 100 100 32 equivocal 2+ 100 200 33 negative 1-2+ 100 150 34 negative 1-2+ 100 150 35 equivocal 1-2+ 100 150 36 negative 1-2+ 100 150
[0553]
[0554] Table 13: HER2 expression by IHC in CRC.
[0555] HER2-IHC assay of the present disclosure MSI-high MSS
[0556] > 10% (any intensity) 100% (10 / 10) 96.2% (25 / 26)
[0557] > 50% (2+ & 3+) 20% (2 / 10) 15.4% (4 / 26)
[0558] > 75% (2+ & 3+) 20% (2 / 10) 15.4% (4 / 26)
[0559]
[0560] Overview of HER2 expression by IHC in BrCa NSCLC, GC, Bladder cancer and CRCAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) A total of 199 patient surgical resections, including 68 BrCa, 46 NSCLC, 26 GC, 23 bladder cancer, and 36 of CRC were included in the HER2 tumor epidemiology study. With clinically established HER2 clinical IHC, about 47% of BrCa, 76% NSCLC, 81% GC, 35% bladder cancer and 56% CRC were with ASCO score 0 (Figure 19A). Note that currently, there are no ASCO / CAP scoring guidelines for HER2 in indications beyond BrCa and Gastric / GEJ cancer. The ASCO / CAP 2016 guideline on HER2 testing in Gastric / GEJ cancer was applied to the NSCLC, bladder cancer, and CRC samples. The data indicate that BrCa and bladder cancer samples have relatively more detectable HER2 with HER2 clinical IHC assay, compared to NSCLC, GC, and CRC (Figure 19A). With the HER2-IHC assay of the present disclosure, nearly all BrCa, NSCLC, GC, bladder cancer, and CRC patient samples were found to express detectable HER2 protein (Figure 19B).
[0561] By experimentally dividing the Score of the HER2-IHC assay of the present disclosure which ranged from 0-300 into 4 bins, 1) <50; 2) >50, <100; 3) >100, <200, and 4) >200, <300, to represent very low, low, moderate, and high HER2 protein expression, respectively. The data show that in the very low bin, 100% (17 / 17) samples had an ASCO score 0; in the low bin (>50, <100), 90% (44 / 49) samples were with ASCO score 0; in the moderate bin (>100, <200), majority samples (62%, 37 / 60) also had an ASCO score 0, with 22% and 15% having ASCO scores of 1+ and 2+, respectively. Interestingly, in the high Score bin (>200, <300) of the HER2-IHC assay of the present disclosure, samples were distributed almost evenly across ASCO score groups (Figure 20A).
[0562] Figure 20B illustrates the distribution of the HER2-IHC assay of the present disclosure score bins for each indication. BrCa samples predominantly fall in the HER2 high and moderate bins (57 / 68, 84%), with very few in the very low HER2 bin (2 / 68, 3%); NSCLC samples are distributed almost evenly across the HER2 bins, with slightly more cases in the HER2 high bin (17 / 46, 37%); close to half of the bladder cancer samples are in the HER2 high bin (10 / 23, 43%); and GC and CRC samples predominantly fall in the HER2 low and moderate bins, 81% GC (21 / 26) and 81% CRC (29 / 36).
[0563] CONCLUSION AND DISCUSSION
[0564] Clinical characterization of HER2 status has historically been primarily determined by HER2 IHC; however, clinically established HER2 IHC assay(s) and the accompanying ASCO / CAP HER2 scoring guidelines have been focused on detecting HER2 protein overexpression and / or ERBB2 gene amplification (Wolff, et aL, 2023; Bartley, et aL, 2016), for selecting patients that are eligible for HER2-targeted therapy. Recently, T-DXd has shown efficacy in patients with advanced breast cancer with low expression of HER2, including patients in the “HER2-low” (Modi, et aL, 2020; Modi, et aL, 2022) and “HER2 ultralow” categories (Bardia, et aL, 2024). Accurately and reproducibly classifying patients asAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) HER2-low or HER2 ultra-low with the existing HER2 clinical IHC assays is challenging, due to the inherent insensitivity of these assays.
[0565] As the importance of assessing low levels HER2 expression has grown, three types of solutions have been proposed. First, Baez-Navarro and colleagues have proposed practical steps to improve the robustness of existing HER2 clinical IHC assays, including increasing pathologist awareness of distinguishing HER2 scores 0, 1+, and 2+, concordance studies between different HER2 clinical IHC assays, concordance studies between pathologists, revisiting the ASCO / CAP definition of HER2 score 0, and requiring data to demonstrate that companion diagnostic assays work as anticipated in the real-world setting (Baez-Navarro, et aL, 2022). However, none of these steps address the fundamental problem that the current HER2 clinical assays are not calibrated to detect low levels of HER2 expression.
[0566] Second, using the existing HER2 clinical IHC assays, Kapil and colleagues have developed a deep-learning-based quantitative continuous scoring (QCS) - IA model, estimating the percentage of HER2-positive cells by providing a drug efficacy-driven definition of cellular positivity and adding a spatial component (spatial proximity score) to capture spatial heterogeneity and its effect on patient outcome (Kapil, et aL, 2024). Their approach seems to potentially enhance the ability to predict patient response to T-DXd, especially in the HER2-negative population (Kapil, et aL, 2024). Nevertheless, significant barriers exist to integrate this model into routine practice, including the requirement for a large amount of clinical data to fully validate the model, access to whole slide scanners, data analysis and advanced bioinformatic skills to run the model on whole-slide images, and the potentially long turn-around times for results.
[0567] Third, Moutafi and colleagues have developed an immunofluorescence (IF) assay with improved sensitivity, centered in the proper dynamic range for detection of unamplified HER2 in breast cancer (Moutafi, et aL, 2022). This HER2 IF assay relies on whole-slide scanning and AQUA (Automated quantitative analysis) for scoring (Moutafi, et aL, 2022). As a result, there are also substantial limitations to adopting HER2 IF / AQUA in the clinical laboratory setting, including reproducibility of IF staining; need for specialized fluorescence microscopy equipment for fluorescent image acquisition; concern of photobleaching, as the fluorophores can fade over time, necessitating timely scanning and review; data analysis and advanced bioinformatic skills to run the AQUA on whole-slide images, and the potentially long turn-around times for results.
[0568] A practical approach was taken to fill the growing need to assess low levels of HER2 expression; A new chromogenic IHC assay was developed with a highly specific anti-HER2 antibody clone (D8F12) that is commercially available. As demonstrated for the HER2 clinical IHC assays, chromogenic IHC is compatible with routine diagnostic pathologyAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) workflows, relatively affordable and easy to implement, with a fast turnaround time. The HER2-IHC assay of the present disclosure can be carried out on the Ventana Benchmark Ultra platform, a locked IHC system, guaranteeing reproducibility of staining. Scoring can be performed manually by pathologists, using a modified Allred H-score method for cyto-membranous HER2 staining.
[0569] A total of 199 patient surgical resections were included in the HER2 tumor epidemiology study. HER2 expression (ASCO / CAP score 1+, 2+ and 3+) with the HER2 clinical IHC assay was found in 52.9% (36 / 68) of BrCa, 23.9% (11 / 46) of NSCLC, 19.2% (5 / 26) of GC, 65.2% (15 / 23) of bladder cancer, and 44.4% (16 / 36) of CRC, while HER2 overexpression (ASCO / CAP score 3+ or 2+ / ISH-pos) was observed in 24% (16 / 68) of BrCa, 2.2% (1 / 46) of NSCLC, 7.7% (2 / 26) of GC, 13.0% (3 / 23) of bladder cancer, and 0% (0 / 36) of CRC. The HER2 overexpression rate in the BrCa sample set is higher than the report of occurs in ~15%-20% of BrCa (Slamon, et aL, 1987), since a balanced number of BrCa samples for the three hormone-receptor / HER2-defined subtypes were studied, to understand the HER2 expression across these subtypes, which introduced bias.
[0570] Consistently, Uzunparmak and coworkers observed similar results applying the HER2 clinical IHC assay to 4701 solid tumor samples from a range of indications identified HER2 overexpression (ASCO / CAP score 3+) in 10.3% (270 / 2611) of BrCa, 2.8% (6 / 211) of NSCLC, 13.9% (29 / 208) of GC / GEJ cancer, 21.6% (38 / 176) of urothelial cancer, and 3.3% (19 / 577) of CRC (Uzunparmak, et aL, 2023). Thus, although the instant dataset has small numbers of patient samples per indication, the results appear representative of the larger patient populations.
[0571] The HER2-IHC assay of the present disclosure was applied to the same set of patient samples and a substantial amount of HER2 protein expression in the HER2-negative (ASCO score 0, 1+ and 2+ / ISH-neg) BrCa, NSCLC, GC, bladder cancer, and CRC samples was discovered. The average H-score for the HER2-IHC assay of the present disclosure in HER2-undetected, HER2-ultralow, HER2-low and HER2-positive BrCa samples was 138, 207, 206, and 269, respectively (Modi, et aL, 2020; Geukens, et aL, 2023; Bardia, et aL, 2024). As expected, the data indicate that HER2 expression in HER2-positive BrCa is significantly higher than HER2 expression in HER2-negative BrCa (PcO.0001). Within HER2-negative BrCa, the HER2 expression in HER2-undetected BrCa is significantly lower than in BrCa above the limit of detection of HER2 clinical IHC (including HER2-ultra-low and HER2-low) (P=0.0014). Surprisingly, there was considerable overlap of HER2 expression in the HER2 low and HER2 ultra-low BrCa samples (P=0.8347). Similar overlap of HER2 expression in HER2-low categories was observed in the NSCLC, bladder cancer, and CRC samples, comparing ASCO 1+ and 2+ categories, the average H-score were 203 vs. 225 for NSCLC, 163 vs. 214 for bladder cancer, and 240 vs. 161 for CRC (all Rvalues > 0.05). InAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) the GC sample set, the average H-scores for ASCO 0, 1+, 2+ and 3+ were 92, 168, 75, and 248, respectively. Since more than 80% (21 / 26) of GC samples were ASCO score 0, with only two were ASCO score 1+, and one case with ASCO score 2+, there was insufficient data to make comparisons between the subgroups.
[0572] A recent imaging study, IMPACT-MBC, assessed whole-body HER2 expression in 200 advanced metastatic BrCa patients by PET imaging with89Zr-trastuzumab (Eisses, et aL, 2024). A total of 5,163 metastases were imaged, 186 of which were biopsied and stained with the clinical HER2 IHC assay. PET tumor uptake exceeded background uptake in HER2-low and even in HER2-negative metastases. The SUVmax of BrCa metastases with HER2 scores 0, 1+ and 2+ is largely overlapping, with mean SUVmax of 7.0, 7.6, and 7.3, respectively (Eisses, et aL, 2024). Although the instant study included predominantly primary treatment-naive BrCa resections, the results are consistent with those of Eisses.
[0573] By applying the HER2-IHC assay of the present disclosure to BrCa, NSCLC, GC, bladder cancer, and CRC patient samples, a substantial amount of HER2 protein expression that was unappreciated using the less sensitive HER2 clinical IHC assay was uncovered. These results potentially expand the patient populations that may benefit from novel HER2-directed therapies targeting tumors with low levels of HER2 expression. In addition, the HER2-IHC assay of the present disclosure assay has the potential to provide a robust means to detect patients who may benefit from these treatments in a routine hospital setting.
[0574] References
[0575] 1. Agrawal, L., Engel, K. B., Greytak, S. R. & Moore, H. M., 2017. Understanding Preanalytical Variables and their Effects on Clinical Biomarkers of Oncology and Immunotherapy. Semin Cancer Biol, Volume 52, pp. 26-38.
[0576] 2. Baez-Navarro, X. et aL, 2022. Selecting patients with HER2-low breast cancer:
[0577] Getting out of the tangle. European Journal of Cancer, Volume 175, pp. 187-192.
[0578] 3. Bardia, A. et aL, 2024. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N ENGL J MED.
[0579] 4. Bartley, A., Washington, M., Ventura, C. & et, a., 2016. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. Am J Clin Pathol, 146(6), pp. 647- 669.
[0580] 5. Eisses, B. et aL, 2024. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer. J Nucl Med, Volume 65, p.
[0581] 1540-1547.
[0582] 6. Geukens, T. et aL, 2023. Intra-patient and inter-metastasis heterogeneity of HER2- low status in metastatic breast cancer. Eur J Cancer, Volume 188, pp. 152-160.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 7. Kapil, A. et aL, 2024. HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer. Scientific Reports, Volume 14, p. 12129.
[0583] 8. McCabe, A., Dolled-Filhart, M., Camp, R. L. & Rimm, D. L., 2005. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. J Natl Cancer Inst, Volume 97, pp. 1808-1815.
[0584] 9. Meric-Bernstam, F. et aL, 2024. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of Clinical Oncology, 42(1).
[0585] 10. Modi, S. et aL, 2020. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase lb study. Journal of Clinical Oncology, 38(17), pp. 1887-1897.
[0586] 11. Modi, S., Jacot, W., Yamashita, T. & et, a., 2022. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med, 387(1), p. 9e20.
[0587] 12. Modi, S. et aL, 2020. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a Phase lb study. J Clin Oncol, 38(17), p. 1887e96.
[0588] 13. Moutafi, M. et aL, 2022. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Laboratory Investigation, Volume 102, p. 1101-1108.
[0589] 14. Schrohl, A., Pedersen, H., Jensen, S. & et, a., 2011. Human epidermal growth factor receptor 2 (HER2)immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology, Volume 59, pp. 975-983.
[0590] 15. Slamon, D. J. et aL, 1987. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2 / neu Oncogene. Science, 235(4785), pp. 177-182.
[0591] 16. Uzunparmak, B. et aL, 2023. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol, 34(11), pp. 1035-1046.
[0592] 17. Wolff, A. C., Somerfield, M. R., Dowsett, M. & et, a., 2023. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. Journal of Clinical Oncology, 41(22), pp. 3867-3872.
[0593] 18. Wolff, A. et aL, 2018. Human Epidermal growth factor receptor 2. J Clin Oncol, 36(20), pp. 2105-2122.
[0594] 19. Wolff, A., Hammond, M., Schwartz, J. & et, a., 2007. American Society of Clinical Oncology / College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25, Volume 25, pp.
[0595] 118-145.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 20. DepMap, Broad (2023): This DepMap release contains data from CRISPR knockout screens from project Achilles, as well as genomic characterization data from the CCLE project. Ghandi et aL, Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503-508 (2019).
[0596] Example II. Analytical validation of Membranous HER2 protein expression in Breast Cancer, Non-small Cell Lung Cancer, Gastric Cancer, and Bladder Cancer.
[0597] Validation was conducted in Formalin-Fixed Paraffin-Embedded (FFPE) specimens on the Ventana™ BenchMark™ Ultra (Roche) staining platform. All evaluated performance characteristics — including accuracy, analytical specificity and sensitivity, inter-method concordance, and precision — met predefined acceptance criteria.
[0598] Validation Cohort
[0599] • A total of 129 FFPE primary tumor resection specimens were included, spanning: Breast cancer (ER-positive and triple-negative);
[0600] • Gastric / gastroesophageal junction carcinoma;
[0601] • Non-small cell lung adenocarcinoma; and
[0602] • Bladder carcinoma.
[0603] While the internal HER2 epidemiology project ensured a balanced selection of hormone-receptor / HER2-defined breast cancer subtypes for each tumor, the Tier 3 assay validation used randomly chosen tumor samples from the laboratory biobank.
[0604] A commercial HER2 dynamic range analyte control cell microarray (HER2 Analyte ControlDR(HCL028, Sigma-Aldrich)) and the HER2-negative HL-60 cell line derived from a 36-year-old female with acute promyelocytic leukemia, were included as run controls.
[0605] Matched isotype controls confirmed staining specificity across all validation runs.
[0606] HER2-US IHC Scoring Approaches:
[0607] Two semi-quantitative scoring methods were validated:
[0608] 1. Manual Pathologist Scoring on glass slides
[0609] • Assessment limited to membranous staining in invasive tumor regions
[0610] • Intensity scored as 0, 1+, 2+, or 3+
[0611] • Membranous H-score (0-300) calculated as:
[0612] (1 x %1+) + (2 x %2+) + (3 x %3+)
[0613] 2. Digital Image Analysis (Tier-3)
[0614] • Whole slide images generated using 3DHistech Pannoramic 1000 scanner
[0615] • Analysis performed in the whole-slide image analysis platform HALO (Indica Labs) • Al-trained classifiers used for tumor identification and membrane segmentationAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) • Thresholds trained to reproduce manual Tumor Proportion Score (TPS) and
[0616] H-scores
[0617] • Algorithms validated across breast, NSCLC, GC / GEJ, and bladder cancers RESULTS
[0618] A broad dynamic range of membranous HER2 expressions was observed across all indications. Intra-run and inter-run precision testing demonstrated 100% concordance, supporting assay robustness (FIGS. 21 A-B). Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, 95% or greater samples were above the threshold across all indications. Applying a more stringent threshold, 20% or greater samples across all indications had 50% or more of tumor cells positive with moderate to strong staining intensity, and at least 12% of samples across indications had 75% or more tumor cells positive with moderate to strong staining intensity, with greater than 40% of BrCa and Bladder Cancer cells with moderate to strong membranous staining intensity (Table 14).
[0619] Table 14: Validated membranous HER2 expression by the HER2-IHC assay of the present disclosure across indications.
[0620] HER2-IHC Breast Cancer NSCLC (Adeno) Gastric Bladder assay of the Cancer Cancer present
[0621] disclosure
[0622] > 10% (any 28 / 29 (96.6%) 39 / 40 (97.5%) 19 / 20 (95%) 19 / 20 (95%) intensity)
[0623] > 50% (2+ & 3+) 19 / 29 (65.5%) 16 / 40 (40%) 4 / 20 (20%) 11 / 20 (55%) > 75% (2+ & 3+) 12 / 29 (41.4%) 5 / 40 (12.5%) 3 / 20 (15%) 9 / 20 (45%)
[0624]
[0625] These results provide further support for selection of indications beyond Hormone receptor-positive breast cancer (HR+CR) for HER2-targeted interventions such as HER2 radioligand therapies, Antibody-based therapeutic agents, and other HER2-targeted modalities.
[0626] Example III. Aged Slide Epitope Stability
[0627] HER2 epitope stability was evaluated using six samples stained using the HER2-IHC assay of the present disclosure. The samples spanned low, medium, and high HER2 expression. Serial sections were stained at the following time points: Freshly cut, 1 month, 3 months, 6 months, and 7 months.
[0628] Based on qualitative assessment, HER2 staining remained largely stable for up to 3 months, while observed reduced staining intensity at 6-7 months, particularly in low HER2-Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) expressing samples. These results support performing the HER2-IHC assay of the present disclosure on cut slides <3 months of post-sectioning. Additional aged slide time points between 3-6 months are under evaluation.
[0629] Example IV. HER2 protein expression in High-grade Serous Ovarian Carcinoma (HGSOC), Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC), Prostate Carcinoma (PCa), Small Cell Lung Cancer (SCLC).
[0630] Using the IHC assay techniques described above, HER2 protein expression was evaluated by the HER2 IHC assay of the present disclosure in five additional tumor types:
[0631] • High-grade serous ovarian carcinoma (HGSOC)
[0632] • Head and neck squamous cell carcinoma (HNSCC)
[0633] • Pancreatic ductal adenocarcinoma (PDAC)
[0634] • Prostate carcinoma (PCa)
[0635] • Small cell lung cancer (SCLC)
[0636] Across indications, the HER2-IHC assay of the present disclosure revealed broader and more continuous HER2 expression compared with conventional ASCO scoring. Applying low threshold criteria (>10% tumor cells with any membranous staining) identified a substantial fraction of samples as HER2 expressing, while stricter thresholds enriched subsets with higher expression levels. Detailed scoring distributions, summary tables, and representative images are provided for each indication, below
[0637] IV(a). HER2 protein expression by IHC in high-grade serous ovarian carcinoma (HGSOC)
[0638] A set of 20 treatment-naive HGSOC primary resection samples were analyzed by HER2 IHC. Table 15 lists the manual pathologist scoring results for HER2 ASCO score and the score of the HER2-IHC assay of the present disclosure. Representative images of staining are shown in Figure 22.
[0639] HER2 ASCO score distribution in this set of HGSOC sample was as follows: 60% (12 / 20) with ASCO score 0, 20% (4 / 20) with ASCO score 1+, 10% (2 / 20) with ASCO score 2+, and 10% (2 / 20) with ASCO score 3+.
[0640] Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, all HGSOC samples were above the threshold. Applying a more stringent threshold, a quartile of HGSOC samples (5 / 20, 25%) had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 16).
[0641] Table 15: Manual pathologist scoring of HER2-expression in HGSOC.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Tissue
[0642] HER2 HER2-IHC assay of the present disclosure
[0643] Sample
[0644] ASCO
[0645] No. IS %TPS score
[0646] 27 0 1 + 90 90
[0647] 28 0 1 + 90 90
[0648] 29 0 1 + 80 80
[0649] 30 0 1 + 95 95
[0650] 31 1 1-2+ 95 142.5
[0651] 32 2 2+ 100 200
[0652] 33 1 1 + 95 95
[0653] 34 0 2+ 100 200
[0654] 35 0 1 + 80 80
[0655] 36 0 1 + 100 100
[0656] 37 0 2+ 100 200
[0657] 38 3 3+ 100 300
[0658] 39 3 3+ 100 300
[0659] 40 0 1 + 80 80
[0660] 41 0 1 + 98 98
[0661] 42 1 1 + 95 95
[0662] 43 1 1 + 95 95
[0663] 44 0 1 + 75 75
[0664] 45 0 1 + 100 100
[0665] 46 0 1 + 98 98
[0666]
[0667] Table 16: HER2 expression by IHC in HGSOC.
[0668] HER2 IHC Assay HGSOC
[0669] of the present disclosure
[0670] > 10% (any intensity) 20 / 20 (100%)
[0671] > 50% (2+ & 3+) 5 / 20 (25%)
[0672] > 75% (2+ & 3+) 5 / 20 (25%)
[0673]
[0674] IV(b). HER2 protein expression by IHC in Head and Neck squamous cell carcinoma (HNSCC).
[0675] A set of 26 treatment-naive HNSCC primary resection samples were analyzed by HER2 IHC. Table 17 lists the manual pathologist scoring results for HER2 ASCO score andAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) the score of the HER2-IHC assay of the present disclosure. Representative images of staining are shown in Figure 23.
[0676] HER2 ASCO score distribution in this set of HNSCC sample was as follows: 84.62% (22 / 26) with ASCO score 0, 0% (0 / 26) with ASCO score 1+, 0% (0 / 26) with ASCO score 2+, and 15.38% (4 / 26) with ASCO score 3+.
[0677] Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, all HNSCC samples were above the threshold. Applying a more stringent threshold, a small subset of the HNSCC samples (5 / 26, 19.23%) had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 18).
[0678] Table 17: Manual pathologist scoring of HER2-expression in HNSCC.
[0679] Tissue
[0680] HER2 HER2-IHC assay of the present disclosure
[0681] Sample
[0682] ASCO
[0683] No. IS %TPS score
[0684] 1 0 1 + 90 90
[0685] 2 0 1 + 100 100
[0686] 3 0 1 + 95 95
[0687] 4 0 1 + 90 90
[0688] 5 3 3+ 100 300
[0689] 6 0 1 + 90 90
[0690] 7 0 0-1 + 70 35
[0691] 8 0 1 + 80 80
[0692] 9 0 1 + 100 100
[0693] 10 0 1 + 80 80
[0694] 11 0 1 + 100 100
[0695] 12 3 3+ 100 300
[0696] 13 3 2+ 100 200
[0697] 14 0 1 + 95 95
[0698] 15 0 1 + 95 95
[0699] 16 0 1 + 100 100
[0700] 17 0 1 + 100 100
[0701] 18 0 0-1 + 50 25
[0702] 19 0 1 + 50 50
[0703] 20 0 1 + 50 50
[0704]
[0705] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Tissue
[0706] HER2 HER2-IHC assay of the present disclosure
[0707] Sample
[0708] ASCO
[0709] No. IS %TPS score
[0710] 21 0 1 + 50 50
[0711] 22 3 2+ 100 200
[0712] 23 0 1 + 100 100
[0713] 24 0 1 + 90 90
[0714] 25 0 1 + 50 50
[0715] 26 0 2+ 100 200
[0716]
[0717] Table 18: HER2 expression by IHC in HNSCC.
[0718] HER2 IHC Assay HNSCC
[0719] of the present disclosure
[0720] > 10% (any intensity) 26 / 26 (100%)
[0721] > 50% (2+ & 3+) 5 / 26 (19.23%)
[0722] > 75% (2+ & 3+) 5 / 26 (19.23%)
[0723]
[0724] IV(c). HER2 protein expression by IHC in pancreatic ductal adenocarcinoma (PDAC).
[0725] A set of 30 treatment-naive PDAC primary resection samples were analyzed by HER2 IHC. Table 19 lists the manual pathologist scoring results for HER2 ASCO score and the score of the HER2-IHC assay of the present disclosure. Representative images of staining are shown in Figure 24.
[0726] HER2 ASCO score distribution in this set of PDAC sample was as follows: 46.67% (14 / 30) with ASCO score 0, 43.33% (13 / 30) with ASCO score 1+, 10% (3 / 30) with ASCO score 2+, and 0% (0 / 30) with ASCO score 3+.
[0727] Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, 96.67% (29 / 30) PDAC samples were above the threshold. Applying a more stringent threshold, about one-third of the PDAC samples (9 / 30, 30%) had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 20).
[0728] Table 19: Manual pathologist scoring of HER2-expression in PDAC
[0729] Tissue
[0730] HER2 HER2-IHC assay of the present disclosure
[0731] Sample
[0732] ASCO
[0733] No. IS %TPS score
[0734] 1 0 0 100 0
[0735] 2 0 2+ 95 200
[0736]
[0737] Attorney Docket No. 776519: NIT-59888PC
[0738] (PAT059888-PCT-SEC01)
[0739] Tissue
[0740] HER2 HER2-IHC assay of the present disclosure Sample
[0741] ASCO
[0742] No. IS %TPS score 3 0 2+ 100 190 4 0 1 + 100 100 5 0 1 + 100 100 6 0 1 + 100 100 7 0 1 + 100 100 8 0 0-1 + 100 50 9 0 1 + 100 100 10 0 1 + 100 100 11 0 1 + 100 100 12 0 1 + 100 100 13 0 1 + 100 100 14 0 1 + 100 100 15 1 2+ 100 200 16 1 1-2+ 100 150 17 1 1 + 100 100 18 1 2+ 100 200 19 1 2+ 100 200 20 1 1 + 100 100 21 1 1 + 100 100 22 1 2+ 100 200 23 1 1 + 100 100 24 1 1 + 100 100 25 1 1-2+ 100 150 26 1 1 + 100 100 27 1 2+ 100 200 28 2 2+ 100 200 29 2 1-2+ 100 150 30 2 2+ 100 200
[0743]
[0744] Table 20: HER2 expression by IHC in PDACAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) HER2 IHC Assay PDAC
[0745] of the present disclosure
[0746] > 10% (any intensity) 29 / 30 (96.67%)
[0747] > 50% (2+ & 3+) 9 / 30 (30%)
[0748] > 75% (2+ & 3+) 9 / 30 (30%)
[0749]
[0750] IV(d). HER2 protein expression by IHC in prostate carcinoma (PCa).
[0751] A set of 23 treatment-naive PCa primary resection samples were analyzed by HER2 IHC. Table 21 lists the manual pathologist scoring results for HER2 ASCO score and the score of the HER2-IHC assay of the present disclosure. Representative images of staining are shown in Figure 25.
[0752] HER2 ASCO score distribution in this set of PCa sample was as follows: 91.30 % (21 / 23) with ASCO score 0, 4.35% (1 / 23) with ASCO score 1+, 4.35% (1 / 23) with ASCO score 2+, and 0% (0 / 23) with ASCO score 3+.
[0753] Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, all PCa samples were above the threshold. Applying a more stringent threshold, more than one-third of the PCa samples (9 / 23, 39.13%) had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 22).
[0754] Table 21: Manual pathologist scoring of HER2-expression in SCLC.
[0755] Tissue
[0756] HER2 HER2-IHC assay of the present disclosure
[0757] Sample
[0758] ASCO
[0759] No. IS %TPS score
[0760] 1 0 1 + 100 100
[0761] 2 0 2+ 100 200
[0762] 3 0 1 + 100 100
[0763] 4 0 1 + 100 100
[0764] 5 0 1 + 100 100
[0765] 6 0 1 + 100 100
[0766] 7 0 1 + 100 100
[0767] 8 0 1 + 100 100
[0768] 9 0 2+ 100 200
[0769] 10 0 2+ 100 200
[0770] 11 0 2+ 100 200
[0771] 12 0 1 + 100 100
[0772] 13 0 1-2+ 95 142.5
[0773]
[0774] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Tissue
[0775] HER2 HER2-IHC assay of the present disclosure
[0776] Sample
[0777] ASCO
[0778] No. IS %TPS score
[0779] 14 0 2+ 100 200
[0780] 15 0 1 + 100 100
[0781] 16 0 1 + 100 100
[0782] 17 0 1 + 100 100
[0783] 18 0 1-2+ 100 150
[0784] 19 0 2+ 100 200
[0785] 20 0 2+ 100 200
[0786] 21 0 2+ 100 200
[0787] 22 1 1 + 100 100
[0788] 23 2 2+ 100 200
[0789]
[0790] Table 22: HER2 expression by IHC in PCa
[0791] HER2 IHC Assay PCa
[0792] of the present disclosure
[0793] > 10% (any intensity) 23 / 23 (100%)
[0794] > 50% (2+ & 3+) 9 / 23 (39.13%)
[0795] > 75% (2+ & 3+) 9 / 23 (39.13%)
[0796]
[0797] IV(e). HER2 protein expression by IHC in Small-cell Lung cancer (SCLC).
[0798] A set of 36 treatment-naive SCLC primary resection samples were analyzed by HER2 IHC. Table 23 lists the manual pathologist scoring results for HER2 ASCO score and the score of the HER2-IHC assay of the present disclosure. Representative images of staining are shown in Figure 26.
[0799] HER2 ASCO score distribution in this set of SCLC sample was as follows: 94.44 % (34 / 36) with ASCO score 0, 5.56% (2 / 36) with ASCO score 1+, 0% (0 / 36) with ASCO score 2+, and 0% (0 / 36) with ASCO score 3+.
[0800] Using the HER2-IHC assay of the present disclosure and applying an arbitrary threshold at 10% of tumor cells positive with any staining intensity, one-third (12 / 36) SCLC samples were above the threshold.
[0801] Using a more stringent threshold, only one SCLC sample (1 / 36, 2.78%) had 50% or more of tumor cells positive with moderate to strong staining intensity (Table 24).
[0802] Table 23: Manual pathologist scoring of HER2-expression in SCLC.Attorney Docket No. 776519: NIT-59888PC
[0803] (PAT059888-PCT-SEC01)
[0804] Tissue
[0805] HER2 HER2-IHC assay of the present disclosure Sample
[0806] ASCO
[0807] No. IS %TPS score
[0808] 1 0 0 0 0
[0809] 2 0 0 0 0
[0810] 3 0 0 0 0
[0811] 4 0 0 0 0
[0812] 5 0 1 5 5
[0813] 6 0 0 0 0
[0814] 7 0 0 0 0
[0815] 8 0 0 0 0
[0816] 9 0 0 0 0
[0817] 10 0 1 + 50 50
[0818] 11 0 0 0 0
[0819] 12 0 0 0 0
[0820] 13 0 0 0 0
[0821] 14 0 0 0 0
[0822] 15 0 0 0 0
[0823] 16 0 0 0 0
[0824] 17 0 1 + 70 70
[0825] 18 0 0 0 0
[0826] 19 0 1 + 30 30 20 0 1 + 50 50 21 0 1 + 70 70
[0827] 22 0 0 0 0
[0828] 23 0 0 0 0
[0829] 24 0 0 0 0
[0830] 25 0 0 0 0
[0831] 26 0 1-2+ 95 142.5 27 0 1 + 95 95 28 0 0 0 0
[0832] 29 0 0-1 + 10 5
[0833] 30 0 0 0 0
[0834] 31 0 0 0 0
[0835] 32 0 0 0 0
[0836] 33 0 0 0 0
[0837]
[0838] Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01)
[0839] Tissue
[0840] HER2 HER2-IHC assay of the present disclosure
[0841] Sample
[0842] ASCO
[0843] No. IS %TPS score
[0844] 34 0 0-1 + 70 35
[0845] 35 1 2+ 95 190
[0846] 36 1 1 + 95 95
[0847]
[0848] Table 24: HER2 expression by IHC in SCLC
[0849] HER2 IHC Assay SCLC
[0850] of the present disclosure
[0851] > 10% (any intensity) 12 / 36 (33.33%)
[0852] > 50% (2+ & 3+) 1 / 36 (2.78%)
[0853] > 75% (2+ & 3+) 1 / 36 (2.78%)
[0854]
[0855] Example V. Quantitative HER2 Measurement Strategy
[0856] This example describes a standardized quantitative flow cytometry (QFCM) / quantitative fluorescence-activated cell sorting assay using Phycoerythrin (PE)-conjugated anti-HER2 monoclonal antibody (clone D8F12) to measure cell surface HER2 antigen density. The assay is calibrated using Quantibrite™ PE beads with known ratio of PE molecules / bead to build a PE calibration curve with high linearity. Cell PE fluorescence is converted to PE molecules per cell, then computed to HER2 antibody binding capacity (ABC), and subsequently converted to HER2 molecules per cell.
[0857] A back-up approach includes single-cell Inductively Coupled Plasma Mass Spectrometry (ICP-MS), using an unique isotope metal-labeled HER2 antibody (e.g., clone D8F12, as described above). The approach uses Quantum Simply Cellular (QSC) beads to bind a precise amount of antibody, allowing for the quantitative analysis of cell antigens, which in this case are measured by the metal tags via ICP-MS rather than fluorophores. The QSC beads are stained with known ABC with the same metal-tagged HER2 antibody to create the calibration curve, and subsequently the cell events are converted to obtain ABC-like outputs.
[0858] A cell mixing experiment combining a high HER2-expressing cell line (e.g., HCC1569) with a HER2 negative cell line (HL 60) was performed in serial dilutions to model a range of HER2 expression levels. This approach enables generation of a linear regression model to cross-check the assay sensitivity.
[0859] HER2 molecules per cell were quantified in seven cell lines (HL-60, Jurkat, BT-20, T47D, BT-483, ZR-75-1, and BT-474) cultured in standardized cell culture conditions using the qFACS / QFCM assay (and / or ISP-MS assay). Same passage cell lines were processedAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) and embedded into FFPE cell pellet blocks, and FFPE cell pellet microarrays (CPA) containing these cell lines were stained using the HER2-IHC assay of the present disclosure.
[0860] Digital image analysis was applied to derive semi quantitative HER2 membranous Flscores. A mathematical model (under development) is utilized to convert membranous Flscores into absolute HER2 molecules per cell.
[0861] These assays are suitable for use in quantification of HER2 molecules per cell across FFPE tissues, correlation of absolute HER2 expression with preclinical and clinical outcomes, and development of image analysis-based predictive models for response to HER2 targeted therapies.
[0862] Example VI. Development of a Quantitative Continuous Scoring (QCS) Al model
[0863] The HER2-IHC assay of the present disclosure is combined with validated digital image analysis and applied to baseline samples from HER2-targeted clinical trials, with clinical outcome data to develop a deep learning-based QCS model.
[0864] Standard pathology slides stained for HER2 using the IHC assay of the present disclosure are digitized using high-resolution whole-slide imaging. The digital images preserve the full tissue context while enabling automated, computer-based analysis. The digital images are then processed to identify individual cells within the tissue, which are analyzed at the single cell level for staining in the cell membrane and / or the interior of the cell. The QCS provides numerical values based on the intensity of HER2 staining, with reduced variability between pathologists, laboratories, and institutions. The consistency is particularly advantageous in cases that currently fall near diagnostic thresholds, such as HER2 low or equivocal samples.
[0865] By linking the digital image analysis to clinical outcomes, the method strengthens the evidence based foundation for HER2 classification and provides clinically actionable insights. This approach aims to provide continuous HER2 quantification and enable prediction of therapeutic response and resistance, supporting development of HER2 radioligand therapies (Lu, Ac-based) as well as Antibody-based and other HER2-targeted modalities (e.g., ADCs). This approach may also uncover subtle differences not readily apparent through conventional scoring methods, enabling more nuanced patient stratification.
[0866] It is to be understood that the disclosure is not limited to the particular embodiments of the disclosure described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present disclosure will be established by the appended claims.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification are incorporated herein by reference, in their entirety.
[0867] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
[0868] As used herein, the singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. The term “includes” is defined inclusively, such that “includes A or B” means including A, B, or A and B.
[0869] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, or” or “and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the
[0870] inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of or “exactly one of” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
[0871] The terms “comprising,” “including,” “having,” and the like are used interchangeably and have the same meaning. Similarly, “comprises,” “includes,” “has,” and the like are used interchangeably and have the same meaning. Specifically, each of the terms is defined consistent with the common United States patent law definition of “comprising” and is therefore interpreted to be an open term meaning “at least the following,” and is also interpreted not to exclude additional features, limitations, aspects, etc. Thus, for example, “a system having components a, b, and c” means that the system includes at least components a, b, and c. Similarly, the phrase: “a method involving steps a, b, and c” means that the method includes at least steps a, b, and c. Moreover, while the steps and processes may be outlined herein in a particular order, the skilled artisan will recognize that the ordering steps and processes may vary.
[0872] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within theAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
[0873] Reasonable variations and modifications are possible in the component parts and / or arrangements of the subject combination arrangement within the scope of the foregoing disclosure, the drawings, and the appended claims without departing from the spirit of the disclosure. In addition to variations and modifications in the component parts and / or arrangements, alternative uses will also be apparent to those skilled in the art.
Claims
Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) WHAT IS CLAIMED IS:
1. A method of treating a tumor expressing a human epidermal growth factor receptor-2 (HER2) protein in a subject in need thereof, comprising:(a) identifying the subject by detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a potential subject;wherein HER2 positive tumor cells are detected by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein,wherein the reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors;wherein the HER2 positive tumor cell exhibits membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions; and(b) administering a therapeutically effective dose of a HER2-directed therapy to the subject.
2. The method of claim 1 , wherein the reagent specifically binds an epitope within a domain of the HER2 protein that is targeted by the HER2-directed therapy.
3. The method of claim 1 or 2, wherein the reagent specifically binds an epitope within an extracellular domain of the HER2 protein.
4. The method of any one of claims 1 -3, wherein the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein.
5. The method of any one of the preceding claims, wherein the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1.
6. The method of any one of the preceding claims, wherein the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1.
7. The method of any one of the preceding claims, wherein the reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 8. The method of any one of the preceding claims, wherein the membrane and / or cytomembrane staining intensity is determined using light microscopy, virtual microscopy, whole slide imaging, an image-transmitting camera, imaging sensor, a charge-coupled device (CCD), a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
9. The method of any one of the preceding claims, wherein the HER2 positive tumor cells are detected by computer-assisted image analysis or manual analysis of the tissue sample.
10. The method of claim 9, wherein computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample.
11. The method of claim 9 or 10, wherein the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis.
12. The method of claim 11 , wherein the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
13. The method of any one of the preceding claims, further comprising assessing the intensity of the IHC staining for each HER2 positive cell.
14. The method of any one of the preceding claims, further comprising determining a percentage of HER2 positive tumor cells in an area of the tissue sample.
15. The method of claim 14, wherein the percentage of HER2 positive tumor cells in the area is equal to or greater than 1%.
16. The method of claim 14 or 15, wherein the percentage of HER2 positive tumor cells in the area is equal to or greater than 10%.
17. The method of any one of claims 14 to 16, wherein the percentage of HER2 positive tumor cells in the area is equal to or greater than 30%.
18. The method of any one of the preceding claims, further comprising determining an IHC score.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01)19. The method of claim 18, wherein the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
20. The method of claim 19, wherein the IHC score is an H-score.
21. The method of claim 19 or 20, wherein determining the IHC score comprises manual analysis, digital imaging analysis, computer-assisted image analysis, an AI / ML-assisted image analysis, fully automated analysis, and / or an end-to-end analysis.22 . The method of any one of the preceding claims, wherein the tumor is an epithelial-derived carcinoma.
23. The method of claim 22, wherein the epithelial-derived carcinoma is selected from gastric cancer, gastroesophageal junction cancer, colorectal cancer, breast cancer, lung cancer, small cell lung cancer, salivary gland cancer, ovarian cancer, esophageal cancer, bladder cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, uterine cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma.
24. The method of any one of the preceding claims, wherein the tumor is a solid tumor selected from breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, gastroesophageal junction cancer, bladder cancer, head and neck squamous cell carcinoma, prostate cancer, ovarian cancer, and colorectal cancer.
25. The method of any one of the preceding claims, wherein the tissue sample is a biopsy sample or a surgical resection sample.
26. The method of any one of the preceding claims, wherein the tissue sample is a tissue section with a thickness between 4 pm and 5 pm.
27. The method of claim 26, wherein the tissue section includes equal to or greater than 100 viable tumor cells.
28. The method of claim 26 or 27, wherein the IHC staining is performed within six months, within five months, within four months, within three months, within two months, orAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) within one month after sectioning the tissue, or performed within about 3 to 5 months, within about 2 to 4 months, or within about 1 to 3 months after sectioning the tissue.
29. The method of any one of the preceding claims, wherein the tissue sample is a formalin-fixed tissue sample.
30. The method of any one of the preceding claims, wherein the tissue sample is a deparaffinized tissue sample.31 . The method of any one of the preceding claims, wherein administering the therapeutically effective dose of the HER2-directed therapy to the subject comprises administration of a HER2-targeting compound, a HER2-targeting radioligand, or a HER2-targeting radiotherapeutic the subject.
32. The method of any one of the preceding claims, wherein administering the therapeutically effective dose of the HER2-directed therapy comprises administration of a HER2-targeting antibody, or a drug conjugate thereof, or a radiolabeled conjugate thereof, to the subject.
33. The method of any one of the preceding claims, wherein administering the therapeutically effective dose of the HER2-directed therapy comprises administration of trastuzumab, trastuzumab emtansine, ado-trastuzumab emtansine (TM1), trastuzumab deruxtecan (T-DXd), pertuzumab, margetuximab, zanidatamab, ertumaxomab, neratinib, tucatinib, pyrotinib, or lapatinib, or a bioequivalent or biosimilar thereof, or a radiolabeled conjugate thereof, to the subject.
34. The method of any one of the preceding claims, wherein administering the therapeutically effective dose of the HER2-directed therapy comprises administration of a HER2-targeting radiotherapeutic to the subject.
35. The method of claim 34, wherein the HER2-targeting radiotherapeutic comprises at least one of67Cu,186Re,188Re,90Y,177Lu,161Tb,153Sm,213Bi,1311,149Tb,47Sc,225Ac,212Pb,211At,223Ra,227Th, and226Th.
36. The method of claim 34 or 35, wherein the HER2-targeting radiotherapeutic comprises90Y,177Lu,1311,225Ac,211At, or227Th.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 37. The method of any one of claims 34-36, wherein the HER2-targeting radiotherapeutic comprises225Ac.
38. The method of any one of claims 34-37, wherein the HER2-targeting radiotherapeutic comprises177Lu.
39. The method of any one of the preceding claims, wherein the IHC staining further comprises contacting the tissue sample with an enzyme-labeled antibody specific for the reagent.
40. The method of claim 39, wherein the enzyme-labeled antibody comprises an oxidoreductase, hydrolase, or peroxidase.
41. The method of claim 39 or 40, wherein the enzyme-labeled antibody comprises a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, p-galactosidase, p-glucuronidase, or p-lactamase.
42. The method of claim 41 , wherein the enzyme-labeled antibody comprises HRP or AP.
43. The method of any one of the preceding claims, wherein the IHC staining further comprises contacting the tissue sample with 3,3’-diamino-benzidine (DAB), 4-nitrophenylphospate (pNPP), bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, fast red, AP Orange, AP blue, tetramethylbenzidine (TMB), 2,2'-azino-di-[3-ethylbenzothiazoline sulphonate] (ABTS), o-dianisidine, 4-chloronaphthol (4-CN), 4-Aminophenyl phosphate monosodium salt, Naphthol AS-BI-phosphate, nitrophenyl-p-D-galactopyranoside (ONPG), o-phenylenediamine (OPD), 5-bromo-4-chloro-3-indolyl-p-galactopyranoside (X-Gal), methylumbelliferyl-p-D-galactopyranoside (Mil-Gal), p-nitrophenyl-a-D-galactopyranoside (PNP), 5-bromo-4-chloro-3-indolyl-p-D-glucuronide (X-Gluc), 3-amino-9-ethyl carbazol (AEC), fuchsin, iodonitrotetrazolium (INT), tetrazolium blue, or tetrazolium violet.
44. The method of claim 43, wherein the tissue sample is contacted with DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 45. The method of any one of the preceding claims, wherein the HER2 negative cell line comprises HL-60 or Farage cells.
46. An in vitro method of identifying a HER2 protein expressing tumor, the method comprising:detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a potential subject;wherein HER2 positive tumor cells are detected by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein, which reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors;wherein the HER2 positive tumor cell exhibits membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions, thereby identifying the tumor as the HER2 protein expressing tumor.
47. The method of claim 46, wherein the reagent specifically binds an epitope within a domain of the HER2 protein that is targeted by a HER2-directed therapy.
48. The method of claim 46 or 47, wherein the reagent specifically binds an epitope within an extracellular domain of the HER2 protein.
49. The method of any one of claims 46-48, wherein the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein.
50. The method of any one of claims 46-49, wherein the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1.
51. The method of any one of claims 46-50, wherein the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1.
52. The method of any one of claims 46-50, wherein the reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.
53. The method of any one of claims 46-52, wherein the membrane and / or cytomembrane staining intensity is determined using light microscopy, virtual microscopy, whole slide imaging, an image-transmitting camera, an imaging sensor, a charge-coupledAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
54. The method of any one of claims 46-53, wherein the HER2 positive tumor cells are detected by computer-assisted image analysis or manual analysis of the tissue sample.
55. The method of claim 54, wherein computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample.
56. The method of claim 54 or 55, wherein the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis.
57. The method of claim 56, wherein the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
58. The method of any one of claims 46-57, further comprising assessing the intensity of the IHC staining for each HER2 positive cell.
59. The method of any one of claims 46-58, further comprising determining a percentage of HER2 positive tumor cells in an area of the tissue sample.
60. The method of claim 59, wherein the percentage of HER2 positive tumor cells in the area is equal to or greater than 1%, equal to or greater than 10%, or equal to or greater than 30%.
61. The method of any one of claims 46-60, further comprising determining an IHC score.
62. The method of claim 61 , wherein the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
63. The method of claim 62, within the IHC score is an H-score.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 64. The method of any one of claims 61 -63, wherein determining the IHC score comprises manual analysis, digital imaging analysis, computer-assisted image analysis, an AI / ML-assisted image analysis, fully automated analysis, and / or an end-to-end analysis.
65. The method of any one of claims 46-64, wherein the tumor is an epithelial-derived carcinoma.
66. The method of claim 65, wherein the epithelial-derived carcinoma is selected from gastric cancer, gastroesophageal junction cancer, colorectal cancer, breast cancer, lung cancer, small cell lung cancer, salivary gland cancer, ovarian cancer, esophageal cancer, bladder cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, uterine cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma.
67. The method of any one of claims 46-66, wherein the tumor is a solid tumor selected from breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, gastroesophageal junction cancer, bladder cancer, head and neck squamous cell carcinoma, prostate cancer, ovarian cancer, and colorectal cancer.
68. The method of any one of claims 46-67, wherein the tissue sample is a biopsy sample or a surgical resection sample.
69. The method of any one of claims 46-66, wherein the tissue sample is a tissue section with a thickness between 4 pm and 5 pm.
70. The method of claim 69, wherein the tissue section includes equal to or greater than 100 viable tumor cells.
71. The method of claim 69 or 70, wherein the IHC staining is performed within six months after sectioning the tissue or within about five months, within about four months, within about three months, within about two months or within about 1 month after sectioning the tissue.
72. The method of any one of claims 46-61 , wherein the tissue sample is a formalin-fixed tissue sample.
73. The method of any one of claims 46-72, wherein the tissue sample is a deparaffinized tissue sample.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01)74. The method of any one of claims 46-73, wherein the IHC staining further comprises contacting the tissue sample with an enzyme-labeled antibody specific for the reagent.
75. The method of claim 74, wherein the enzyme-labeled antibody comprises an oxidoreductase, hydrolase, or peroxidase.
76. The method of claim 774 or 75, wherein the enzyme-labeled antibody comprises a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, p-galactosidase, p-glucuronidase, or p-lactamase.
77. The method of claim 76, wherein the enzyme-labeled antibody comprises HRP or AP.
78. The method of any one of claims 46-77, wherein the IHC staining further comprises contacting the tissue sample with 3,3’-diamino-benzidine (DAB), 4-nitrophenylphospate (pNPP), bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, AP Orange, AP blue, tetramethylbenzidine (TMB), 2,2'-azino-di-[3-ethylbenzothiazoline sulphonate] (ABTS), o-dianisidine, 4-chloronaphthol (4-CN), 4-Aminophenyl phosphate monosodium salt, Fast Red, Naphthol AS-BI-phosphate, nitrophenyl-p-D-galactopyranoside (ONPG), o-phenylenediamine (OPD), 5-bromo-4-chloro-3-indolyl-p-galactopyranoside (X-Gal), methylumbelliferyl-p-D-galactopyranoside (Mil-Gal), p-nitrophenyl-a-D-galactopyranoside (PNP), 5-bromo-4-chloro-3-indolyl-p-D-glucuronide (X-Gluc), 3-amino-9-ethyl carbazol (AEC), fuchsin, iodonitrotetrazolium (INT), tetrazolium blue, or tetrazolium violet.
79. The method of claim 78, wherein the IHC staining further comprises contacting the tissue sample with DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
80. The method of any one of claims 46-79, wherein the HER2 negative cell line sample comprises HL-60 or Farage cells.
81. An in vitro method for predicting responsiveness of a tumor to a HER2-directed therapy, the method comprising:(A) assessing HER2 expression in a tumor by detecting viable HER2 positive tumor cells in at least one tissue sample obtained from a tumor of a potential subject;Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) wherein the HER2 positive tumor cells are detected by immunohistochemistry (IHC) staining using a reagent that specifically binds an epitope of a HER2 protein, which reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors; and(B) predicting that the tumor is responsive to HER2-directed therapy if a tumor cell of the tissue sample exhibits membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions.
82. The method of claim 81 , wherein:the reagent specifically binds an epitope within a domain of the HER2 protein that is targeted by the HER2-directed therapy,the reagent specifically binds an epitope within an extracellular domain of HER2 protein;the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein;the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1 ;the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1 ; and / orthe reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.
83. The method of 81 or 82, wherein the membrane and / or cytomembrane staining intensity is determined using light microscopy, virtual microscopy, whole slide imaging, an image-transmitting camera, an imaging sensor, a charge-coupled device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.
84. The method of any one of claims 81 -83, wherein the HER2 positive tumor cells are detected by computer-assisted image analysis or manual analysis of the tissue sample.
85. The method of claim 84, wherein computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue sample.
86. The method of claim 84 or 85, wherein the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 87. The method of claim 86, wherein the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
88. The method of any one of claims 81 -87, further comprising assessing the intensity of the IHC staining for each HER2 positive cell.
89. The method of any one of claims 81 -88, further comprising determining a percentage of HER2 positive tumor cells in an area of the tissue sample.
90. The method of claim 89, wherein the percentage of HER2 positive tumor cells in the area is equal to or greater than 1%, optionally equal to or greater than 10%, or equal to or greater than 30%.
91. The method of any one of claims 81 -90, further comprising determining an IHC score.
92. The method of claim 91 , wherein the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.
93. The method of claim 92, wherein the IHC score is an H-score.
94. The method of claim 93, wherein determining the IHC score comprises manual analysis, digital imaging analysis, computer-assisted image analysis, an AI / ML-assisted image analysis, fully automated analysis, and / or an end-to-end analysis.
95. The method of any one of claims 81 -94, wherein the tumor is an epithelial-derived carcinoma.
96. The method of claim 95, wherein the epithelial-derived carcinoma is selected from gastric cancer, gastroesophageal junction cancer, colorectal cancer, breast cancer, lung cancer, small cell lung cancer, salivary gland cancer, ovarian cancer, esophageal cancer, bladder cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, uterine cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma.
97. The method of any one of claims 81 -96, wherein the tumor is a solid tumor selected from breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer,Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) pancreatic ductal adenocarcinoma, gastroesophageal junction cancer, bladder cancer, head and neck squamous cell carcinoma, prostate cancer, ovarian cancer, and colorectal cancer.
98. The method of any one of claims 81 -97, wherein the tissue sample is a biopsy sample or a surgical resection sample.
99. The method of any one of claims 81 -98, wherein the tissue sample is a tissue section with a thickness between 4 pm and 5 pm.
100. The method of claim 99, wherein the tissue section includes equal to or greater than 100 viable tumor cells.
101. The method of claim 98 or 99, wherein the IHC staining is performed within six months after sectioning the tissue or within about five months, within about four months, within about three months, within about two months or within about 1 month after sectioning the tissue.
102. The method of any one of claims 81-101, wherein the tissue sample is a formalin-fixed tissue sample.
103. The method of any one of claims 81 -102, wherein the tissue sample is a deparaffinized tissue sample.
104. The method of any one of claims 81 -103, wherein the IHC staining further comprises contacting the tissue sample with an enzyme-labeled antibody specific for the reagent.
105. The method of claim 104, wherein the enzyme-labeled antibody comprises an oxidoreductase, hydrolase, or peroxidase, optionally wherein the enzyme-labeled antibody comprises a horseradish peroxidase (HRP), alkaline phosphatase (AP), acid phosphatase, glucose oxidase, p-galactosidase, p-glucuronidase, or p-lactamase.
106. The method of claim 105, wherein the enzyme-labeled antibody comprises HRP or AP.
107. The method of any one of claims 81 -106, wherein the IHC staining further comprises contacting the tissue sample with 3,3’-diamino-benzidine (DAB), 4-nitrophenylphospate (pNPP), bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, APAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) Orange, AP blue, tetramethylbenzidine (TMB), 2,2'-azino-di-[3-ethylbenzothiazoline sulphonate] (ABTS), o-dianisidine, 4-chloronaphthol (4-CN), 4-Aminophenyl phosphate monosodium salt, Fast Red, Naphthol AS-BI-phosphate, nitrophenyl-p-D-galactopyranoside (ONPG), o-phenylenediamine (OPD), 5-bromo-4-chloro-3-indolyl-p-galactopyranoside (X-Gal), methylumbelliferyl-p-D-galactopyranoside (Mil-Gal), p-nitrophenyl-a-D-galactopyranoside (PNP), 5-bromo-4-chloro-3-indolyl-p-D-glucuronide (X-Gluc), 3-amino-9-ethyl carbazol (AEC), fuchsin, iodonitrotetrazolium (INT), tetrazolium blue, or tetrazolium violet.
108. The method of claim 107, wherein the IHC staining further comprises contacting the tissue sample with DAB, pNPP, BCIP, NBT, BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
109. The method of any one of claims 81 -108, wherein the HER2 negative cell line comprises HL-60 or Farage cells.
110. A kit for characterizing responsiveness of a tumor to a HER2-directed therapy, the kit comprising:(a) a reagent that specifically binds an epitope of a HER2 protein, wherein the reagent lacks cross-reactivity with any other epidermal growth factor family member of tyrosine kinase receptors;(b) a HER2 negative cell line; and(c) a set of instructions for:(i) using the reagent for IHC staining on a tumor tissue sample obtained from a tumor of a potential subject, and(ii) characterizing a tumor as being responsive to a HER2-directed therapy when a tumor cell exhibits HER2-positive membrane and / or cytomembrane staining at an intensity greater than the staining intensity of a HER2 negative cell line contacted with the reagent under substantially similar conditions.
111. The kit of claim 110, wherein:the reagent specifically binds an epitope within a HER2 protein domain targeted by the HER2-directed therapy;the reagent specifically binds an epitope within an extracellular domain of the HER2 protein;the reagent specifically binds an epitope within amino acid residues 25 to 60 of the HER2 protein;Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) the reagent specifically binds an epitope comprising at least three consecutive amino acid residues of SEQ ID NO: 1 ;the reagent specifically binds an epitope consisting of the amino acid sequence of SEQ ID NO: 1 ; and / orthe reagent comprises a monoclonal anti-HER2 / ErbB2 D8F12 antibody.
112. The kit of claim 110 or 111 , wherein the set of instructions further comprises instructions for preparing the tissue sample, preparing a negative control using the HER2 negative cell line, preparing a positive control, determining the membrane and / or cytomembrane staining intensity, determining a percentage of HER2 positive tumor cells, and / or determining an IHC score.
113. The kit of any one of claims 110-112, further comprising:(c) at least one enzyme-labeled antibody that binds to the reagent of component (a), and(d) at least one chromogenic substrate of the at least one enzyme-labeled antibody.
114. The kit of any one of claims 110-113, further comprising at least one counterstain, optionally wherein the counterstain comprises hematoxylin.
115. The kit of any one of claims 110-114, wherein the HER2 negative cell line comprises HL-60 or Farage cells.
116. An in vitro method for determining eligibility of a subject for treatment with a HER2-directed therapy, the method comprising:(a) performing an immunohistochemistry (IHC) assay on a tissue section from a tumor of the subject using a monoclonal anti-HER2 / ErbB2 D8F12 antibody;(b) calculating a IHC score; and(c)(1) determining the subject is eligible for the treatment when the IHC score is greater than or equal to a pre-determined threshold for the tissue section, or (c)(2) determining the subject is ineligible for the treatment when the IHC score is less than the pre-determined threshold for the tissue section.
117. The method of claim 116, wherein the IHC score is selected from the group consisting of an H-score, a percent positive score, a tumor proportion score, an intensity score, an Allred score, a modified Allred score, a Quick score, or an Immunoreactivity score.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 118. The method of claim 117, wherein the IHC score is an H-score.
119. The method of any one of claims 116 or 118, wherein the IHC assay comprises staining the tissue section by incubation with the monoclonal anti-HER2 / ErbB2 D8F12 antibody for about 1 minute to about 2 hours at a temperature between about 15 to 45°C followed by contacting the tissue section with an horseradish peroxidase-conjugated secondary antibody that binds the monoclonal anti-HER2 / ErbB2 D8F12 antibody for about 0.5 to 30 minutes.
120. The method of claim 119, further comprising counterstaining the stained tissue section with hematoxylin for about 0.5 to 10 minutes; followed by bluing for about 0.5 to 10 minutes.
121. The method of any one of claims 116-120, wherein the IHC assay is performed using the monoclonal anti-HER2 / ErbB2 D8F12 antibody at a dilution of about 1 :2 to about 1:10000.
122. The method of any one of claims 116-121 , wherein the IHC assay is performed using the monoclonal anti-HER2 / ErbB2 D8F12 antibody at a dilution of about 1 :25 to about 1:5000.
123. The method of any one of claims 116-122, wherein the IHC assay is performed using the monoclonal anti-HER2 / ErbB2 D8F12 antibody at a dilution of about 1:100.
124. The method of any one of claims 116-123, wherein the tissue section is deparaffinized.
125. The method of any one of claims 116-124, wherein the tissue section is treated with an antigen retrieval buffer for about 25 minutes to about 75 minutes.
126. The method of any one of claims 116-125, wherein the tissue section is evaluated by light microscopy, virtual microscopy, whole slide imaging, an image-transmitting camera, an imaging sensor, a charge-coupled device, a complimentary metal-oxide semiconductor (CMOS) image sensor, or a digital scanner.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 127. The method of any one of claims 116-126, wherein the IHC score is determined by manual analysis of the tissue section or by computer-assisted image analysis of the stained tissue.
128. The method of claim 127, wherein computer-assisted image analysis comprises image enhancement, noise reduction, background subtraction, and / or artifact removal of a digital image of the tissue section.
129. The method of claim 127 or 128, wherein the computer-assisted image analysis comprises artificial intelligence / machine learning (AI / ML)-assisted image analysis.
130. The method of claim 129, wherein the AI / ML-assisted image analysis comprises an artificial neural network, optionally a pre-trained neural network or a foundational model.
131. A kit for determining eligibility of a subject for treatment with a HER2-directed therapy comprising:(a) a monoclonal anti-HER2 / ErbB2 D8F12 antibody in an immunochemistry (IHC) buffer;(b) at least one HER2 negative cell line; and(c) a set of instructions for performing an immunohistochemistry (IHC) assay on a tissue section from a tumor of the subject and determining the eligibility of the subject based membrane and / or cytomembrane staining intensity, wherein a HER2 positive tumor cell exhibits greater membrane and / or cytomembrane staining intensity than a HER2 negative cell line contacted with the monoclonal anti-HER2 / ErbB2 D8F12 antibody under substantially similar conditions.
132. The kit of claim 131, wherein the set of instructions further comprises instructions for preparing the tissue section, preparing the HER2 negative cell line, preparing a positive control, determining the intensity of the stained cells, determining a percentage of stained cells, and / or determining an IHC score.
133. The kit of claim 131 or 132, further comprising:(d) an enzyme-labeled antibody that binds to the monoclonal anti-HER2 / ErbB2 D8F12 antibody, and(e) a chromogenic substrate of the enzyme-labeled antibody.Attorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) 134. The kit of claim 133, wherein the enzyme-labeled antibody comprises horseradish peroxidase (HRP) or alkaline phosphatase (AP).
135. The kit of claim 133 or 134, wherein the chromogenic substrate comprises 3,3’-diamino-benzidine (DAB), para-Nitrophenylphosphate (pNPP), 5-Bromo-4-chloro-3-indolyl phosphate (BCIP), nitro blue tetrazolium (NBT), BCIP / NBT, 4-Aminophenyl phosphate monosodium salt, Fast Red, or Naphthol AS-BI-phosphate.
136. The kit of any one of claims 131-135, further comprising a counterstain, optionally wherein the counterstain comprises hematoxylin.
137. The kit of any one of claims 131-136, wherein the HER2 negative cell line comprises HL-60 or Farage cells.
138. A system for predicting whether a tumor will be responsive to HER2-directed therapy using an image of a solid tumor sample stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, the system comprising:(i) a processor, and(ii) a memory coupled to the processor, where the memory stores computerexecutable instructions that, when executed by the processor, cause the system to perform operations comprising:a. detecting, with a ML / AI assisted image analyzer, a region of interest within a sample image of a solid tumor sample stained for HER2 expressing cells;b. extracting stained features from the detected region of interest;c. grouping data points representing the detected region of interest based on the extracted stained features to identify homogeneous groups; andd. signaling that the tumor is predicted to be responsive to HER2-directed therapy when one or more homogeneous groups of regions of interest are identified in the sample image.
139. The system of claim 138, wherein the ML / AI analyzer is trained using a dataset comprising a plurality of training images, wherein each training image of the plurality is derived from a biological specimen stained with the monoclonal anti-HER2 / ErbB2 D8F12 antibody.
140. A non-transitory computer-readable medium storing instructions for predicting whether a tumor will be responsive to HER2-directed therapy using an image of a solidAttorney Docket No. 776519: NIT-59888PC (PAT059888-PCT-SEC01) tumor sample stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, which, when executed by a processor, performs a method comprising:a. detecting, with a ML / AI assisted image analyzer, a region of interest within a sample image of a solid tumor sample stained for HER2 expressing cells;b. extracting stained features from the detected region of interest;c. grouping data points representing the detected region of interest based on the extracted stained features to identify homogenous groups; andd. signaling that the tumor is predicted to be responsive to HER2-directed therapy when one or more homogeneous groups of regions of interest are identified in the sample image.
141. A method of predicting whether a subject’s tumor will be responsive to HER2-directed therapy using an image of a solid tumor obtained from the subject, the solid tumor being stained for HER2 expressing cells by a monoclonal anti-HER2 / ErbB2 D8F12 antibody, the method comprising:a. detecting, with a ML / AI assisted image analyzer, a region of interest within a sample image of a solid tumor sample stained for HER2 expressing cells;, wherein the ML / AI assisted image analyzer comprises a first portion and a second portion, wherein the first portion is configured to identify stained features within the sample image and wherein the second portion is configured to detect the region of interest based on the stained features;b. extracting a portion of the identified stained features from the first portion of the ML / AI assisted image analyzer; c. grouping data points representing the detected region of interest based on the extracted stained features to identify homogeneous groups; andd. signaling that the tumor is predicted to be responsive to HER2-directed therapy when one or more homogeneous groups of regions of interest are identified in the sample image.
142. A kit for predicting whether a tumor will be responsive to HER2-directed therapy comprising:(a) a monoclonal anti-HER2 / ErbB2 D8F12 antibody in an immunochemistry (IHC) buffer; and(b) the non-transitory computer-readable medium of claim 140.
